0001140361-18-022751.txt : 20180510 0001140361-18-022751.hdr.sgml : 20180510 20180510150347 ACCESSION NUMBER: 0001140361-18-022751 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 43 CONFORMED PERIOD OF REPORT: 20180331 FILED AS OF DATE: 20180510 DATE AS OF CHANGE: 20180510 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOSPECIFICS TECHNOLOGIES CORP CENTRAL INDEX KEY: 0000875622 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 113054851 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-34236 FILM NUMBER: 18821994 BUSINESS ADDRESS: STREET 1: 35 WILBUR ST CITY: LYNBROOK STATE: NY ZIP: 11563 BUSINESS PHONE: 5165937000 MAIL ADDRESS: STREET 1: 35 WILBUR STREET CITY: LYNBROOK STATE: NY ZIP: 11563 10-Q 1 form10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2018

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE

ACT OF 1934

For the transition period from __________________to __________________

001-34236

(Commission file number)

BIOSPECIFICS TECHNOLOGIES CORP.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		11-3054851
(State or Other Jurisdiction		(I.R.S. Employer
of Incorporation or Organization)		Identification No.)

35 Wilbur Street Lynbrook, NY 11563

(Address of Principal Executive Offices) (Zip Code)

516.593.7000

(Registrant’s Telephone Number, Including Area Code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☒
Non-accelerated filer ☐ (Do not check if a smaller reporting company)	Smaller reporting company ☐
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for comply with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

Indicate the number of shares outstanding of the issuer’s classes of common stock, as of the latest practicable date:

Class of Stock		Outstanding May 9, 2018
Common Stock ($.001 par value)		7,214,233

BIOSPECIFICS TECHNOLOGIES CORP.

TABLE OF CONTENTS

		Page
	PART I – FINANCIAL INFORMATION
ITEM 1.	Financial Statements Unaudited Condensed Consolidated Financial Statements
	Condensed Consolidated Balance Sheets	4
	Condensed Consolidated Income Statements	5
	Condensed Consolidated Statements of Cash Flows	6
	Notes to Condensed Consolidated Financial Statements	7
ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17
ITEM 3.	Quantitative and Qualitative Disclosures About Market Risk	23
ITEM 4.	Controls and Procedures	24

	PART II – OTHER INFORMATION
ITEM 1.	Legal Proceedings	24
ITEM 1A.	Risk Factors	24
ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	24
ITEM 6.	Exhibits	25
	Signatures	26

Table of Contents

Introductory Comments – Terminology

Throughout this Quarterly Report on Form 10-Q, the terms “BioSpecifics,” “Company,” “we,” “our,” and “us” refer to BioSpecifics Technologies Corp. and its subsidiary, Advance Biofactures Corp.

Throughout this Quarterly Report on Form 10-Q, Endo Global Ventures, a Bermuda unlimited liability company, an affiliate of Endo International plc, and Endo International plc are referred to collectively as “Endo”.

Introductory Comments – Forward-Looking Statements

This Report includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, expected revenue growth, and the assumptions underlying or relating to such statements, are “forward-looking statements.” The forward-looking statements in this Report include statements concerning, among other things, the continued commercialization of XIAFLEX to treat Dupuytren’s contracture and Peyronie’s disease; the continued marketing and commercialization of XIAFLEX to treat Dupuytren’s contracture and Peyronie’s disease in Europe, Eurasia, Japan, Canada and Australia; Endo’s ability to obtain required regulatory approvals; Endo’s ability to manufacture XIAFLEX at an acceptable cost, in a timely manner and with appropriate quality; successful development of XIAFLEX for additional indications; the ability to successfully develop, market and commercialize our drug candidates; the funding of research and development at medical institutions under agreements that are generally cancellable; the future receipt of payments from Endo, including milestone and royalty payments, in connection with the License Agreement; the recognition of the $8.25 million payment from Endo in connection with the First Amendment; the plans for the repurchase of stock and reacquired stock; the suspension or discontinuation of the stock repurchase plan; the risk of doubtful accounts and how we provide for estimates of uncollectable accounts; the adoption of new accounting pronouncements and their impact; which accounting policies we consider to be critical to the estimates and judgments used to prepare the unaudited condensed consolidated financial statements; the effect of changes in interest rates on the Company’s results of operations, financial position and cash flow; changes in internal controls; the ability of internal controls and procedures to achieve desired control objectives; the existence of significant uncertain tax positions and provision for income taxes; the sufficiency of the Company’s available funds and cash flow from operations to meet our operational cash needs; whether the carrying amounts of the Company’s financial instruments approximate fair value due to the nature of the instruments; the changes in the Company’s exposure to market risk; the fair value of the Company’s stock option awards; whether the Company’s bank account balances will exceed insured limits; whether the Company is exposed to any significant credit risk on our cash; our milestone achievements and payments; whether we will continue to make payments to buy down our future royalty obligations; whether we will experience uneven payment flows due to the variance in financial terms in contracts with third parties to perform clinical trial activities and ongoing development of potential drugs; estimates concerning our development period; our interpretation of the definition of milestone; whether the Company will choose to cancel the lease prior to the expiration of the term; whether and when we will hear from Endo the results of their ongoing commercial review regarding the XIAFLEX pipeline; the timing of Endo’s determination of clinical trial timelines for additional indications; the nature of our accounts receivable balance and the timing of the Company’s release of top-line data in connection with its Phase 1 clinical trial of XIAFLEX for the treatment of uterine fibroids. In some cases, these statements can be identified by forward-looking words such as “believe,” “expect,” “anticipate,” “estimate,” “likely,” “may,” “will,” “can,” and “could,” the negative or plural of these words, and other similar expressions. These forward-looking statements are predictions based on our current expectations and our projections about future events and various assumptions. There can be no assurance that we will realize our expectations or that our beliefs will prove correct. There are a number of important factors that could cause BioSpecifics’ actual results to differ materially from those indicated by such forward-looking statements, including the timing of regulatory filings and action; the ability of Endo and its partners, Asahi Kasei Pharma Corporation, Actelion Ltd. and Swedish Orphan Biovitrum AB, to achieve their objectives for XIAFLEX in their applicable territories; the market for XIAFLEX in, and timing, initiation and outcome of clinical trials for, additional indications that will determine the amount of milestone, royalty, mark-up on cost of goods sold, license and sublicense income BioSpecifics may receive; the potential of XIAFLEX to be used in additional indications; Endo modifying its objectives or allocating resources other than to XIAFLEX; and other risk factors identified in BioSpecifics’ Annual Report on Form 10-K for the year ended December 31, 2017 and its Current Reports on Form 8-K filed with the Securities and Exchange Commission. All forward-looking statements included in this Report are made as of the date hereof, are expressly qualified in their entirety by the cautionary statements included in this Report and, except as may be required by law, we assume no obligation to update these forward-looking statements.

Table of Contents

PART I – FINANCIAL INFORMATION

Item 1:

Condensed Consolidated Financial Statements

BioSpecifics Technologies Corp.

Condensed Consolidated Balance Sheets

	March 31, 2018⁽¹⁾			December 31, 2017
	(unaudited)			(audited)
Assets
Current assets:
Cash and cash equivalents	$	12,558,901		$	7,333,810
Short term investments		48,751,206			51,973,971
Accounts receivable		19,165,670			4,655,105
Deferred royalty buy-down		1,648,319			1,794,126
Prepaid expenses and other current assets		580,920			623,503
Total current assets		82,705,016			66,380,515

Long-term investments		2,840,191			5,745,974
Deferred royalty buy-down – long term, net		-			732,206
Deferred tax assets, net		403,944			1,739,706
Patent costs, net		425,785			397,993

Total assets	$	86,374,936		$	74,996,394

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable and accrued expenses		1,781,163		$	933,998
Income tax payable		2,535,676			68,733
Deferred revenue		117,635			1,057,979
Accrued liabilities of discontinued operations		78,138			78,138
Total current liabilities		4,512,612			2,138,848

Long-term deferred revenue		17,635			5,340,708

Stockholders’ equity:
Series A Preferred stock, $.50 par value, 700,000 shares authorized; none outstanding		-			-
Common stock, $.001 par value; 10,000,000 shares authorized; 7,610,167 and 7,600,167 shares issued, 7,199,233 and 7,189,233 shares outstanding as of March 31, 2018 and December 31, 2017, respectively		7,610			7,600
Additional paid-in capital		33,633,225			33,468,323
Retained earnings		56,102,054			41,939,115
Treasury stock, 410,934 shares at cost as of each period ended March 31, 2018 and December 31, 2017		(7,898,200	)		(7,898,200	)
Total stockholders’ equity		81,844,689			67,516,838

Total liabilities and stockholders’ equity	$	86,374,936		$	74,996,394

See accompanying notes to condensed consolidated financial statements.

⁽¹⁾As of January 1, 2018, the Company adopted the requirements of ASC 606 using the modified retrospective adoption method, and as a result, there is a lack of comparability of certain amounts to the prior periods presented. See Note 2 for additional discussion.

Table of Contents

BioSpecifics Technologies Corp.

Condensed Consolidated Income Statements

(unaudited)

	Three Months Ended March 31,
	2018⁽¹⁾			2017
Revenues:
Royalties	$	7,085,000		$	7,686,210
Licensing revenues		4,409			4,409
Total Revenues		7,089,409			7,690,619

Costs and expenses:
Research and development		195,227			254,781
General and administrative		2,069,633			2,425,717
Total Cost and Expenses		2,264,860			2,680,498

Operating income		4,824,549			5,010,121

Other income:
Interest income		217,951			101,753
Other income		14,678			2,562
		232,629			104,315

Income before income tax expense		5,057,178			5,114,436
Provision for income tax expense		(1,078,574	)		(1,769,683	)

Net income	$	3,978,604		$	3,344,753


Basic net income per share	$	0.55		$	0.47
Diluted net income per share	$	0.54		$	0.46

Shares used in computation of basic net income per share		7,192,900			7,164,248
Shares used in computation of diluted net income per share		7,303,336			7,332,736

See accompanying notes to condensed consolidated financial statements.

Table of Contents

BioSpecifics Technologies Corp.

Condensed Consolidated Statements of Cash Flows

(unaudited)

	Three Months Ended March 31,
Cash flows from operating activities:	2018⁽¹⁾			2017
Net income	$	3,978,604		$	3,344,753
Adjustments to reconcile net income to net cash provided by operating activities:
Amortization		699,703			545,067
Stock-based compensation expense		32,512			33,476
Deferred tax expense		-			97,508
Changes in operating assets and liabilities:
Accounts receivable		(6,955,839	)		(1,117,501	)
Income tax receivable		1,067,002			212,174
Prepaid expenses and other current assets		42,582			40,709
Patent costs		(44,598	)		-
Accounts payable and accrued expenses		308,152			422,793
Deferred revenue		(4,409	)		(259,713	)
Net cash (used in) provided by operating activities		(876,291	)		3,319,266

Cash flows from investing activities:
Maturity of marketable investments		20,287,000			18,217,000
Purchases of marketable investments		(14,318,018	)		(17,304,251	)
Net cash provided by investing activities		5,968,982			912,749

Cash flows from financing activities:
Proceeds from stock option exercises		132,400			258,250
Payments for repurchase of common stock		-			(221,821	)
Net cash provided by financing activities		132,400			36,429

Increase in cash and cash equivalents		5,225,091			4,268,444
Cash and cash equivalents at beginning of year		7,333,810			4,763,364
Cash and cash equivalents at end of period	$	12,558,901		$	9,031,808

Supplemental disclosures of cash flow information:
Cash paid during the period for:
Interest		-			-
Taxes		-		$	1,460,000

See accompanying notes to condensed consolidated financial statements.

Table of Contents

BIOSPECIFICS TECHNOLOGIES CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2018

(Unaudited)

1. ORGANIZATION AND DESCRIPTION OF BUSINESS

We are a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. We currently have a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (“Endo Global Ventures”), an affiliate of Endo International plc (“Endo”), for injectable collagenase for marketed indications and indications in development. Endo assumed this agreement when Endo acquired Auxilium Pharmaceuticals, Inc. (“Auxilium”) on January 29, 2015 (the “Acquisition”). Injectable collagenase clostridium histolyticum is marketed as XIAFLEX® (or Xiapex® in Europe).

On February 1, 2016, we entered into with Endo the First Amendment (the “First Amendment”) to the Second Amended and Restated Development and Licensing Agreement (the “Auxilium Agreement”), by and between us and Auxilium, now a wholly-owned subsidiary of Endo, to amend certain provisions of the Auxilium Agreement (as amended by the First Amendment, the “License Agreement”). The effective date of the First Amendment was January 1, 2016. Pursuant to the First Amendment, we and Endo mutually agreed that in exchange for a $8.25 million lump sum payment, we will not receive future additional mark-up on cost of goods sold for sales by non-affiliated sublicensees of Endo outside of the U.S.; provided, however, that Endo will still be required to pay a mark-up on cost of goods sold for sales made in the “Endo Territory,” which includes sales made in the U.S. and sales made in any other country where Endo sells the product directly or through affiliated sublicensees. We received this $8.25 million lump sum payment in February 2016 and began recognizing this income over time based on sales by non-affiliated sublicensees of Endo outside of the U.S. according to our previous revenue recognition policy in the second quarter of 2016.

Additionally, we agreed that Endo may opt-in early to indications, prior to our submission of a clinical trial report, with our consent, such consent not to be unreasonably withheld. For early opt-ins, Endo will be required to make an opt-in payment of $0.5 million on a per indication basis. For regular opt-ins, following our submission of a clinical trial report, Endo will be required to make an opt-in payment of $0.75 million on a per indication basis.

The two marketed indications involving our injectable collagenase are Dupuytren’s contracture and Peyronie’s disease. Prior to the Acquisition, Auxilium had, and after the Acquisition, Endo has, opted-in to the following indications: frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis and human lipoma. Endo exercised, with our consent, an early opt-in for lateral hip fat and plantar fibromatosis in November 2015. Endo opted-in for human lipoma in July 2016. We manage the development of XIAFLEX for uterine fibroids and initiate the development of XIAFLEX in new potential indications, not licensed by Endo.

On November 8, 2016, following a change in Endo management, Endo announced that a commercial review is ongoing of the XIAFLEX exercised but non-marketed indications, including frozen shoulder, cellulite, lateral hip fat, plantar fibromatosis and human lipoma, so that Endo can best prioritize its R&D efforts and determine clinical trial timelines moving forward.

Endo is currently selling XIAFLEX in the U.S. for the treatment of Dupuytren’s contracture and Peyronie’s disease and has an agreement with Swedish Orphan Biovitrum AB (“Sobi”), pursuant to which Sobi has marketing rights for Xiapex for Dupuytren’s contracture and Peyronie’s disease in Europe and certain Eurasian countries. Sobi is currently selling Xiapex in Europe and certain Eurasian countries for the treatment of Dupuytren’s contracture and Peyronie’s disease. In addition, Endo has an agreement with Asahi Kasei Pharma Corporation (“Asahi”) pursuant to which Asahi has the right to commercialize XIAFLEX for the treatment of Dupuytren’s contracture and Peyronie’s disease in Japan. Asahi is selling XIAFLEX for the treatment of Dupuytren’s contracture in Japan. Endo is currently distributing XIAFLEX in Canada through Paladin Labs Inc, an operating company of Endo. In December 2016, Endo entered into a new out-licensing agreement with Actelion Pharmaceuticals Ltd. (“Actelion”), pursuant to which Actelion obtained marketing and commercial rights for XIAFLEX in Australia and New Zealand.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Except as detailed below, there have been no material changes to the Company’s significant accounting policies during the three months ended March 31, 2018, as compared to the significant accounting policies disclosed in Note 2 of the Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

Table of Contents

Basis of Presentation

The accompanying condensed consolidated financial statements are unaudited, but include all adjustments (consisting only of normal, recurring adjustments) which we consider necessary for a fair presentation of our financial position at such dates and the operating results and cash flows for those periods. Although we believe that the disclosures in our financial statements are adequate to make the information presented not misleading, certain information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) has been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for quarterly reporting.

The information included in this Report should be read in conjunction with the risk factors discussed in “Part I, Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC on March 14, 2018.

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its subsidiary, Advance Biofactures Corp. All intercompany balances and transactions have been eliminated.

Critical Accounting Policies, Estimates and Assumptions

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the use of management’s estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company makes certain assumptions and estimates for its revenues, deferred tax assets, third party royalties and deferred royalty buy-down. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions. For further details, see notes “Revenue Recognition”, “Provision for Income Taxes” and “Third-Party Royalties and Royalty Buy-Down.” Actual results may differ from those estimates.

Revenue Recognition

Beginning in 2014, Financial Accounting Standards Board (“FASB”) issued several Accounting Standards Updates establishing ASC Topic 606, “Revenue from Contracts with Customers” (“ASC 606”). ASC 606 requires retrospective implementation, and replaces most industry-specific revenue recognition guidance in U.S. GAAP with a new principles-based, five-step revenue recognition model. The Company adopted ASC 606 effective January 1, 2018. Under ASC 606, we recognize revenues when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation(s).

Revenues, and their respective treatment for financial reporting purposes under ASC 606 and our license agreement with Endo, are as follows:

Royalty / Mark-Up on Cost of Goods Sold

We receive royalty revenues on net sales and mark-up on cost of goods sold revenue in the U.S. under our License Agreement with Endo. These are presented in “Royalties” in our condensed consolidated statements of income. We do not have future performance obligations under this revenue stream. In accordance with ASC 606, we record these revenues based on estimates of the net sales that occurred during the relevant period, thereby eliminating the one quarter lag convention in previous periods. The relevant period estimates of these royalties are based on interim data provided by Endo and analysis of historical royalties and mark-up on cost of goods sold revenue that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. The royalties payable by Endo to us are subject to set-off for certain patent costs.

Table of Contents

Licensing Revenue

We include revenue recognized from upfront licensing, sublicensing and milestone payments in “License Revenues” in our condensed consolidated statements of income.

The Company recognizes licensing revenues generated through development and/or commercialization agreements. The terms of these agreements typically include payment to the Company of one or more of the following: nonrefundable, upfront license fees; sublicensing; development and commercial milestone payments; development activities; and royalties on net sales of licensed products. Each of these types of payments results in licensing revenues except for revenues from royalties on net sales of licensed products and the mark-up of cost of goods sold revenues which are classified as royalty revenues. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the customer.

For each development and/or commercialization agreement that result in revenues, the Company identifies all material performance obligations, which may include a license to intellectual property and know-how, development activities and/or transition activities. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company’s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required.

If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, upfront license fees based on the relative standalone selling price prescribed to the license compared to the total value of the arrangement. The revenue is recognized when the license is transferred to the collaborator and the collaborator is able to use and benefit from the license. For licenses that are not distinct from other obligations identified in the arrangement, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the combined performance obligation is satisfied over time, the Company applies an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

Development and Regulatory Milestone Payments

Depending on facts and circumstances, the Company may conclude that it is appropriate to include the milestone, representing variable consideration, in the estimated total transaction price, or that it is appropriate to fully constrain the milestone. The Company may include revenues from certain milestones in the total transaction price in a reporting period before the milestone is achieved if the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods. The Company records a corresponding contract asset when this conclusion is reached. Milestone payments that have not been included in the transaction price to date are fully constrained. The Company re-evaluates the probability of achievement of such development milestones and any related constraint each reporting period. The Company adjusts its estimate of the total transaction price, including the amount of revenue that it has recorded, if necessary.

Table of Contents

RECENT ACCOUNTING PRONOUNCEMENTS

Accounting Pronouncements Adopted

Effective January 1, 2018, the Company adopted ASC 606, which provides principles for recognizing revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The Company adopted ASC 606 on a modified retrospective basis through a cumulative adjustment to equity. See Note 2 – Significant Accounting Policies – Revenue Recognition.

The adoption of ASC 606 as of January 1, 2018, applying the modified-retrospective method, changed the timing of our recognition of royalty and mark-up cost of goods sold revenue. Beginning in 2018, we recorded these royalty revenues based on estimates of the net sales and mark-up cost of goods sold that occurred during the relevant period thereby eliminating the one quarter lag. Previously, these amounts were not recognized until they were fixed and determinable. In addition, deferred revenue associated with the prepayment of foreign mark-up on cost of goods sold revenue will no longer be recognized over time based on sales by non-affiliated sublicensees of Endo outside of the U.S. and, under ASC 606, would have been recognized when the transaction occurred in 2016.

The cumulative effect of applying the new guidance of ASC 606 to our License Agreement with Endo as of January 1, 2018 was recorded as an adjustment to retained earnings as of the adoption date. As a result of applying the modified retrospective method to adopt the new revenue guidance, the following adjustments were made to accounts on the Condensed Consolidated Balance Sheet as of January 1, 2018:

The Company recorded the following cumulative effect as of January 1, 2018, itemized here (in millions):

	As reported December 31, 2017			Adjustments			Adjusted January 1, 2018
Accounts receivable	$	4.7		$	7.6	⁽¹⁾	$	12.3
Deferred revenue		(6.4	)		6.3	⁽²⁾		(0.1	)
Deferred royalty buy-down		(2.5	)		(0.4	)⁽³⁾		(2.9	)
Accounts payable and accrued expenses -third party royalties		(0.4	)		(0.5	)⁽³⁾		(0.9	)
Deferred tax assets, net		1.7			(1.3	)⁽⁴⁾		0.4
Income tax payable		-			(1.4	)⁽⁵⁾		(1.4	)

Retained earnings adjustment	$	(2.9	)	$	10.3		$	7.4

(1)	This adjustment represents the elimination of the one quarter lag by recognizing royalty revenues based on of XIALFLEX net sales and mark-up on cost of goods sold revenues reported to us by Endo for the fourth quarter of 2017.

(2)	Represents the remaining deferred revenue balance of the prepaid mark-up on cost of goods sold based on sales by non-affiliated sublicensees of Endo outside of the U.S.

(3)	Represents the amortization of the royalty buy-down and third party royalties expense associated royalty revenues based on XIALFLEX net sales reported to us by Endo for the fourth quarter of 2017.

(4)	To reverse a deferred tax asset associated with the deferred revenue balance of the prepaid mark-up on cost of goods sold by non-affiliated sublicensees of Endo outside of the U.S.

(5)	To create a tax liability associated the elimination of the one quarter lag by recognizing royalty revenues based on of XIALFLEX net sales and mark-up on cost of goods sold revenues reported to us by Endo for the fourth quarter of 2017.

At March 31, 2018, contract assets of $7.0 million for which there’s an unconditional right to receive payment was included in accounts receivable on the condensed consolidated balance sheet.

In accordance with the new revenue standard requirements, the impact of adoption on our condensed consolidated balance sheet was as follows:

	March 31, 2018
	As Reported		Balances Without Adoption of New Revenue Standard		Effect of Change Higher / (Lower)
Assets
Accounts receivable	$	19,165,670	$	12,120,670	$	7,045,000
Deferred royalty buy-down		1,648,319		2,014,598		(366,279	)
Deferred tax assets		403,944		1,696,932		(1,292,988	)
Liabilities
Accounts payable and accrued expenses		1,781,163		1,271,163		510,000
Deferred revenue		117,635		1,023,854		(906,219	)
Income tax payable		2,535,676		1,288,977		1,246,699
Deferred revenue, long term		17,635		5,173,564		(5,155,930	)
Equity
Retained earnings		56,102,054		46,440,716		9,661,338

Table of Contents

In accordance with the new revenue standard requirements, the impact of adoption on our condensed consolidated statement of operations was as follows:

	Three Months Ended March 31, 2018
	As Reported		Balances Without Adoption of New Revenue Standard		Effect of Change Higher / (Lower)
Revenues
Royalties	$	7,085,000	$	7,731,566	$	(646,566	)
Costs and expenses
General and administrative	$	2,069,633	$	2,087,921	$	(17,418	)
Provision for income taxes		1,078,574		1,220,244		(141,670	)
Net income		3,978,604		4,500,918		(522,314	)

In January 2016, the FASB issued new guidance on recognition and measurement of financial assets and financial liabilities. The new guidance will impact the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. All equity investments in unconsolidated entities (other than those accounted for under the equity method of accounting) will generally be measured at fair value with changes in fair value recognized through earnings. There will no longer be an available-for-sale classification (changes in fair value reported in other comprehensive income (loss) for equity securities with readily determinable fair values). In addition, the FASB clarified the need for a valuation allowance on deferred tax assets resulting from unrealized losses on available-for-sale debt securities. In general, the new guidance will require modified retrospective application to all outstanding instruments, with a cumulative effect adjustment recorded to opening retained earnings. The adoption of the new standard as of January 1, 2018 had no impact on our consolidated financial statements and related disclosure as we do not currently have any available-for-sale equity investments.

Accounting Pronouncements Not Yet Adopted

In February 2016, FASB issued Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842) (“ASU 2016-02”). Under the new guidance, lessees will be required to recognize the following for all leases (with the exception of short-term leases) at the lease commencement date: a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. Under the new guidance, lessor accounting is largely unchanged. Certain targeted improvements were made to align, where necessary, lessor accounting with the lessee accounting model and Topic 606, Revenue from Contracts with Customers. The new lease guidance simplified the accounting for sale and leaseback transactions primarily because lessees must recognize lease assets and lease liabilities. Lessees will no longer be provided with a source of off-balance sheet financing. Public business entities should apply the amendments in ASU 2016-02 for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years (i.e., January 1, 2019, for a calendar year entity). Early application is permitted. Lessees (for capital and operating leases) and lessors (for sales-type, direct financing, and operating leases) must apply a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The modified retrospective approach would not require any transition accounting for leases that expired before the earliest comparative period presented. Lessees and lessors may not apply a full retrospective transition approach. We are currently evaluating the expected impact that the standard could have on our consolidated financial statements and related disclosures.

In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses. The amendment revises the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in more timely recognition of losses on financial instruments, including, but not limited to, available for sale debt securities and accounts receivable. The Company is required to adopt this standard starting in the first quarter of fiscal year 2021. Early adoption is permitted. We are currently evaluating the impact of the adoption of this standard on our consolidated financial statements and related disclosures.

Cash, Cash Equivalents and Investments

Cash equivalents include only securities having a maturity of 90 days or less at the time of purchase. Investments are stated on an amortized cost basis. The Company limits its credit risk associated with cash, cash equivalents and investments by placing its investments with banks it believes are highly creditworthy and with highly rated money market funds, certificates of deposit, municipal bonds and corporate bonds. All investments are classified as held to maturity. As of March 31, 2018 and December 31, 2017, the amortized cost of these investments was $51.6 million and $57.7 million, respectively. No unrealized gains or losses were recorded in either period.

Fair Value Measurements

Management believes that the carrying amounts of the Company’s financial instruments, including cash, cash equivalents, held to maturity investments, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term nature of those instruments. As of March 31, 2018 and December 31, 2017, there were no recorded unrealized gains or losses on our investments as they are held to maturity. As of March 31, 2018 and December 31, 2017, amortized cost basis of the investments approximated their fair value. At March 31, 2018 and December 31, 2017, the amortized premium included in interest income was $160,000 and $673,000, respectively.

The following table presents the Company’s schedule of maturities at March 31, 2018 and December 31, 2017:

	Maturities as of March 31, 2018				Maturities as of December 31, 2017
	1 Year or Less		Greater than 1 Year		1 Year or Less		Greater than 1 Year
Municipal bonds	$	3,425,134	$	100,000	$	1,002,650	$	100,000
Corporate bonds		41,828,133		500,230		48,143,495		3,155,573
Certificates of deposit		3,497,939		2,239,961		2,827,826		2,490,401
Total	$	48,751,206	$	2,840,191	$	51,973,971	$	5,745,974

Table of Contents

The authoritative literature for fair value measurements established a three-tier fair value hierarchy, which prioritizes the inputs in measuring fair value. These tiers are as follows: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than the quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as significant unobservable inputs (entity developed assumptions) in which little or no market data exists.

As of March 31, 2018, the Company held certain investments that are required to be measured at fair value on a recurring basis. The following tables present the Company’s fair value hierarchy for these financial assets as of March 31, 2018 and December 31, 2017:

March 31, 2018	Type of Instrument	Fair Value		Level 1		Level 2		Level 3

Cash equivalents	Institutional Money Market	$	7,432,432	$	7,432,432	$	-	$	-

Cash equivalents	Certificates of Deposit		250,000		250,000		-		-

Cash equivalents	Corporate Bonds		2,585,000		2,585,000		-		-

Investments	Municipal Bonds		3,525,134		-		3,525,134		-

Investments	Corporate Bonds		42,328,363		-		42,328,363		-

Investments	Certificates of Deposit		5,737,900		5,737,900		-		-

December 31, 2017	Type of Instrument	Fair Value		Level 1		Level 2		Level 3

Cash equivalents	Institutional Money Market	$	3,108,549	$	3,108,549	$	-	$	-

Cash equivalents	Municipal Bonds		800,000		-		800,000		-

Investments	Municipal Bonds		1,102,650		-		1,102,650		-

Investments	Corporate Bonds		51,299,068		-		51,299,068		-

Investments	Certificates of Deposit		5,318,227		5,318,227		-		-

Concentration of Credit Risk and Major Customers

The Company maintains investments in FDIC insured certificates of deposits, municipal bonds and corporate bonds.

The Company is currently dependent on one customer, Endo, who generates almost all its revenues. For the periods ended March 31, 2018 and 2017, the licensing, sublicensing, milestones, royalty and mark-up on cost of goods sold revenues under the License Agreement with Endo were approximately $7.1 and $7.7 million, respectively.

At March 31, 2018 and December 31, 2017, our accounts receivable balances from Endo were $19.2 million and $4.7 million, respectively.

Table of Contents

Treasury Stock

The Company accounts for treasury stock under the cost method and includes treasury stock as a component of stockholders’ equity. For the three months ended March 31, 2018, there were no shares repurchased as compared to the repurchase of 4,260 shares at an average price of $52.07 in the corresponding 2017 period.

Receivables and Doubtful Accounts

Trade accounts receivable are stated at the amount the Company expects to collect. We may maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. We consider the following factors when determining the collectability of specific customer accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. Our accounts receivable balance is typically due from Endo, our one large specialty pharmaceutical customer. Endo has historically paid timely and has been a financially stable organization. Due to the nature of the accounts receivable balance, we believe the risk of doubtful accounts is minimal. If the financial condition of our customer were to deteriorate, adversely affecting its ability to make payments, additional allowances would be required. We may provide for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. Balances that remain outstanding after we have used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable. At March 31, 2018 and December 31, 2017 our accounts receivable balance was $19.2 million and $4.7 million, respectively, and was from one customer, Endo. With the adoption of ASC 606 as of January 1, 2018, using the modified-retrospective adoption method, we recorded an adjustment to our accounts receivable balance of $7.6 million related to royalties associated with the net sales of XIAFLEX that occurred during the fourth quarter of 2017 thereby eliminating the one quarter lag. (For more a more detailed discussion regarding ASC 606 see Note 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - RECENT ACCOUNTING PRONOUNCEMENTS - Accounting Pronouncements Adopted.

Deferred Revenue

Deferred revenue consists of approximately $35,000 related to nonrefundable upfront product license fees for product candidates for which we are providing continuing services related to product development and $100,000 related to a milestone payment withheld by Endo due to a foreign tax withholding which remains uncollected. Currently, the Company expects to recover the full amount. With the adoption of ASC 606 using the modified retrospective adoption method as of January 1, 2018, the remaining deferred revenue balance associated with the mark-up on cost of goods sold for sales by non-affiliated sublicensees of Endo outside of the U.S. as of December 31, 2017 of $6.3 million was recorded as an adjustment to our retained earnings. As of March 31, 2018 and December 31, 2017, deferred revenue was $135,000 and $6.4 million, respectively. (For more a more detailed discussion regarding ASC 606 see Note 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - RECENT ACCOUNTING PRONOUNCEMENTS - Accounting Pronouncements Adopted.

Reimbursable Third-Party Patent Costs

We accrue patent costs that are reimbursable to Endo by us under the License Agreement. We capitalize certain patent costs related to patent prosecution and maintenance and expense others. As of March 31, 2018 and December 31, 2017, our net reimbursable third party patent expense was $134,000 and zero, respectively.

Third-Party Royalties

We have entered into licensing and royalty agreements with third parties and agreed to pay certain royalties on net sales of products for specific indications. The royalty rates differ from agreement to agreement and, in certain cases, have been redacted with the permission of the SEC. No assumptions should be made that any disclosed royalty rate payable to a particular third party is the same or similar with respect to any royalty rate payable to any other third parties. We accrue third-party royalty expenses on net sales reported to us by Endo. Third-party royalty costs are generally expensed under general and administrative in the quarter that the net sales have occurred. For the three month periods ended March 31, 2018 and 2017, third-party royalty expenses were $0.5 million in each period. With the adoption of ASC 606 as of January 1, 2018 using the modified-retrospective adoption method, we recorded an adjustment to our retained earnings for third party royalties expense of $0.5 million associated with the net sales of XIAFLEX that occurred during the fourth quarter of 2017 thereby eliminating the one quarter lag. Our third-party royalty expense under general and administrative expenses may increase if net sales by Endo and its partners for XIAFLEX and Xiapex increase and potential new indications for XIAFLEX and Xiapex are approved, marketed and sold. (For more a more detailed discussion regarding ASC 606 see Note 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - RECENT ACCOUNTING PRONOUNCEMENTS - Accounting Pronouncements Adopted.

Table of Contents

Royalty Buy-Down

On March 31, 2012, we entered into an amendment to our existing agreement with Dr. Martin K. Gelbard, dated August 27, 2008, related to our future royalty obligations in connection with Peyronie’s disease. The amendment enables us to buy down a portion of our future royalty obligations in exchange for an initial cash payment of $1.5 million and five additional cash payments of $600,000, all of which have been paid as of March 31, 2018. Royalty obligations terminate five years after first commercial sale which occurred in January 2014. The Company amortizes long-term contracts with finite lives in a manner that reflects the pattern in which the economic benefits of the assets are consumed or otherwise used up. Dr. Gelbard’s agreement is amortized based on an income forecast method by estimating sales of XIAFLEX and Xiapex for Peyronie’s disease on an annual basis as measured by the proportion of the total estimated sales over the five year period. For the three months ended March 31, 2018 and 2017, we amortized approximately $0.5 million and $0.4 million related to this agreement, respectively. With the adoption of ASC 606 as of January 1, 2018 using the modified-retrospective adoption method, we recorded an adjustment to our capitalized balance of $0.4 million related to royalties associated with the net sales of XIAFLEX that occurred during the fourth quarter of 2017 thereby eliminating the one quarter lag. As of March 31, 2018 and December 31, 2017, the remaining capitalized balances were approximately $1.6 million and $2.5 million, respectively. We perform an evaluation of the recoverability of the carrying value to determine if facts and circumstances indicate that the carrying value of the assets may be impaired and if any adjustment is warranted. As of March 31, 2018, there was no indicator that an impairment existed. (For more a more detailed discussion regarding ASC 606 see Note 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - RECENT ACCOUNTING PRONOUNCEMENTS - Accounting Pronouncements Adopted.

Research and Development Expenses

R&D expenses include, but are not limited to, internal costs, such as salaries and benefits, costs of materials, lab expense, facility costs and overhead. R&D expenses also consist of third party costs, such as medical professional fees, product costs used in clinical trials, consulting fees and costs associated with clinical study arrangements. We may fund R&D at medical research institutions under agreements that are generally cancelable. All of these costs are charged to R&D as incurred, which may be measured by percentage of completion, contract milestones, patient enrollment, or the passage of time.

Clinical Trial Expenses

Our cost accruals for clinical trials are based on estimates of the services received and efforts expended pursuant to contracts with various clinical trial centers and clinical research consultants. In the normal course of business, we contract with third parties to perform various clinical trial activities in the ongoing development of potential drugs. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events, the successful enrollment of patients, the completion of portions of the clinical trial, or similar conditions. The objective of our accrual policy is to match the recording of expenses in our financial statements to the actual cost of services received and efforts expended. As such, expenses related to each patient enrolled in a clinical trial are recognized ratably beginning upon entry into the trial and over the course of the patient’s continued participation in the trial. In the event of early termination of a clinical trial, we accrue an amount based on our estimate of the remaining non-cancelable obligations associated with the winding down of the clinical trial. Our estimates and assumptions could differ significantly from the amounts that may actually be incurred.

Stock-Based Compensation

The Company has one stock-based compensation plan in effect. Accounting Standards Codification 718, Compensation - Stock Compensation (“ASC 718”), requires the recognition of compensation expense, using a fair-value based method, for costs related to all stock options including stock options and common stock issued to our employees and directors under our stock plans. ASC 718 requires companies to estimate the fair value of stock option awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service periods in our condensed consolidated statements of operations.

Table of Contents

Under ASC 718, we estimate the fair value of our employee stock option awards at the date of grant using the Black-Scholes option-pricing model, which requires the use of certain subjective assumptions. The most significant of these assumptions are our estimates of the expected volatility of the market price of our stock and the expected term of an award. When establishing an estimate of the expected term of an option award, we consider the vesting period for the award, our recent historical experience of employee stock option exercises (including forfeitures) and the expected volatility of our common stock. As required under the accounting rules, we review our estimates at each grant date and, as a result, the valuation assumptions that we use to value employee stock-based awards granted in future periods may change. On March 15, 2018, we granted a total of 30,000 stock options to two members of our Board of Directors, valued at approximately $540,000. We used the Black-Scholes valuation model to estimate the value of options using 39.6% volatility, a risk free rate of 2.62% and an expected term of 6.25 years.

Further, ASC 718 requires that employee stock-based compensation costs be recognized over the requisite service period, or the vesting period, in a manner similar to all other forms of compensation paid to employees. The allocation of employee stock-based compensation costs to each operating expense line are estimated based on specific employee headcount information at each grant date and estimated stock option forfeiture rates and revised, if necessary, in future periods if actual employee headcount information or forfeitures differ materially from those estimates. As a result, the amount of employee stock-based compensation costs we recognize in each operating expense category in future periods may differ significantly from what we have recorded in the current period.

Stock-based compensation expense recognized in general and administrative expenses was approximately $33,000 for each three month period ended March 31, 2018 and 2017.

Stock Option Activity

A summary of our stock option activity during the three months ended March 31, 2018 is presented below:

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding at December 31, 2017		232,000		$	21.56		2.52	$	5,050,990
Grants		30,000			41.82		-		-
Exercised		(10,000	)		13.24		-		-
Forfeitures or expirations		-			-		-		-
Outstanding at March 31, 2018		252,000		$	24.30		3.29	$	5,049,910
Exercisable at March 31, 2018		207,000		$	20.80		2.04	$	4,873,810

During the three months ended March 31, 2018 and 2017, the Company received approximately $132,000 and $258,000, respectively, from stock options exercised by option holders.

Aggregate intrinsic value represents the total pre-tax intrinsic value based on the closing price of our common stock of $44.34 on March 29, 2018, which would have been received by the option holders had all option holders exercised their options as of that date. We have approximately $648,000 in unrecognized compensation cost related to stock options outstanding as of March 31, 2018, which we expect to recognize over the next 3.45 years.

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation. Machinery and equipment, furniture and fixtures, and autos are depreciated on a straight-line basis over their estimated useful lives of five to ten years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the remaining life of the lease. At each of March 31, 2018 and December 31, 2017, property and equipment were fully depreciated.

Table of Contents

Comprehensive Income

For each of the three month periods ended March 31, 2018 and 2017, we had no components of other comprehensive income other than net income itself.

Provision for Income Taxes

Deferred tax assets and liabilities are recognized based on the expected future tax consequences, using current tax rates, of temporary differences between the financial statement carrying amounts and the income tax basis of assets and liabilities. A valuation allowance is applied against any net deferred tax asset if, based on the weighted available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

We use the asset and liability method of accounting for income taxes, as set forth in Accounting Standards Codification 740-10-25-2. Under this method, deferred income taxes, when required, are provided on the basis of the difference between the financial reporting and income tax basis of assets and liabilities at the statutory rates enacted for future periods. In accordance with Accounting Standards Codification 740-10-45-25, Income Statement Classification of Interest and Penalties, we classify interest associated with income taxes under interest expense and tax penalties under other.

The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon the ultimate settlement. As of March 31, 2018 and December 31, 2017, the Company has not recorded any unrecognized tax benefits.

Commitments and Contingencies

On November 6, 2017, the Company entered into an agreement with the Landlord to extend the term of the lease to the Headquarters for an additional one year period (the “Extended Lease Agreement”). The one year extension will end on November 30, 2018. Pursuant to the Extended Lease Agreement, the base rent is $11,165 per month and the Company may cancel the lease with three months’ prior written notice to the Landlord at any time during the term.

3. NET INCOME PER SHARE

In accordance with Accounting Standards Codification 260, Earnings Per Share, basic net income per share amount is computed using the weighted-average number of shares of common stock outstanding during the periods presented, while diluted net income per share is computed using the sum of the weighted-average number of common and common equivalent shares outstanding. Common equivalent shares used in the computation of diluted earnings per share result from the assumed exercise of stock options using the treasury stock method.

The following table summarizes the number of common equivalent shares that were excluded for the calculation of diluted net income per share reported in the condensed consolidated statement of operations.

	Three Months Ended March 31,
	2018		2017
Stock options		-		20,000

For the three months ended March 31, 2017, the Company had 20,000 options, which have an exercise price of $29.21, and will vest upon the achievement of certain performance criteria, which have not yet been met. These options expire on December 2, 2019. As of October 25, 2017, these 20,000 options have been cancelled due to a change in status of a certain consultant.

Table of Contents

4. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses consisted of the following:

	March 31, 2018		December 31, 2017
Trade accounts payable	$	215,639	$	152,542
Accrued legal and other professional fees		194,565		150,691
Accrued payroll and related costs		204,311		215,322
Third party royalties		1,049,013		329,211
Other accruals		117,635		86,232
Total	$	1,781,163	$	933,998

5. PATENT COSTS

We amortize intangible assets with definite lives on a straight-line basis over their remaining estimated useful lives, ranging from two to ten years, and review for impairment on a quarterly basis and when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. We analyze our intangible assets, specifically, capitalized patent costs, on an annual basis for any indicator that an impairment exists.

For the three months ended March 31, 2018, we increased our capitalized patent costs based on reports provided to us by Endo. Patent costs may be creditable against future royalty revenues. For each period presented below, net patent costs consisted of:

	March 31, 2018			December 31, 2017
Patents		969,614		$	925,016
Accumulated amortization		(543,829	)		(527,023	)
	$	425,785		$	397,993

The amortization expense for patents for the three months ended March 31, 2018 was approximately $16,800 and $10,200, respectively. The estimated aggregate amortization expense for the remaining nine months of 2018 and each of the years below is approximately as follows:

April 1, 2018 - December 31, 2018	$	51,000
2019		66,200
2020		50,400
2021		34,500
2022		34,500
Thereafter		189,185

6. PROVISION FOR INCOME TAXES

Our deferred tax liabilities and deferred tax assets are impacted by events and transactions arising in the ordinary course of business, R&D activities, vesting of nonqualified options and other items. The provision for income taxes is based on an estimated effective tax rate derived from our consolidated earnings before taxes, adjusted for nondeductible expenses and other permanent differences for the fiscal year. For the three months ended March 31, 2018 and 2017, the provision for income taxes was $1.1 million and $1.8 million, respectively. As of March 31, 2018 and December 31, 2017, our remaining deferred tax assets were approximately $0.4 million and $1.7 million, respectively.

As of March 31, 2018, the Company has no unrecognized tax benefits or related interest and penalties. Management does not believe that there is any tax position which it is reasonably possible that will result in unrecognized tax benefit within the next 12 months.

Item 2:

Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with the condensed consolidated financial statements and the related notes thereto included elsewhere in this Report and is qualified by reference to them.

Table of Contents

Overview

On February 1, 2016, we entered into with Endo the First Amendment (the “First Amendment”) to the Second Amended and Restated Development and Licensing Agreement (the “Auxilium Agreement”), by and between us and Auxilium, now a wholly-owned subsidiary of Endo, to amend certain provisions of the Auxilium Agreement (as amended by the First Amendment, the “License Agreement”). The effective date of the First Amendment was January 1, 2016. Pursuant to the First Amendment, we and Endo mutually agreed that in exchange for a $8.25 million lump sum payment, we will not receive future additional mark-up on cost of goods sold for sales by non-affiliated sublicensees of Endo outside of the U.S.; provided, however, that Endo will still be required to pay a mark-up on cost of goods sold for sales made in the “Endo Territory,” which includes sales made in the U.S. and sales made in any other country where Endo sells the product directly or through affiliated sublicensees. We received this $8.25 million lump sum payment in February 2016 and began recognizing this income over time based on sales by non-affiliated sublicensees of Endo outside of the U.S. according to our revenue recognition policy in the second quarter of 2016.

Operational Highlights

Our Phase 1 clinical trial of Collagenase Clostridium Histolyticum (CCH) of for the treatment of uterine fibroids is ongoing and we plan to announce the results in 2018. The study, being conducted at the Department of Gynecology & Obstetrics at Johns Hopkins University, is designed to enroll 15 female subjects treated prior to hysterectomy. The primary endpoint of the study will assess the safety and tolerability of a single injection of XIAFLEX directly into the uterine fibroids under transvaginal ultrasound guidance. The secondary endpoints will assess symptoms of pain and bleeding, quality of life throughout the study, shrinkage of XIAFLEX treated fibroids in size, increased rates of apoptosis in treated fibroids and a decrease in the collagen content of the treated fibroids.

Table of Contents

On March 12, 2018, we announced the presentation of interim data from our ongoing Phase 1 clinical trial of XIALEX for the treatment of uterine fibroids at the 65^th Annual Scientific Meeting of the Society for Reproductive Investigation on Friday, March 9, 2018 in San Diego, CA. The data showed the safety and effectiveness of the XIALFEX injection method in five patients.

Outlook

We generated revenue from primarily one source, the License Agreement. Under the License Agreement, we receive license, sublicense income, royalties, milestones and mark-up on cost of goods sold payments related to the sale, regulatory submissions and approval of XIAFLEX as described above.

Significant Risks

We are dependent to a significant extent on third parties, and our principal licensee, Endo, may not be able to continue successfully commercializing XIAFLEX for Dupuytren’s contracture and Peyronie’s disease, successfully develop XIAFLEX for additional indications, obtain required regulatory approvals, manufacture XIAFLEX at an acceptable cost, in a timely manner and with appropriate quality, or successfully market products or maintain desired margins for products sold, and, as a result, we may not achieve sustained profitable operations.

The Company maintains bank account balances, which, at times, may exceed insured limits. The Company has not experienced any losses with these accounts and believes that it is not exposed to any significant credit risk on cash. The Company maintains its investment in FDIC insured certificates of deposits with several banks, municipal bonds and corporate bonds.

For more information regarding the risks facing the Company, please see the risk factors discussed under the heading “Risk Factors” under item 1A of Part 1 of our Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC on March 14, 2018.

Critical Accounting Policies, Estimates and Assumptions

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates are based on historical experience and on various other assumptions that we believe are reasonable under the circumstances. The financial information at March 31, 2018 and for the three months ended March 31, 2018 and 2017 is unaudited, but includes all adjustments (consisting only of normal recurring adjustments) which, in the opinion of management, are necessary to state fairly the financial information set forth herein. The December 31, 2017 balance sheet amounts and disclosures included herein have been derived from the Company’s December 31, 2017 audited consolidated financial statements. The interim results are not necessarily indicative of results to be expected for the full fiscal year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2017 included in the Company’s Annual Report on Form 10-K filed with the SEC. While our significant accounting policies are described in more detail in the notes to our unaudited condensed consolidated financial statements, we believe the following accounting policies to be critical to the judgments and estimates used in the preparation of our unaudited condensed consolidated financial statements. Actual results have differed in the past, and may differ in the future, from our estimates and could impact our earnings in any period during which an adjustment is made.

Except as described in Note 2 to our accompanying Condensed Consolidated Financial Statements with respect to changes in our revenue recognition policy related to our adoption of the requirements of ASC 606, there have been no significant changes to our critical accounting policies and estimates during the three months ended March 31, 2018, compared to the critical accounting policies and estimates disclosed in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K for the year ended December 31, 2017

Reimbursable Third-Party Patent Costs

Table of Contents

Receivables

At March 31, 2018 and December 31, 2017 our accounts receivable balance which consists of royalties, mark-up on costs of goods sold and a portion of a milestone payment from Endo due to a foreign tax withholding, was $19.2 million and $4.7 million, respectively, and was from one customer, Endo.

Deferred Revenue

Third-Party Royalties

Royalty Buy-Down

On March 31, 2012, we entered into an amendment to our existing agreement with Dr. Martin K. Gelbard, dated August 27, 2008, related to our future royalty obligations in connection with Peyronie’s disease. The amendment enables us to buy down a portion of our future royalty obligations in exchange for an initial cash payment of $1.5 million and five additional cash payments of $600,000, all of which have been paid as of March 31, 2018. Royalty obligations terminate five years after first commercial sale which occurred in January 2014. The Company amortizes long-term contracts with finite lives in a manner that reflects the pattern in which the economic benefits of the assets are consumed or otherwise used up. Dr. Gelbard’s agreement is amortized based on an income forecast method by estimating sales of XIAFLEX and Xiapex for Peyronie’s disease on an annual basis as measured by the proportion of the total estimated sales over the five year period. For the three months ended March 31, 2018 and 2017, we amortized approximately $0.5 million and $0.4 million related to this agreement, respectively. As of March 31, 2018 and December 31, 2017, the remaining capitalized balances were approximately $1.6 million and $2.5 million, respectively. We perform an evaluation of the recoverability of the carrying value to determine if facts and circumstances indicate that the carrying value of the assets may be impaired and if any adjustment is warranted. As of March 31, 2018, there was no indicator that an impairment existed.

Stock Based Compensation

Under Accounting Standards Codification 718, Compensation - Stock Compensation, or ASC 718, we estimate the fair value of our employee stock awards at the date of grant using the Black-Scholes option-pricing model, which requires the use of certain subjective assumptions. The most significant assumptions are our estimates of the expected volatility of the market price of our common stock and the expected term of an award. Expected volatility is based on the historical volatility of our common stock. When establishing an estimate of the expected term of an award, we consider the vesting period for the award, our historical experience of employee stock option exercises (including forfeitures) and the expected volatility. As required under the accounting rules, we review our valuation assumptions at each grant date and, as a result, we are likely to change our valuation assumptions used to value future employee stock-based awards granted, to the extent any such awards are granted.

Table of Contents

Further, ASC 718 requires that employee stock-based compensation costs to be recognized over the requisite service period, or the vesting period, in a manner similar to all other forms of compensation paid to employees. The allocation of employee stock-based compensation costs to each operating expense line are estimated based on specific employee headcount information at each grant date and estimated stock option forfeiture rates and revised, if necessary, in future periods if actual employee headcount information or forfeitures differ materially from those estimates. As a result, the amount of employee stock-based compensation costs we recognize in each operating expense category in future periods may differ significantly from what we have recorded in the current period.

RESULTS OF OPERATIONS

THREE MONTHS ENDED MARCH 31, 2018 COMPARED TO THREE MONTHS ENDED MARCH 31, 2017

Revenues

Royalties

Royalties consist of royalties and the mark-up on cost of goods sold under the License Agreement. Total royalty and mark-up on cost of goods sold for the three month period ended March 31, 2018 were $7.1 million as compared to $7.7 million in the corresponding 2017 period, a decrease of $0.6 million or 8%. The decrease in total revenues for the quarterly period was primarily due to lower mark-up on cost of goods sold revenue in the U.S and prepaid foreign mark-up on cost of goods sold revenue recognized under new revenue standard ASC 606, as of January 1, 2018, which was partially offset by an increase in royalties associated with slightly higher overall net sales of XIAFLEX.

Licensing Revenue

Licensing revenue consists of licensing fees, sublicensing fees and milestones. We recognized certain licensing fees related to the cash payments received under the License Agreement in prior years and amortized them over the expected development period. For the three month periods ended March 31, 2018 and 2017, we recognized licensing revenue related to the development of injectable collagenase of $4,409 in each period.

Milestone revenue recognized for the three months ended March 31, 2018 and 2017 was zero in each period.

Research and Development Activities and Expenses

R&D expenses include, but are not limited to, internal costs, such as salaries and benefits, costs of materials, lab expenses, facility costs and overhead. R&D expenses also consist of third party costs, such as medical professional fees, product costs used in clinical trials, consulting fees, and costs associated with clinical study arrangements. For the three month periods ended March 31, 2018 and 2017, R&D expenses were approximately $195,000 and $255,000, respectively and in each case, are primarily related to the development work associated with our clinical, preclinical and other R&D programs.

We manage the development of XIAFLEX for uterine fibroids and initiate the development of XIAFLEX in new potential indications, not licensed by Endo. On April 18, 2017, we announced the initiation of an open-label, dose escalation Phase 1 clinical trial of XIAFLEX for the treatment of uterine fibroids. On March 12, 2018, we announced the presentation of data that shows the safety and effectiveness of the XIALFELX injection method in five patients.

The following table summarizes our R&D expenses related to our development programs:

	Three Months Ended March 31, 2018		Three Months Ended March 31, 2017
Program
Uterine Fibroids	$	22,331	$	120,386
Pre-clinical/other research projects		172,896		134,395

The successful development of drugs is inherently difficult and uncertain. Our business requires investments in R&D over many years, often for drug candidates that may fail during the R&D process. Even if the Company is able to successfully complete the development of our drug candidates, our long-term prospects depend upon our ability and the ability of our partners, particularly with respect to XIAFLEX and Xiapex, to continue to commercialize these drug candidates.

Table of Contents

There is significant uncertainty regarding our ability to successfully develop drug candidates in other indications. These risks include the uncertainty of:

the nature, timing and estimated costs of the efforts necessary to complete the development of our drug candidate projects;

the anticipated completion dates for our drug candidate projects;

the scope, rate of progress and cost of our clinical trials that we are currently running or may commence in the future with respect to our drug candidate projects;

the scope, rate of progress of our preclinical studies and other R&D activities related to our drug candidate projects;

clinical trial results for our drug candidate projects;

the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights relating to our drug candidate projects;

the terms and timing of any strategic alliance, licensing and other arrangements that we have or may establish in the future relating to our drug candidate projects;

the cost and timing of regulatory approvals with respect to our drug candidate projects; and

the cost of establishing clinical supplies for our drug candidate projects.

We believe that our current resources and liquidity are sufficient to advance our current clinical and R&D projects.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and other related costs for personnel, third-party royalty fees, amortization of deferred royalty buy-down, consultant costs, legal fees, investor relations, professional fees and overhead costs. General and administrative expenses for the three months ended March 31, 2018 and 2017 were $2.1 million and $2.4 million, respectively. The decrease in general and administrative expenses was mainly due to the lower consulting, legal and patent fees partially offset by higher amortization associated with deferred royalty buy-down.

Other Income

Other income for the three months ended March 31, 2018 was approximately $233,000 compared to $104,000 in the corresponding 2017 period. Other income consists of interest earned on our investments and product sales of collagenase for laboratory use.

Provision for Income Taxes

Our deferred tax liabilities and deferred tax assets are impacted by events and transactions arising in the ordinary course of business, R&D activities, vesting of nonqualified options, deferred revenues and other items. The provision for income taxes is based on an estimated effective tax rate derived from an estimate of condensed consolidated earnings before taxes, adjusted for nondeductible expenses and other permanent differences for the fiscal year. Under the new tax law, Tax Cuts and Jobs Act, our effective tax rate decrease to approximately 21% from 35%. For the three month period ended March 31, 2018, our provision for income taxes was $1.1 million. Our deferred tax assets as of March 31, 2018 were $0.4 million. For the three month period ended March 31, 2017, the provision for income taxes was $1.8 million.

Net Income

For the three months ended March 31, 2018, we recorded net income of $4.0 million, or $0.55 per basic common share and $0.54 per diluted common share, compared to a net income of $3.3 million, or $0.47 per basic common share and $0.46 per diluted common share, for the same period in 2017.

Table of Contents

Liquidity and Capital Resources

To date, we have financed our operations primarily through product sales, licensing revenues and royalties under agreements with third parties and sales of our common stock. At March 31, 2018 and December 31, 2017, we had cash and cash equivalents and investments in the aggregate of approximately $64.2 million and $65.1 million, respectively. We currently anticipate that our available funds and cash flow from operations will be sufficient to meet our operational cash needs for at least the next 12 months from this filing.

Net cash used in operating activities for the three months ended March 31, 2018 was $0.9 million and as compared to net cash provided operating activities of $3.3 million in the 2017 period. Net cash used in operating activities in the 2018 period was primarily attributable to an increase in accounts receivable of $7.0 million due to the timing of Endo’s payment of our quarterly XIAFLEX royalties partially offset by an increase in accounts payable and accrued expenses of $1.4 million related to third party royalties Non-cash items included amortization, stock-based compensation expense, and deferred taxes which was reduced by adjustments to reconcile net income to net cash provided by operating activities of $0.7 million. Net cash provided by operating activities in the 2017 period was primarily attributable to our net income of $3.3 million, an increase in operating assets and liabilities of $0.7 million of which $1.1 million was related to an increase in accounts receivable due to sales of XIAFLEX. Non-cash items included amortization, stock-based compensation expense, and deferred taxes which was reduced by adjustments to reconcile net income to net cash provided by operating activities of $0.7 million.

Net cash provided by investing activities for the three months ended March 31, 2018 was $6.0 million as compared $0.9 million for the corresponding 2017 period. The net cash provided by investing activities in the 2018 period reflects the maturing of $20.3 million and investment of $14.4 million in marketable securities. The net cash provided by investing activities in the 2017 period reflects the maturing of $18.2 million and investment of $17.3 million in marketable securities.

Net cash provided by financing activities for the three months ended March 31, 2018 was approximately $132,000 as compared to approximately $36,000 in the corresponding 2017 period. In the 2018 period, net cash provided by financing activities was due to proceeds received from stock option exercises. In the 2017 period, net cash provided by financing activities was mainly due to the proceeds received from stock option exercises of approximately $258,000 partially offset by the repurchase of approximately $222,000 of our common stock under our stock repurchase program.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K.

Item 3:

Quantitative and Qualitative Disclosures About Market Risk

We do not use derivative financial instruments or derivative commodity instruments for trading purposes. Our financial instruments consist of cash, cash equivalents, investments, trade accounts receivable, accounts payable and long-term obligations. We consider investments that, when purchased, have a remaining maturity of three months or less to be cash equivalents.

Our investment portfolio is subject to interest rate risk, although limited given the short term nature of the investments, and will fall in value in the event market interest rates increase. All of our cash and cash equivalents and investments at March 31, 2018, amounting to approximately $64.2 million, were maintained in bank demand accounts, money market accounts, certificates of deposit, corporate bonds and municipal bonds. We do not hedge our interest rate risks, as we believe reasonably possible near-term changes in interest rates would not materially affect our results of operations, financial position or cash flows.

We are subject to market risks in the normal course of our business, including changes in interest rates. There have been no significant changes in our exposure to market risks since March 31, 2018.

Table of Contents

Item 4:

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The Company, under the supervision and with the participation of Thomas L. Wegman, the Company’s President, Principal Executive Officer and Principal Financial Officer, evaluated the effectiveness of its disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, Thomas L. Wegman, in his capacity as the sole named executive officer of the Company, the Company’s Principal Executive Officer and the Company’s Principal Financial Officer, concluded that the Company’s disclosure controls and procedures are effective to ensure that information required to be disclosed by it in reports the Company files or submits under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that such material information is accumulated and communicated to the Company’s management, including its Principal Executive Officer and Principal Financial Officer, to allow timely decisions regarding required disclosure. Because of the inherent limitations in all control systems, any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Furthermore, the Company’s controls and procedures can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of such control, and misstatements due to error or fraud may occur and not be detected on a timely basis.

Changes in Internal Controls

During the three months ended March 31, 2018, we implemented certain internal controls as a result of our adoption of the new revenue standard on January 1, 2018. There were no other changes in our internal control over financial reporting (as defined in Rules 13a–15(f) and 15d–15(f) under the Exchange Act) that occurred during the three months ended March 31, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II: OTHER INFORMATION

Item 1.

Legal Proceedings

None.

Item 1A.

Risk Factors

In addition to the other information contained elsewhere in this Report, you should carefully consider the risk factors discussed in “Part I, Item 1A. Risk Factors” our Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC on March 14, 2018, which could materially affect our business, financial condition or future results.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

During the three month period ended March 31, 2018, we did not issue any unregistered shares of securities.

Issuer Purchases of Equity Securities

During the three month period ended March 31, 2018, we did not repurchase any of our securities.

Table of Contents

Item 6.

Exhibits

	31**	Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rule13a-14(a)/15d-14(a).
	32**	Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of Sarbanes-Oxley Act of 2002.
	101*	The following materials from BioSpecifics Technologies Corp.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, (i) the Condensed Consolidated Statements of Operations, (ii) the Condensed Consolidated Statements of Cash Flows, and (iii) the Notes to the Condensed Consolidated Financial Statements.

* filed herewith

** furnished herewith

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

	BIOSPECIFICS TECHNOLOGIES CORP.
	(Registrant)

Date: May 10, 2018	/s/ Thomas L. Wegman
	Thomas L. Wegman
	President, Principal Executive Officer and
	Principal Financial Officer

EX-31 2 ex31.htm EXHIBIT 31

Exhibit 31

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULES 13a-14(a) AND 15d-14(a) OF

THE SECURITIES EXCHANGE ACT OF 1934

I, Thomas L. Wegman, certify that:

1.	I have reviewed this report on Form 10-Q for the quarterly period ended March 31, 2018 of BioSpecifics Technologies Corp.;

2.	Based on my knowledge, the report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

Date: May 10, 2018

/s/ Thomas L. Wegman
Thomas L. Wegman
President, Principal Executive Officer and Principal Financial Officer

EX-32 3 ex32.htm EXHIBIT 32

Exhibit 32

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULES 13a-14(b) AND 15d-14(b) OF

THE SECURITIES EXCHANGE ACT OF 1934 AND

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, Thomas L. Wegman, the President, Principal Executive Officer and Principal Financial Officer of BioSpecifics Technologies Corp. (the “Company”), DOES HEREBY CERTIFY that:

1.	The Company’s report on Form 10-Q for the quarterly period ended March 31, 2018 (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”); and

2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

IN WITNESS WHEREOF, the undersigned has executed this certification this 10^th day of May 2018.

/s/ Thomas L. Wegman
Thomas L. Wegman
President, Principal Executive Officer and Principal Financial Officer

This certification shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to liability pursuant to that section. Such certification shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.INS 4 bstc-20180331.xml XBRL INSTANCE DOCUMENT 0000875622 2018-01-01 2018-03-31 0000875622 2018-05-09 0000875622 2017-12-31 0000875622 2018-03-31 0000875622 us-gaap:SeriesAPreferredStockMember 2017-12-31 0000875622 us-gaap:SeriesAPreferredStockMember 2018-03-31 0000875622 2017-01-01 2017-03-31 0000875622 bstc:RoyaltiesMember 2017-01-01 2017-03-31 0000875622 bstc:RoyaltiesMember 2018-01-01 2018-03-31 0000875622 bstc:LicensingRevenuesMember 2018-01-01 2018-03-31 0000875622 bstc:LicensingRevenuesMember 2017-01-01 2017-03-31 0000875622 2016-12-31 0000875622 2017-03-31 0000875622 bstc:LicensingRevenuesMember bstc:EndoMember 2018-03-31 0000875622 bstc:LicensingRevenuesMember bstc:EndoMember 2016-02-01 2016-02-29 0000875622 bstc:EndoMember 2017-12-31 0000875622 us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member bstc:EndoMember us-gaap:AccountingStandardsUpdate201409Member 2017-12-31 0000875622 us-gaap:AccountingStandardsUpdate201409Member bstc:EndoMember 2017-12-31 0000875622 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member us-gaap:AccountingStandardsUpdate201409Member 2018-03-31 0000875622 us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member us-gaap:AccountingStandardsUpdate201409Member 2018-03-31 0000875622 us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member bstc:RoyaltiesMember us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 2018-03-31 0000875622 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member bstc:RoyaltiesMember us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 2018-03-31 0000875622 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 2018-03-31 0000875622 us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 2018-03-31 0000875622 2017-01-01 2017-12-31 0000875622 us-gaap:CertificatesOfDepositMember 2017-12-31 0000875622 us-gaap:MunicipalBondsMember 2018-03-31 0000875622 us-gaap:MunicipalBondsMember 2017-12-31 0000875622 us-gaap:CorporateBondSecuritiesMember 2017-12-31 0000875622 us-gaap:CorporateBondSecuritiesMember 2018-03-31 0000875622 us-gaap:CertificatesOfDepositMember 2018-03-31 0000875622 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2017-12-31 0000875622 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2017-12-31 0000875622 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2018-03-31 0000875622 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2017-12-31 0000875622 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2018-03-31 0000875622 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-03-31 0000875622 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000875622 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-03-31 0000875622 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember us-gaap:FairValueInputsLevel2Member 2017-12-31 0000875622 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member 2018-03-31 0000875622 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2018-03-31 0000875622 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member 2018-03-31 0000875622 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-03-31 0000875622 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel3Member 2018-03-31 0000875622 us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-03-31 0000875622 us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-03-31 0000875622 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2018-03-31 0000875622 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember us-gaap:FairValueInputsLevel3Member 2017-12-31 0000875622 us-gaap:MunicipalBondsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000875622 us-gaap:MunicipalBondsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000875622 us-gaap:MunicipalBondsMember us-gaap:FairValueMeasurementsRecurringMember 2018-03-31 0000875622 us-gaap:MunicipalBondsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-03-31 0000875622 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalBondsMember 2018-03-31 0000875622 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000875622 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000875622 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel3Member 2017-12-31 0000875622 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2017-12-31 0000875622 us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000875622 us-gaap:FairValueInputsLevel1Member us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000875622 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:CorporateBondSecuritiesMember 2017-12-31 0000875622 us-gaap:MunicipalBondsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2018-03-31 0000875622 us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000875622 bstc:EndoMember 2018-03-31 0000875622 bstc:EndoMember 2018-01-01 2018-03-31 0000875622 bstc:EndoMember 2017-01-01 2017-03-31 0000875622 bstc:NonrefundableUpfrontProductLicenseFeesMember 2018-03-31 0000875622 bstc:MilestonePaymentDueForeignTaxWithholdingMember 2018-03-31 0000875622 2012-01-01 2012-03-31 0000875622 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-03-31 0000875622 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-03-31 0000875622 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-03-31 0000875622 us-gaap:EmployeeStockOptionMember 2017-12-31 0000875622 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-03-31 0000875622 us-gaap:EmployeeStockOptionMember 2018-03-31 0000875622 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-12-31 0000875622 2018-03-29 0000875622 us-gaap:MinimumMember 2018-01-01 2018-03-31 0000875622 us-gaap:MaximumMember 2018-01-01 2018-03-31 0000875622 us-gaap:StockOptionMember 2018-01-01 2018-03-31 0000875622 us-gaap:StockOptionMember 2017-01-01 2017-03-31 0000875622 bstc:ExercisePriceTwoMember us-gaap:StockOptionMember 2017-03-31 0000875622 us-gaap:StockOptionMember bstc:ExercisePriceTwoMember 2017-10-25 2017-10-25 0000875622 us-gaap:PatentsMember us-gaap:MaximumMember 2018-01-01 2018-03-31 0000875622 us-gaap:MinimumMember us-gaap:PatentsMember 2018-01-01 2018-03-31 0000875622 us-gaap:PatentsMember 2018-03-31 0000875622 us-gaap:PatentsMember 2017-12-31 0000875622 us-gaap:PatentsMember 2018-01-01 2018-03-31 0000875622 us-gaap:PatentsMember 2017-01-01 2017-03-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares bstc:Customer bstc:Payment bstc:Plan bstc:Director xbrli:pure false --12-31 2018-03-31 No No Yes Accelerated Filer BIOSPECIFICS TECHNOLOGIES CORP 0000875622 7214233 2018 Q1 10-Q

152542

215639

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">4. ACCOUNTS PAYABLE AND ACCRUED EXPENSES</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Accounts payable and accrued expenses consisted of the following:</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 80%;"><tr><td valign="bottom" style="width: 56%; vertical-align: top; padding-bottom: 2px;">  </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">  </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31,</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2018</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">  </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid;">  </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">December 31,</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">  </td></tr><tr><td valign="bottom" style="width: 56%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Trade accounts payable</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">215,639</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">152,542</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 56%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Accrued legal and other professional fees</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">194,565</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">150,691</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 56%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Accrued payroll and related costs</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">204,311</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">215,322</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 56%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Third party royalties</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,049,013</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">329,211</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 56%; vertical-align: top; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Other accruals</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">117,635</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">86,232</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 56%; vertical-align: top; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">1,781,163</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">933,998</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td></tr></table></div>

933998

1781163

1271163

510000

19165670

4655105

7600000

12300000

12120670

7045000

19165670

329211

1049013

150691

194565

33633225

33468323

400000

500000

33000

-160000

-673000

16800

10200

20000

74996394

86374936

82705016

66380515

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">Basis of Presentation</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The accompanying condensed consolidated financial statements are unaudited, but include all adjustments (consisting only of normal, recurring adjustments) which we consider necessary for a fair presentation of our financial position at such dates and the operating results and cash flows for those periods. Although we believe that the disclosures in our financial statements are adequate to make the information presented not misleading, certain information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) has been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for quarterly reporting.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The information included in this Report should be read in conjunction with the risk factors discussed in “Part I, Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC on March 14, 2018.</div></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">Cash, Cash Equivalents and Investments</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Cash equivalents include only securities having a maturity of 90 days or less at the time of purchase.  Investments are stated on an amortized cost basis. The Company limits its credit risk associated with cash, cash equivalents and investments by placing its investments with banks it believes are highly creditworthy and with highly rated money market funds, certificates of deposit, municipal bonds and corporate bonds. All investments are classified as held to maturity. As of March 31, 2018 and December 31, 2017, the amortized cost of these investments was $51.6 million and $57.7 million, respectively. No unrealized gains or losses were recorded in either period.</div></div>

7333810

12558901

4763364

9031808

4268444

5225091

3108549

7432432

3108549

800000

250000

2585000

800000

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Commitments and Contingencies</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">On November 6, 2017, the Company entered into an agreement with the Landlord to extend the term of the lease to the Headquarters for an additional one year period (the “Extended Lease Agreement”). The one year extension will end on November 30, 2018. Pursuant to the Extended Lease Agreement, the base rent is $11,165 per month and the Company may cancel the lease with three months’ prior written notice to the Landlord at any time during the term.</div></div>

10000000

7600167

7610167

0.001

7610

7600

7189233

7199233

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">Concentration of Credit Risk and Major Customers</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The Company maintains bank account balances, which, at times, may exceed insured limits. The Company has not experienced any losses with these accounts and believes that it is not exposed to any significant credit risk on cash.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The Company maintains investments in FDIC insured certificates of deposits, municipal bonds and corporate bonds.</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The Company is currently dependent on one customer, Endo, who generates almost all its revenues. For the periods ended March 31, 2018 and 2017, the licensing, sublicensing, milestones, royalty and mark-up on cost of goods sold revenues under the License Agreement with Endo were approximately $7.1 and $7.7 million, respectively.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">At March 31, 2018 and December 31, 2017, our accounts receivable balances from Endo were $19.2 million and $4.7 million, respectively.</div></div>

17635

5340708

5173564

-5155930

6300000

-6400000

-100000

35000

100000

135000

6400000

1057979

117635

1023854

-906219

7000000

2680498

2264860

-2900000

-2500000

-400000

2500000

1600000

1794126

1648319

2014598

-366279

732206

8250000

403944

1739706

-1292988

1696932

400000

-1300000

1739706

400000

1700000

545067

699703

78138

0.54

0.46

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">3. NET INCOME PER SHARE</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">In accordance with Accounting Standards Codification 260,<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> Earnings Per Share</font>, basic net income per share amount is computed using the weighted-average number of shares of common stock outstanding during the periods presented, while diluted net income per share is computed using the sum of the weighted-average number of common and common equivalent shares outstanding. Common equivalent shares used in the computation of diluted earnings per share result from the assumed exercise of stock options using the treasury stock method.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The following table summarizes the number of common equivalent shares that were excluded for the calculation of diluted net income per share reported in the condensed<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> </font>consolidated statement of operations.</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 40%;"><tr><td valign="bottom" style="width: 16%; vertical-align: bottom; padding-bottom: 2px;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="6" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Three Months Ended</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31,</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 16%; vertical-align: bottom; padding-bottom: 2px;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2018</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 16%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Stock options</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">20,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr></table><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">For the three months ended March 31, 2017, the Company had 20,000 options, which have an exercise price of $29.21, and will vest upon the achievement of certain performance criteria, which have not yet been met.  These options expire on December 2, 2019.  As of October 25, 2017, these 20,000 options have been cancelled due to a change in status of a certain consultant.</div></div>

0.55

0.47

648000

540000

P3Y5M12D

215322

204311

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Fair Value Measurements</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Management believes that the carrying amounts of the Company’s financial instruments, including cash, cash equivalents, held to maturity investments, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term nature of those instruments. As of March 31, 2018 and December 31, 2017, there were no recorded unrealized gains or losses on our investments as they are held to maturity. <font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">As of March 31, 2018 and December 31, 2017, amortized cost basis of the investments approximated their fair value.</font> At March 31, 2018 and December 31, 2017, the amortized premium included in interest income was $160,000 and $673,000, respectively.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The following table presents the Company’s schedule of maturities at March 31, 2018 and December 31, 2017:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 90%;"><tr><td valign="bottom" style="width: 42%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td colspan="6" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Maturities as of</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31, 2018</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td colspan="6" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Maturities as of</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">December 31, 2017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 42%; vertical-align: bottom; padding-bottom: 2px;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">1 Year or</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Less</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Greater than 1</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Year</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">1 Year or</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Less</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Greater than</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">1 Year</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 42%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Municipal bonds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,425,134</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">100,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,002,650</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">100,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 42%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Corporate bonds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">41,828,133</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">500,230</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">48,143,495</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,155,573</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 42%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Certificates of deposit</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,497,939</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,239,961</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,827,826</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,490,401</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 42%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">48,751,206</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">2,840,191</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">51,973,971</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">5,745,974</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td></tr></table><div> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The authoritative literature for fair value measurements established a three-tier fair value hierarchy, which prioritizes the inputs in measuring fair value. These tiers are as follows: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than the quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as significant unobservable inputs (entity developed assumptions) in which little or no market data exists.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">As of March 31, 2018, the Company held certain investments that are required to be measured at fair value on a recurring basis. The following tables present the Company’s fair value hierarchy for these financial assets as of March 31, 2018 and December 31, 2017:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 90%;"><tr><td valign="bottom" style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; width: 21%; vertical-align: top; font-weight: bold; padding-bottom: 2px; font-style: normal;"><div style="text-align: left;"><u>March 31, 2018</u></div></td><td valign="bottom" style="width: 1%; vertical-align: top; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; width: 20%; vertical-align: top; font-weight: bold; padding-bottom: 2px; font-style: normal;"><div style="text-align: left;"><u>Type of Instrument</u></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Fair Value</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Level 1</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Level 2</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Level 3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: top;"> </td><td valign="bottom" style="width: 1%; vertical-align: top;"> </td><td valign="bottom" style="width: 20%; vertical-align: top;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Cash equivalents</div></td><td valign="bottom" style="width: 1%; vertical-align: top; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Institutional Money Market</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,432,432</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,432,432</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Cash equivalents</div></td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Certificates of Deposit</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">250,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">250,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Cash equivalents</div></td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Corporate Bonds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,585,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,585,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: top; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: top; background-color: #ffffff;"> </td><td valign="bottom" style="width: 20%; vertical-align: top; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Investments</div></td><td valign="bottom" style="width: 1%; vertical-align: top; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Municipal Bonds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,525,134</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,525,134</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: top; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: top; background-color: #ffffff;"> </td><td valign="bottom" style="width: 20%; vertical-align: top; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Investments</div></td><td valign="bottom" style="width: 1%; vertical-align: top; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Corporate Bonds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">42,328,363</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">42,328,363</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: top; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: top; background-color: #ffffff;"> </td><td valign="bottom" style="width: 20%; vertical-align: top; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Investments</div></td><td valign="bottom" style="width: 1%; vertical-align: top; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Certificates of Deposit</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,737,900</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,737,900</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr></table><div> </div><table align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 90%;"><tr><td valign="bottom" style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; width: 21%; vertical-align: top; font-weight: bold; padding-bottom: 2px; font-style: normal;"><div style="text-align: left;"><u>December 31, 2017</u></div></td><td valign="bottom" style="width: 1%; vertical-align: top; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; width: 20%; vertical-align: top; font-weight: bold; padding-bottom: 2px; font-style: normal;"><div style="text-align: left;"><u>Type of Instrument</u></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Fair Value</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Level 1</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Level 2</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Level 3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle;"> </td><td valign="bottom" style="width: 1%; vertical-align: middle;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Cash equivalents</div></td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Institutional Money Market</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,108,549</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,108,549</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Cash equivalents</div></td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Municipal Bonds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">800,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">800,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Investments</div></td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Municipal Bonds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,102,650</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,102,650</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Investments</div></td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Corporate Bonds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">51,299,068</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">51,299,068</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Investments</div></td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Certificates of Deposit</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,318,227</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,318,227</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr></table></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">As of March 31, 2018, the Company held certain investments that are required to be measured at fair value on a recurring basis. The following tables present the Company’s fair value hierarchy for these financial assets as of March 31, 2018 and December 31, 2017:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 90%;"><tr><td valign="bottom" style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; width: 21%; vertical-align: top; font-weight: bold; padding-bottom: 2px; font-style: normal;"><div style="text-align: left;"><u>March 31, 2018</u></div></td><td valign="bottom" style="width: 1%; vertical-align: top; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; width: 20%; vertical-align: top; font-weight: bold; padding-bottom: 2px; font-style: normal;"><div style="text-align: left;"><u>Type of Instrument</u></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Fair Value</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Level 1</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Level 2</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Level 3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: top;"> </td><td valign="bottom" style="width: 1%; vertical-align: top;"> </td><td valign="bottom" style="width: 20%; vertical-align: top;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Cash equivalents</div></td><td valign="bottom" style="width: 1%; vertical-align: top; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Institutional Money Market</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,432,432</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,432,432</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Cash equivalents</div></td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Certificates of Deposit</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">250,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">250,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Cash equivalents</div></td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Corporate Bonds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,585,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,585,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: top; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: top; background-color: #ffffff;"> </td><td valign="bottom" style="width: 20%; vertical-align: top; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Investments</div></td><td valign="bottom" style="width: 1%; vertical-align: top; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Municipal Bonds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,525,134</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,525,134</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: top; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: top; background-color: #ffffff;"> </td><td valign="bottom" style="width: 20%; vertical-align: top; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Investments</div></td><td valign="bottom" style="width: 1%; vertical-align: top; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Corporate Bonds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">42,328,363</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">42,328,363</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: top; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: top; background-color: #ffffff;"> </td><td valign="bottom" style="width: 20%; vertical-align: top; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Investments</div></td><td valign="bottom" style="width: 1%; vertical-align: top; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Certificates of Deposit</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,737,900</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,737,900</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr></table><div> </div><table align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 90%;"><tr><td valign="bottom" style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; width: 21%; vertical-align: top; font-weight: bold; padding-bottom: 2px; font-style: normal;"><div style="text-align: left;"><u>December 31, 2017</u></div></td><td valign="bottom" style="width: 1%; vertical-align: top; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; width: 20%; vertical-align: top; font-weight: bold; padding-bottom: 2px; font-style: normal;"><div style="text-align: left;"><u>Type of Instrument</u></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Fair Value</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Level 1</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Level 2</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Level 3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle;"> </td><td valign="bottom" style="width: 1%; vertical-align: middle;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Cash equivalents</div></td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Institutional Money Market</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,108,549</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,108,549</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Cash equivalents</div></td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Municipal Bonds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">800,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">800,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Investments</div></td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Municipal Bonds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,102,650</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,102,650</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Investments</div></td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Corporate Bonds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">51,299,068</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">51,299,068</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Investments</div></td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Certificates of Deposit</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,318,227</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,318,227</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr></table><div><br /></div></div>

51000

34500

527023

543829

189185

50400

P10Y

P2Y

34500

969614

925016

66200

2069633

2425717

2087921

-17418

2827826

3425134

48751206

1002650

48143495

41828133

3497939

51973971

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The following table presents the Company’s schedule of maturities at March 31, 2018 and December 31, 2017:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 90%;"><tr><td valign="bottom" style="width: 42%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td colspan="6" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Maturities as of</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31, 2018</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td colspan="6" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Maturities as of</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">December 31, 2017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 42%; vertical-align: bottom; padding-bottom: 2px;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">1 Year or</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Less</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Greater than 1</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Year</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">1 Year or</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Less</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Greater than</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">1 Year</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 42%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Municipal bonds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,425,134</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">100,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,002,650</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">100,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 42%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Corporate bonds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">41,828,133</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">500,230</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">48,143,495</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,155,573</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 42%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Certificates of deposit</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,497,939</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,239,961</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,827,826</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,490,401</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 42%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">48,751,206</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">2,840,191</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">51,973,971</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">5,745,974</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td></tr></table></div>

57700000

51600000

2490401

5745974

2239961

500230

3155573

2840191

100000

5057178

5114436

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">6. PROVISION FOR INCOME TAXES</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Our deferred tax liabilities and deferred tax assets are impacted by events and transactions arising in the ordinary course of business, R&D activities, vesting of nonqualified options and other items. The provision for income taxes is based on an estimated effective tax rate derived from our consolidated earnings before taxes, adjusted for nondeductible expenses and other permanent differences for the fiscal year. For the three months ended March 31, 2018 and 2017, the provision for income taxes was $1.1 million and $1.8 million, respectively. As of March 31, 2018 and December 31, 2017, our remaining deferred tax assets were approximately $0.4 million and $1.7 million, respectively.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">As of March 31, 2018, the Company has no unrecognized tax benefits or related interest and penalties. Management does not believe that there is any tax position which it is reasonably possible that will result in unrecognized tax benefit within the next 12 months.</div></div>

1078574

1769683

1220244

-141670

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">Provision for Income Taxes</div><div style="text-align: left;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Deferred tax assets and liabilities are recognized based on the expected future tax consequences, using current tax rates, of temporary differences between the financial statement carrying amounts and the income tax basis of assets and liabilities. A valuation allowance is applied against any net deferred tax asset if, based on the weighted available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">We use the asset and liability method of accounting for income taxes, as set forth in Accounting Standards Codification 740-10-25-2. Under this method, deferred income taxes, when required, are provided on the basis of the difference between the financial reporting and income tax basis of assets and liabilities at the statutory rates enacted for future periods. </font>In accordance with Accounting Standards Codification 740-10-45-25, <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Income Statement Classification of Interest and Penalties</font>, we classify interest associated with income taxes under interest expense and tax penalties under other.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon the ultimate settlement. As of March 31, 2018 and December 31, 2017, the Company has not recorded any unrecognized tax benefits.</div></div>

1460000

1117501

6955839

422793

308152

-1067002

-212174

-97508

44598

-40709

-42582

425785

397993

425785

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">5. PATENT COSTS</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">We amortize intangible assets with definite lives on a straight-line basis over their remaining estimated useful lives, ranging from two to ten years, and review for impairment on a quarterly basis and when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  We analyze our intangible assets, specifically, capitalized patent costs, on an annual basis for any indicator that an impairment exists.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">For the three months ended March 31, 2018, we increased our capitalized patent costs based on reports provided to us by Endo. Patent costs may be creditable against future royalty revenues. For each period presented below, net patent costs consisted of:</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 60%;"><tr><td valign="bottom" style="width: 36%; vertical-align: top; padding-bottom: 2px;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31,</div>2018</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">December 31,</div>2017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 36%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Patents</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">969,614</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">925,016</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 36%; vertical-align: top; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Accumulated amortization</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(543,829</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(527,023</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 36%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">425,785</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">397,993</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The amortization expense for patents for the three months ended March 31, 2018 was approximately $16,800 and $10,200, respectively. The estimated aggregate amortization expense for the remaining nine months of 2018 and each of the years below is approximately as follows:</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 50%; margin-left: 36pt;"><tr><td valign="bottom" style="width: 38%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">April 1, 2018 - December 31, 2018</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">51,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 38%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">2019</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">66,200</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 38%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">2020</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">50,400</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 38%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">2021</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">34,500</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 38%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">2022</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">34,500</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 38%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Thereafter</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">189,185</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr></table></div>

217951

101753

3525134

5737900

3525134

1102650

42328363

5318227

5737900

1102650

51299068

5318227

42328363

51299068

P1Y

74996394

86374936

2138848

4512612

2840191

5745974

36429

132400

5968982

912749

-876291

3319266

3978604

3344753

4500918

-522314

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify; background-color: #ffffff;">Recent Accounting Prnouncements</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify; text-indent: 36pt;">Accounting Pronouncements Adopted</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify; text-indent: 36pt;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Effective January 1, 2018, the Company adopted ASC 606, which provides principles for recognizing revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The Company adopted ASC 606 on a modified retrospective basis through a cumulative adjustment to equity. See Note 2 –<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> Significant Accounting Policies</font> – <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Revenue Recognition.</font></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">The adoption of ASC 606 as of January 1, 2018, applying the modified-retrospective method, changed the timing of our recognition of </font>royalty and mark-up cost of goods sold revenue. <font style="font-size: 10pt; font-family: 'Times New Roman';">Beginning in 2018, we recorded these royalty revenues based on estimates of the net sales and mark-up cost of goods sold that occurred during the relevant period thereby eliminating the one quarter lag. </font>Previously, these amounts were not recognized until they were fixed and determinable. In addition, deferred revenue associated with the prepayment of foreign mark-up on cost of goods sold<font style="font-size: 10pt; font-family: 'Times New Roman';"> revenue will no longer be r</font>ecognized over time based on sales by non-affiliated sublicensees of Endo outside of the U.S. and, under ASC 606, <font style="font-size: 10pt; font-family: 'Times New Roman';">would have been recognized when the transaction occurred in 2016.</font></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The cumulative effect of applying the new guidance of ASC 606 to our License Agreement with Endo as of January 1, 2018 was recorded as an adjustment to retained earnings as of the adoption date. As a result of applying the modified retrospective method to adopt the new revenue guidance, the following adjustments were made to accounts on the Condensed Consolidated Balance Sheet as of January 1, 2018:</div><div style="background-color: #ffffff;"><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company recorded the following cumulative effect as of January 1, 2018, itemized here (in millions):</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">As reported</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">December 31, 2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Adjustments</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Adjusted</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">January 1, 2018</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Accounts receivable</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">4.7</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7.6</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup> </div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">12.3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: middle; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Deferred revenue</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(6.4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6.3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(2)</sup> </div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.1</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Deferred royalty buy-down</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(2.5</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(3)</sup></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(2.9</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: middle; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Accounts payable and accrued expenses<font style="font-size: 10pt; font-family: 'Times New Roman';"> -third party royalties</font></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.5</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(3)</sup></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.9</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Deferred tax assets, net</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1.7</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1.3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(4)</sup></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">0.4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: middle; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Income tax payable</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1.4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(5)</sup></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1.4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: middle; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: middle; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Retained earnings adjustment</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(2.9</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">10.3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7.4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr></table></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"> </div></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">(1)</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">This adjustment represents the elimination of the one quarter lag by recognizing royalty revenues based on of XIALFLEX net sales and mark-up on cost of goods sold revenues reported to us by Endo for the fourth quarter of 2017.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">(2)</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';">Represents </font>the remaining deferred revenue balance <font style="font-size: 10pt; font-family: 'Times New Roman';">of the prepaid mark-up on cost of goods sold</font> based on sales by non-affiliated sublicensees of Endo outside of the U.S.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">(3)</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">Represents the amortization of the royalty buy-down and third party royalties expense associated royalty revenues based on XIALFLEX net sales reported to us by Endo for the fourth quarter of 2017.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">(4)</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';">To reverse a deferred tax asset associated with the </font>deferred revenue balance <font style="font-size: 10pt; font-family: 'Times New Roman';">of the prepaid mark-up on cost of goods sold</font> by non-affiliated sublicensees of Endo outside of the U.S.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">(5)</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">To create a tax liability associated the elimination of the one quarter lag by recognizing royalty revenues based on of XIALFLEX net sales and mark-up on cost of goods sold revenues reported to us by Endo for the fourth quarter of 2017.</div></td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">At March 31, 2018, contract assets of $7.0 million for which there’s an unconditional right to receive payment was included in accounts receivable on the condensed consolidated balance sheet.</div><div> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">In accordance with the new revenue standard requirements, the impact of adoption on our condensed consolidated balance sheet was as follows:</font></div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="10" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31, 2018</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">As Reported</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Balances Without Adoption of New Revenue Standard</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Effect of Change</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Higher / (Lower)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Assets</div></td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Accounts receivable</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">19,165,670</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">12,120,670</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,045,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Deferred royalty buy-down</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,648,319</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,014,598</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(366,279</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Deferred tax assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">403,944</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,696,932</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,292,988</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Liabilities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Accounts payable and accrued expenses</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,781,163</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,271,163</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">510,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Deferred revenue</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">117,635</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,023,854</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(906,219</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Income tax payable</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,535,676</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,288,977</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,246,699</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Deferred revenue, long term</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">17,635</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,173,564</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(5,155,930</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Equity</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Retained earnings</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">56,102,054</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">46,440,716</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">9,661,338</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr></table><div style="background-color: #ffffff;"> </div><div style="background-color: #ffffff;"><br />  </div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: normal; text-align: left;"><div style="background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">In accordance with the new revenue standard requirements, the impact of adoption on our condensed consolidated statement of operations was as follows:</font></div><div><br /></div></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"> </div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="10" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Three Months Ended March 31, 2018</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"> </div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">As Reported</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Balances Without Adoption of New Revenue Standard</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Effect of Change</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Higher / (Lower)</div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Revenues</div></td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Royalties</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,085,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,731,566</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(646,566</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Costs and expenses</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">General and administrative</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,069,633</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,087,921</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(17,418</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Provision for income taxes</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,078,574</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,220,244</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(141,670</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net income</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,978,604</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">4,500,918</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(522,314</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr></table><div style="background-color: #ffffff;"> </div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: normal; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">In January 2016, the FASB issued new guidance on recognition and measurement of financial assets and financial liabilities. The new guidance will impact the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. All equity investments in unconsolidated entities (other than those accounted for under the equity method of accounting) will generally be measured at fair value with changes in fair value recognized through earnings. There will no longer be an available-for-sale classification (changes in fair value reported in other comprehensive income (loss) for equity securities with readily determinable fair values). In addition, the FASB clarified the need for a valuation allowance on deferred tax assets resulting from unrealized losses on available-for-sale debt securities. In general, the new guidance will require modified retrospective application to all outstanding instruments, with a cumulative effect adjustment recorded to opening retained earnings. The adoption of the new standard as of January 1, 2018 had no impact on our consolidated financial statements and related disclosure as we do not currently have any available-for-sale equity investments.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> </div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify; text-indent: 36pt;">Accounting Pronouncements Not Yet Adopted</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">In February 2016, FASB issued Accounting Standards Update (ASU) No. 2016-02, </font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; background-color: #ffffff;">Leases (Topic 842)</font><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"> (“ASU 2016-02”)</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; background-color: #ffffff;">. </font><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">Under the new guidance, lessees will be required to recognize the following for all leases (with the exception of short-term leases) at the lease commencement date: a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. Under the new guidance, lessor accounting is largely unchanged. Certain targeted improvements were made to align, where necessary, lessor accounting with the lessee accounting model and Topic 606, </font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; background-color: #ffffff;">Revenue from Contracts with Customers</font><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">. The new lease guidance simplified the accounting for sale and leaseback transactions primarily because lessees must recognize lease assets and lease liabilities. Lessees will no longer be provided with a source of off-balance sheet financing. Public business entities should apply the amendments in ASU 2016-02 for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years (i.e., January 1, 2019, for a calendar year entity). Early application is permitted.  Lessees (for capital and operating leases) and lessors (for sales-type, direct financing, and operating leases) must apply a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The modified retrospective approach would not require any transition accounting for leases that expired before the earliest comparative period presented. Lessees and lessors may not apply a full retrospective transition approach.</font> We are currently evaluating the expected impact that the standard could have on our consolidated financial statements and related disclosures.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">In June 2016, FASB issued ASU 2016-13, <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Financial Instruments - Credit Losses</font>. The amendment revises the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in more timely recognition of losses on financial instruments, including, but not limited to, available for sale debt securities and accounts receivable. The Company is required to adopt this standard starting in the first quarter of fiscal year 2021. Early adoption is permitted. We are currently evaluating the impact of the adoption of this standard on our consolidated financial statements and related disclosures.</div></div>

104315

232629

4824549

5010121

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">1. ORGANIZATION AND DESCRIPTION OF BUSINESS</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">We are a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. We currently have a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (<font style="font-size: 10pt; font-family: 'Times New Roman';">“</font>Endo Global Ventures<font style="font-size: 10pt; font-family: 'Times New Roman';">”</font>), an affiliate of Endo International plc (<font style="font-size: 10pt; font-family: 'Times New Roman';">“</font>Endo<font style="font-size: 10pt; font-family: 'Times New Roman';">”</font>), for injectable collagenase for marketed indications and indications in development. Endo assumed this agreement when Endo acquired Auxilium Pharmaceuticals, Inc. (<font style="font-size: 10pt; font-family: 'Times New Roman';">“</font>Auxilium<font style="font-size: 10pt; font-family: 'Times New Roman';">”</font>) on January 29, 2015 (the <font style="font-size: 10pt; font-family: 'Times New Roman';">“</font>Acquisition<font style="font-size: 10pt; font-family: 'Times New Roman';">”</font>). Injectable collagenase clostridium histolyticum is marketed as XIAFLEX<font style="font-size: 10pt; font-family: 'Times New Roman';">®</font> (or Xiapex<font style="font-size: 10pt; font-family: 'Times New Roman';">®</font> in Europe).</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">On February 1, 2016, we entered into with Endo the First Amendment (the <font style="font-size: 10pt; font-family: 'Times New Roman';">“</font>First Amendment<font style="font-size: 10pt; font-family: 'Times New Roman';">”</font>) to the Second Amended and Restated Development and Licensing Agreement (the <font style="font-size: 10pt; font-family: 'Times New Roman';">“</font>Auxilium Agreement<font style="font-size: 10pt; font-family: 'Times New Roman';">”</font>), by and between us and Auxilium, now a wholly-owned subsidiary of Endo, to amend certain provisions of the Auxilium Agreement (as amended by the First Amendment, the <font style="font-size: 10pt; font-family: 'Times New Roman';">“</font>License Agreement<font style="font-size: 10pt; font-family: 'Times New Roman';">”</font>). The effective date of the First Amendment was January 1, 2016. Pursuant to the First Amendment, we and Endo mutually agreed that in exchange for a $8.25 million lump sum payment, we will not receive future additional mark-up on cost of goods sold for sales by non-affiliated sublicensees of Endo outside of the U.S.; provided, however, that Endo will still be required to pay a mark-up on cost of goods sold for sales made in the <font style="font-size: 10pt; font-family: 'Times New Roman';">“</font>Endo Territory,<font style="font-size: 10pt; font-family: 'Times New Roman';">”</font> which includes sales made in the U.S. and sales made in any other country where Endo sells the product directly or through affiliated sublicensees. We received this $8.25 million lump sum payment in February 2016 and began recognizing this income over time based on sales by non-affiliated sublicensees of Endo outside of the U.S. according to our previous revenue recognition policy in the second quarter of 2016.</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Additionally, we agreed that Endo may opt-in early to indications, prior to our submission of a clinical trial report, with our consent, such consent not to be unreasonably withheld. For early opt-ins, Endo will be required to make an opt-in payment of $0.5 million on a per indication basis. For regular opt-ins, following our submission of a clinical trial report, Endo will be required to make an opt-in payment of $0.75 million on a per indication basis.</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The two marketed indications involving our injectable collagenase are Dupuytren<font style="font-size: 10pt; font-family: 'Times New Roman';">’</font>s contracture and Peyronie<font style="font-size: 10pt; font-family: 'Times New Roman';">’</font>s disease. Prior to the Acquisition, Auxilium had, and after the Acquisition, Endo has, opted-in to the following indications: frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis and human lipoma. Endo exercised, with our consent, an early opt-in for lateral hip fat and plantar fibromatosis in November 2015. Endo opted-in for human lipoma in July 2016. We manage the development of XIAFLEX for uterine fibroids and initiate the development of XIAFLEX in new potential indications, not licensed by Endo.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">On November 8, 2016, following a change in Endo management, Endo announced that a commercial review is ongoing of the XIAFLEX exercised but non-marketed indications, including frozen shoulder, cellulite, lateral hip fat, plantar fibromatosis and human lipoma, so that Endo can best prioritize its R&D efforts and determine clinical trial timelines moving forward.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Endo is currently selling XIAFLEX in the U.S. for the treatment of Dupuytren<font style="font-size: 10pt; font-family: 'Times New Roman';">’</font>s contracture and Peyronie<font style="font-size: 10pt; font-family: 'Times New Roman';">’</font>s disease and has an agreement with Swedish Orphan Biovitrum AB (<font style="font-size: 10pt; font-family: 'Times New Roman';">“</font>Sobi<font style="font-size: 10pt; font-family: 'Times New Roman';">”</font>), pursuant to which Sobi has marketing rights for Xiapex for Dupuytren<font style="font-size: 10pt; font-family: 'Times New Roman';">’</font>s contracture and Peyronie<font style="font-size: 10pt; font-family: 'Times New Roman';">’</font>s disease in Europe and certain Eurasian countries. Sobi is currently selling Xiapex in Europe and certain Eurasian countries for the treatment of Dupuytren<font style="font-size: 10pt; font-family: 'Times New Roman';">’</font>s contracture and Peyronie<font style="font-size: 10pt; font-family: 'Times New Roman';">’</font>s disease. In addition, Endo has an agreement with Asahi Kasei Pharma Corporation (<font style="font-size: 10pt; font-family: 'Times New Roman';">“</font>Asahi<font style="font-size: 10pt; font-family: 'Times New Roman';">”</font>) pursuant to which Asahi has the right to commercialize XIAFLEX for the treatment of Dupuytren<font style="font-size: 10pt; font-family: 'Times New Roman';">’</font>s contracture and Peyronie<font style="font-size: 10pt; font-family: 'Times New Roman';">’</font>s disease in Japan. Asahi is selling XIAFLEX for the treatment of Dupuytren<font style="font-size: 10pt; font-family: 'Times New Roman';">’</font>s contracture in Japan. <font style="font-size: 10pt; font-family: 'Times New Roman';">Endo is currently distributing XIAFLEX in Canada through Paladin Labs Inc, </font><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">an operating company of Endo</font><font style="font-size: 10pt; font-family: 'Times New Roman';">. In December 2016, Endo entered into a new out-licensing agreement with Actelion Pharmaceuticals Ltd. (“Actelion”), pursuant to which Actelion obtained marketing and commercial rights for XIAFLEX in Australia and New Zealand.</font></div></div>

14678

2562

86232

117635

221821

14318018

17304251

0.50

700000

580920

623503

8250000

20287000

18217000

132400

258250

132000

258000

P5Y

P10Y

195227

254781

41939115

56102054

10300000

46440716

9661338

7400000

-2900000

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">Deferred Revenue</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; background-color: #ffffff;">Deferred revenue consists of approximately $35,000 related to nonrefundable upfront product license fees for product candidates for which we are providing continuing services related to product development and $100,000 related to a milestone payment withheld by Endo due to a foreign tax withholding which remains uncollected. Currently, the Company expects to recover the full amount. With the adoption of ASC 606 using the modified retrospective adoption method as of January 1, 2018, the remaining deferred revenue balance associated with the mark-up on cost of goods sold for sales by non-affiliated sublicensees of Endo outside of the U.S. as of December 31, 2017 of $6.3 million <font style="font-size: 10pt; font-family: 'Times New Roman';">was recorded as an adjustment to our retained earnings.</font> As of March 31, 2018 and December 31, 2017, deferred revenue was $135,000 and $6.4 million, respectively. <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(</font>For more a more detailed discussion regarding ASC 606 see <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Note 2</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> - RECENT ACCOUNTING PRONOUNCEMENTS</font> - <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Accounting Pronouncements Adopted.</font></div></div>

7690619

7089409

7686210

7085000

4409

-646566

7731566

7089409

7690619

500000

P6Y3M

P2Y0M14D

4873810

P3Y3M14D

P2Y6M7D

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div>The estimated aggregate amortization expense for the remaining nine months of 2018 and each of the years below is approximately as follows:</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 50%; margin-left: 36pt;"><tr><td valign="bottom" style="width: 38%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">April 1, 2018 - December 31, 2018</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">51,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 38%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">2019</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">66,200</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 38%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">2020</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">50,400</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 38%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">2021</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">34,500</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 38%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">2022</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">34,500</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 38%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Thereafter</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">189,185</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr></table></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">A summary of our stock option activity during the three months ended March 31, 2018 is presented below:</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> </div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 95%;"><tr><td valign="bottom" style="width: 47%; vertical-align: middle; padding-bottom: 2px;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Shares</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Weighted</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Average</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Exercise</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Price</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Weighted</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Average</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Remaining</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Contractual</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Term</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Aggregate</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Intrinsic</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Value</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 47%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Outstanding at December 31, 2017</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">232,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">21.56</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2.52</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,050,990</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 47%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Grants</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">30,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">41.82</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 47%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Exercised</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(10,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">13.24</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 47%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Forfeitures or expirations</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 47%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Outstanding at March 31, 2018</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">252,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">24.30</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">3.29</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">5,049,910</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 47%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Exercisable at March 31, 2018</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">207,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">20.80</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">2.04</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">4,873,810</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr></table></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div>For each period presented below, net patent costs consisted of:</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 60%;"><tr><td valign="bottom" style="width: 36%; vertical-align: top; padding-bottom: 2px;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31,</div>2018</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">December 31,</div>2017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 36%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Patents</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">969,614</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">925,016</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 36%; vertical-align: top; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Accumulated amortization</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(543,829</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(527,023</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 36%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">425,785</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">397,993</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td></tr></table></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Accounts payable and accrued expenses consisted of the following:</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 80%;"><tr><td valign="bottom" style="width: 56%; vertical-align: top; padding-bottom: 2px;">  </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">  </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31,</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2018</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;">  </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid;">  </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">December 31,</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">  </td></tr><tr><td valign="bottom" style="width: 56%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Trade accounts payable</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">215,639</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">152,542</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 56%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Accrued legal and other professional fees</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">194,565</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">150,691</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 56%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Accrued payroll and related costs</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">204,311</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">215,322</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 56%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Third party royalties</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,049,013</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">329,211</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 56%; vertical-align: top; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Other accruals</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">117,635</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">86,232</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 56%; vertical-align: top; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">1,781,163</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">933,998</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td></tr></table></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The following table summarizes the number of common equivalent shares that were excluded for the calculation of diluted net income per share reported in the condensed<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> </font>consolidated statement of operations.</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 40%;"><tr><td valign="bottom" style="width: 16%; vertical-align: bottom; padding-bottom: 2px;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="6" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Three Months Ended</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31,</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 16%; vertical-align: bottom; padding-bottom: 2px;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2018</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 16%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Stock options</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">20,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr></table></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company recorded the following cumulative effect as of January 1, 2018, itemized here (in millions):</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">As reported</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">December 31, 2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Adjustments</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Adjusted</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">January 1, 2018</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Accounts receivable</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">4.7</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7.6</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup> </div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">12.3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: middle; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Deferred revenue</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(6.4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6.3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(2)</sup> </div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.1</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Deferred royalty buy-down</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(2.5</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(3)</sup></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(2.9</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: middle; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Accounts payable and accrued expenses<font style="font-size: 10pt; font-family: 'Times New Roman';"> -third party royalties</font></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.5</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(3)</sup></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.9</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Deferred tax assets, net</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1.7</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1.3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(4)</sup></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">0.4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: middle; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Income tax payable</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1.4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(5)</sup></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1.4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: middle; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: middle; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Retained earnings adjustment</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(2.9</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">10.3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7.4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr></table></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"> </div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">(1)</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">This adjustment represents the elimination of the one quarter lag by recognizing royalty revenues based on of XIALFLEX net sales and mark-up on cost of goods sold revenues reported to us by Endo for the fourth quarter of 2017.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">(2)</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';">Represents </font>the remaining deferred revenue balance <font style="font-size: 10pt; font-family: 'Times New Roman';">of the prepaid mark-up on cost of goods sold</font> based on sales by non-affiliated sublicensees of Endo outside of the U.S.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">(3)</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">Represents the amortization of the royalty buy-down and third party royalties expense associated royalty revenues based on XIALFLEX net sales reported to us by Endo for the fourth quarter of 2017.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">(4)</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';">To reverse a deferred tax asset associated with the </font>deferred revenue balance <font style="font-size: 10pt; font-family: 'Times New Roman';">of the prepaid mark-up on cost of goods sold</font> by non-affiliated sublicensees of Endo outside of the U.S.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">(5)</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">To create a tax liability associated the elimination of the one quarter lag by recognizing royalty revenues based on of XIALFLEX net sales and mark-up on cost of goods sold revenues reported to us by Endo for the fourth quarter of 2017.</div></td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">In accordance with the new revenue standard requirements, the impact of adoption on our condensed consolidated balance sheet was as follows:</font></div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="10" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31, 2018</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">As Reported</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Balances Without Adoption of New Revenue Standard</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Effect of Change</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Higher / (Lower)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Assets</div></td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Accounts receivable</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">19,165,670</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">12,120,670</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,045,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Deferred royalty buy-down</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,648,319</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,014,598</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(366,279</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Deferred tax assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">403,944</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,696,932</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,292,988</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Liabilities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Accounts payable and accrued expenses</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,781,163</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,271,163</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">510,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Deferred revenue</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">117,635</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,023,854</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(906,219</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Income tax payable</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,535,676</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,288,977</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,246,699</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Deferred revenue, long term</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">17,635</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,173,564</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(5,155,930</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Equity</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Retained earnings</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">56,102,054</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">46,440,716</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">9,661,338</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr></table><div style="background-color: #ffffff;"> </div><div style="background-color: #ffffff;"><br />  </div></div><div style="background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">In accordance with the new revenue standard requirements, the impact of adoption on our condensed consolidated statement of operations was as follows:</font></div><div><br /></div></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"> </div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="10" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Three Months Ended March 31, 2018</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"> </div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">As Reported</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Balances Without Adoption of New Revenue Standard</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Effect of Change</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Higher / (Lower)</div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Revenues</div></td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Royalties</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,085,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,731,566</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(646,566</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Costs and expenses</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">General and administrative</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,069,633</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,087,921</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(17,418</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Provision for income taxes</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,078,574</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,220,244</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(141,670</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net income</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,978,604</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">4,500,918</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(522,314</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr></table></div>

44.34

13.24

33476

32512

41.82

30000

207000

0.3960

0.0262

20.80

5050990

5049910

21.56

24.30

29.21

20000

232000

252000

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">Stock-Based Compensation</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The Company has one stock-based compensation plan in effect. Accounting Standards Codification 718, <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Compensation - Stock Compensation </font>(“ASC 718”), requires the recognition of compensation expense, using a fair-value based method, for costs related to all stock options including stock options and common stock issued to our employees and directors under our stock plans. ASC 718 requires companies to estimate the fair value of stock option awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service periods in our condensed<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> </font>consolidated statements of operations.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> </div><div style="background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Under ASC 718, we estimate the fair value of our employee stock option awards at the date of grant using the Black-Scholes option-pricing model, which requires the use of certain subjective assumptions. The most significant of these assumptions are our estimates of the expected volatility of the market price of our stock and the expected term of an award. When establishing an estimate of the expected term of an option award, we consider the vesting period for the award, our recent historical experience of employee stock option exercises (including forfeitures) and the expected volatility of our common stock.  As required under the accounting rules, we review our estimates at each grant date and, as a result, the valuation assumptions that we use to value employee stock-based awards granted in future periods may change. On March 15, 2018, we granted a total of 30,000 stock options to two members of our Board of Directors, valued at approximately $540,000. We used the Black-Scholes valuation model to estimate the value of options using 39.6% volatility, a risk free rate of 2.62% and an expected term of 6.25 years.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Further, ASC 718 requires that employee stock-based compensation costs be recognized over the requisite service period, or the vesting period, in a manner similar to all other forms of compensation paid to employees. The allocation of employee stock-based compensation costs to each operating expense line are estimated based on specific employee headcount information at each grant date and estimated stock option forfeiture rates and revised, if necessary, in future periods if actual employee headcount information or forfeitures differ materially from those estimates. As a result, the amount of employee stock-based compensation costs we recognize in each operating expense category in future periods may differ significantly from what we have recorded in the current period.</div></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Stock-based compensation expense recognized in general and administrative expenses was approximately $33,000 for each three month period ended March 31, 2018 and 2017.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify;">Stock Option Activity</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">A summary of our stock option activity during the three months ended March 31, 2018 is presented below:</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> </div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 95%;"><tr><td valign="bottom" style="width: 47%; vertical-align: middle; padding-bottom: 2px;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Shares</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Weighted</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Average</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Exercise</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Price</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Weighted</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Average</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Remaining</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Contractual</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Term</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Aggregate</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Intrinsic</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Value</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 47%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Outstanding at December 31, 2017</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">232,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">21.56</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2.52</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,050,990</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 47%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Grants</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">30,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">41.82</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 47%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Exercised</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(10,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">13.24</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 47%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Forfeitures or expirations</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 47%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Outstanding at March 31, 2018</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">252,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">24.30</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">3.29</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">5,049,910</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 47%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Exercisable at March 31, 2018</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">207,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">20.80</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">2.04</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">4,873,810</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">During the three months ended March 31, 2018 and 2017, the Company received approximately $132,000 and $258,000, respectively, from stock options exercised by option holders.</div><div style="text-align: left;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Aggregate intrinsic value represents the total pre-tax intrinsic value based on the closing price of our common stock of $44.34 on March 29, 2018, which would have been received by the option holders had all option holders exercised their options as of that date. We have approximately $648,000 in unrecognized compensation cost related to stock options outstanding as of March 31, 2018, which we expect to recognize over the next 3.45 years.</div></div>

51973971

48751206

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Except as detailed below, there have been no material changes to the Company’s significant accounting policies during the three months ended March 31, 2018, as compared to the significant accounting policies disclosed in Note 2 of the Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">Basis of Presentation</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The accompanying condensed consolidated financial statements are unaudited, but include all adjustments (consisting only of normal, recurring adjustments) which we consider necessary for a fair presentation of our financial position at such dates and the operating results and cash flows for those periods. Although we believe that the disclosures in our financial statements are adequate to make the information presented not misleading, certain information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) has been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for quarterly reporting.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The information included in this Report should be read in conjunction with the risk factors discussed in “Part I, Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC on March 14, 2018.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">Principles of Consolidation</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The condensed<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> </font>consolidated financial statements include the accounts of the Company and its subsidiary, Advance Biofactures Corp. All intercompany balances and transactions have been eliminated.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">Critical Accounting Policies, Estimates and Assumptions</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The preparation of condensed<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> </font>consolidated financial statements in conformity with U.S. GAAP requires the use of management’s estimates and assumptions that affect the amounts reported in the condensed<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> </font>consolidated financial statements and accompanying notes. The Company makes certain assumptions and estimates for its revenues, deferred tax assets, third party royalties and deferred royalty buy-down. <font style="font-size: 10pt; font-family: 'Times New Roman';">We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions. </font>For further details, see notes “Revenue Recognition”, “Provision for Income Taxes” and “Third-Party Royalties and Royalty Buy-Down.” Actual results may differ from those estimates.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">Revenue Recognition</div><div style="background-color: #ffffff;"><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Beginning in 2014, Financial Accounting Standards Board (“FASB”) issued several Accounting Standards Updates establishing ASC Topic 606, “Revenue from Contracts with Customers” (“ASC 606”).  ASC 606 requires retrospective implementation, and replaces most industry-specific revenue recognition guidance in U.S. GAAP with a new principles-based, five-step revenue recognition model.  The Company adopted ASC 606 effective January 1, 2018. Under ASC 606, we recognize revenues when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation(s).</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Revenues, and their respective treatment for financial reporting purposes under ASC 606 and our license agreement with Endo, are as follows:</div><div style="text-align: justify;"><br /></div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify; background-color: #ffffff; text-indent: 36pt;">Royalty / Mark-Up on Cost of Goods Sold</div><div style="background-color: #ffffff;"><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">We receive royalty revenues on net sales and mark-up on cost of goods sold revenue in the U.S. under our License Agreement with Endo. These are presented in “Royalties” in our condensed consolidated statements of income.  We do not have future performance obligations under this revenue stream. In accordance with ASC 606, we record these revenues based on estimates of the net sales that occurred during the relevant period, thereby eliminating the one quarter lag convention in previous periods. The relevant period estimates of these royalties are based on interim data provided by Endo and analysis of historical royalties and mark-up on cost of goods sold revenue that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. The royalties payable by Endo to us are subject to set-off for certain patent costs.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> </div></div><div style="background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify; margin-left: 36pt;">Licensing Revenue</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">We include revenue recognized from upfront licensing, sublicensing and milestone payments in “License Revenues” in our condensed consolidated statements of income.</div></div><div style="text-align: left; background-color: #ffffff;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; background-color: #ffffff;">The Company recognizes licensing revenues generated through development and/or commercialization agreements. The terms of these agreements typically include payment to the Company of one or more of the following: nonrefundable, upfront license fees; sublicensing; development and commercial milestone payments; development activities; and royalties on net sales of licensed products. Each of these types of payments results in licensing revenues except for revenues from royalties on net sales of licensed products and the mark-up of cost of goods sold revenues which are classified as royalty revenues. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the customer.</div><div style="text-align: left; background-color: #ffffff; text-indent: 18pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; background-color: #ffffff;">For each development and/or commercialization agreement that result in revenues, the Company identifies all material performance obligations, which may include a license to intellectual property and know-how, development activities and/or transition activities. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company’s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required.</div><div style="text-align: left; background-color: #ffffff;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; background-color: #ffffff;">If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, upfront license fees based on the relative standalone selling price prescribed to the license compared to the total value of the arrangement. The revenue is recognized when the license is transferred to the collaborator and the collaborator is able to use and benefit from the license.  For licenses that are not distinct from other obligations identified in the arrangement, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the combined performance obligation is satisfied over time, the Company applies an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees.  The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</div><div style="text-align: left; background-color: #ffffff; text-indent: 18pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left; background-color: #ffffff; text-indent: 36pt;">Development and Regulatory Milestone Payments</div><div style="text-align: left; background-color: #ffffff;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; background-color: #ffffff;">Depending on facts and circumstances, the Company may conclude that it is appropriate to include the milestone, representing variable consideration, in the estimated total transaction price, or that it is appropriate to fully constrain the milestone. The Company may include revenues from certain milestones in the total transaction price in a reporting period before the milestone is achieved if the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods. The Company records a corresponding contract asset when this conclusion is reached. Milestone payments that have not been included in the transaction price to date are fully constrained. The Company re-evaluates the probability of achievement of such development milestones and any related constraint each reporting period. The Company adjusts its estimate of the total transaction price, including the amount of revenue that it has recorded, if necessary.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; background-color: #ffffff;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify; background-color: #ffffff;">Recent Accounting Prnouncements</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify; text-indent: 36pt;">Accounting Pronouncements Adopted</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify; text-indent: 36pt;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Effective January 1, 2018, the Company adopted ASC 606, which provides principles for recognizing revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The Company adopted ASC 606 on a modified retrospective basis through a cumulative adjustment to equity. See Note 2 –<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> Significant Accounting Policies</font> – <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Revenue Recognition.</font></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">The adoption of ASC 606 as of January 1, 2018, applying the modified-retrospective method, changed the timing of our recognition of </font>royalty and mark-up cost of goods sold revenue. <font style="font-size: 10pt; font-family: 'Times New Roman';">Beginning in 2018, we recorded these royalty revenues based on estimates of the net sales and mark-up cost of goods sold that occurred during the relevant period thereby eliminating the one quarter lag. </font>Previously, these amounts were not recognized until they were fixed and determinable. In addition, deferred revenue associated with the prepayment of foreign mark-up on cost of goods sold<font style="font-size: 10pt; font-family: 'Times New Roman';"> revenue will no longer be r</font>ecognized over time based on sales by non-affiliated sublicensees of Endo outside of the U.S. and, under ASC 606, <font style="font-size: 10pt; font-family: 'Times New Roman';">would have been recognized when the transaction occurred in 2016.</font></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The cumulative effect of applying the new guidance of ASC 606 to our License Agreement with Endo as of January 1, 2018 was recorded as an adjustment to retained earnings as of the adoption date. As a result of applying the modified retrospective method to adopt the new revenue guidance, the following adjustments were made to accounts on the Condensed Consolidated Balance Sheet as of January 1, 2018:</div><div style="background-color: #ffffff;"><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company recorded the following cumulative effect as of January 1, 2018, itemized here (in millions):</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">As reported</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">December 31, 2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Adjustments</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: middle; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Adjusted</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">January 1, 2018</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Accounts receivable</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">4.7</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7.6</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup> </div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">12.3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: middle; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Deferred revenue</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(6.4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6.3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(2)</sup> </div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.1</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Deferred royalty buy-down</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(2.5</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(3)</sup></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(2.9</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: middle; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Accounts payable and accrued expenses<font style="font-size: 10pt; font-family: 'Times New Roman';"> -third party royalties</font></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.5</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(3)</sup></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.9</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Deferred tax assets, net</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1.7</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1.3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(4)</sup></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">0.4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: middle; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Income tax payable</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1.4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(5)</sup></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1.4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: middle; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: middle; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Retained earnings adjustment</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(2.9</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">10.3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7.4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr></table></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"> </div></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">(1)</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">This adjustment represents the elimination of the one quarter lag by recognizing royalty revenues based on of XIALFLEX net sales and mark-up on cost of goods sold revenues reported to us by Endo for the fourth quarter of 2017.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">(2)</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';">Represents </font>the remaining deferred revenue balance <font style="font-size: 10pt; font-family: 'Times New Roman';">of the prepaid mark-up on cost of goods sold</font> based on sales by non-affiliated sublicensees of Endo outside of the U.S.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">(3)</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">Represents the amortization of the royalty buy-down and third party royalties expense associated royalty revenues based on XIALFLEX net sales reported to us by Endo for the fourth quarter of 2017.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">(4)</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';">To reverse a deferred tax asset associated with the </font>deferred revenue balance <font style="font-size: 10pt; font-family: 'Times New Roman';">of the prepaid mark-up on cost of goods sold</font> by non-affiliated sublicensees of Endo outside of the U.S.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">(5)</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">To create a tax liability associated the elimination of the one quarter lag by recognizing royalty revenues based on of XIALFLEX net sales and mark-up on cost of goods sold revenues reported to us by Endo for the fourth quarter of 2017.</div></td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">At March 31, 2018, contract assets of $7.0 million for which there’s an unconditional right to receive payment was included in accounts receivable on the condensed consolidated balance sheet.</div><div> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">In accordance with the new revenue standard requirements, the impact of adoption on our condensed consolidated balance sheet was as follows:</font></div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="10" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31, 2018</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">As Reported</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Balances Without Adoption of New Revenue Standard</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Effect of Change</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Higher / (Lower)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Assets</div></td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Accounts receivable</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">19,165,670</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">12,120,670</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,045,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Deferred royalty buy-down</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,648,319</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,014,598</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(366,279</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Deferred tax assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">403,944</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,696,932</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,292,988</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Liabilities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Accounts payable and accrued expenses</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,781,163</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,271,163</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">510,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Deferred revenue</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">117,635</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,023,854</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(906,219</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Income tax payable</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,535,676</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,288,977</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,246,699</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Deferred revenue, long term</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">17,635</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,173,564</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(5,155,930</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Equity</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Retained earnings</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">56,102,054</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">46,440,716</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">9,661,338</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr></table><div style="background-color: #ffffff;"> </div><div style="background-color: #ffffff;"><br />  </div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: normal; text-align: left;"><div style="background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">In accordance with the new revenue standard requirements, the impact of adoption on our condensed consolidated statement of operations was as follows:</font></div><div><br /></div></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"> </div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="10" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Three Months Ended March 31, 2018</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"> </div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">As Reported</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Balances Without Adoption of New Revenue Standard</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Effect of Change</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Higher / (Lower)</div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Revenues</div></td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Royalties</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,085,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,731,566</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(646,566</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Costs and expenses</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">General and administrative</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,069,633</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,087,921</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(17,418</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Provision for income taxes</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,078,574</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,220,244</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(141,670</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net income</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,978,604</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">4,500,918</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(522,314</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr></table><div style="background-color: #ffffff;"> </div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: normal; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">In January 2016, the FASB issued new guidance on recognition and measurement of financial assets and financial liabilities. The new guidance will impact the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. All equity investments in unconsolidated entities (other than those accounted for under the equity method of accounting) will generally be measured at fair value with changes in fair value recognized through earnings. There will no longer be an available-for-sale classification (changes in fair value reported in other comprehensive income (loss) for equity securities with readily determinable fair values). In addition, the FASB clarified the need for a valuation allowance on deferred tax assets resulting from unrealized losses on available-for-sale debt securities. In general, the new guidance will require modified retrospective application to all outstanding instruments, with a cumulative effect adjustment recorded to opening retained earnings. The adoption of the new standard as of January 1, 2018 had no impact on our consolidated financial statements and related disclosure as we do not currently have any available-for-sale equity investments.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> </div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify; text-indent: 36pt;">Accounting Pronouncements Not Yet Adopted</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">In February 2016, FASB issued Accounting Standards Update (ASU) No. 2016-02, </font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; background-color: #ffffff;">Leases (Topic 842)</font><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"> (“ASU 2016-02”)</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; background-color: #ffffff;">. </font><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">Under the new guidance, lessees will be required to recognize the following for all leases (with the exception of short-term leases) at the lease commencement date: a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. Under the new guidance, lessor accounting is largely unchanged. Certain targeted improvements were made to align, where necessary, lessor accounting with the lessee accounting model and Topic 606, </font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; background-color: #ffffff;">Revenue from Contracts with Customers</font><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">. The new lease guidance simplified the accounting for sale and leaseback transactions primarily because lessees must recognize lease assets and lease liabilities. Lessees will no longer be provided with a source of off-balance sheet financing. Public business entities should apply the amendments in ASU 2016-02 for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years (i.e., January 1, 2019, for a calendar year entity). Early application is permitted.  Lessees (for capital and operating leases) and lessors (for sales-type, direct financing, and operating leases) must apply a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The modified retrospective approach would not require any transition accounting for leases that expired before the earliest comparative period presented. Lessees and lessors may not apply a full retrospective transition approach.</font> We are currently evaluating the expected impact that the standard could have on our consolidated financial statements and related disclosures.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">In June 2016, FASB issued ASU 2016-13, <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Financial Instruments - Credit Losses</font>. The amendment revises the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in more timely recognition of losses on financial instruments, including, but not limited to, available for sale debt securities and accounts receivable. The Company is required to adopt this standard starting in the first quarter of fiscal year 2021. Early adoption is permitted. We are currently evaluating the impact of the adoption of this standard on our consolidated financial statements and related disclosures.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">Cash, Cash Equivalents and Investments</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Cash equivalents include only securities having a maturity of 90 days or less at the time of purchase.  Investments are stated on an amortized cost basis. The Company limits its credit risk associated with cash, cash equivalents and investments by placing its investments with banks it believes are highly creditworthy and with highly rated money market funds, certificates of deposit, municipal bonds and corporate bonds. All investments are classified as held to maturity. As of March 31, 2018 and December 31, 2017, the amortized cost of these investments was $51.6 million and $57.7 million, respectively. No unrealized gains or losses were recorded in either period.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Fair Value Measurements</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Management believes that the carrying amounts of the Company’s financial instruments, including cash, cash equivalents, held to maturity investments, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term nature of those instruments. As of March 31, 2018 and December 31, 2017, there were no recorded unrealized gains or losses on our investments as they are held to maturity. <font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">As of March 31, 2018 and December 31, 2017, amortized cost basis of the investments approximated their fair value.</font> At March 31, 2018 and December 31, 2017, the amortized premium included in interest income was $160,000 and $673,000, respectively.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The following table presents the Company’s schedule of maturities at March 31, 2018 and December 31, 2017:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 90%;"><tr><td valign="bottom" style="width: 42%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td colspan="6" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Maturities as of</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31, 2018</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td colspan="6" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Maturities as of</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">December 31, 2017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 42%; vertical-align: bottom; padding-bottom: 2px;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">1 Year or</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Less</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Greater than 1</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Year</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">1 Year or</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Less</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Greater than</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">1 Year</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 42%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Municipal bonds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,425,134</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">100,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,002,650</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">100,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 42%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Corporate bonds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">41,828,133</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">500,230</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">48,143,495</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,155,573</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 42%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Certificates of deposit</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,497,939</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,239,961</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,827,826</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,490,401</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 42%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">48,751,206</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">2,840,191</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">51,973,971</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">5,745,974</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td></tr></table><div> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The authoritative literature for fair value measurements established a three-tier fair value hierarchy, which prioritizes the inputs in measuring fair value. These tiers are as follows: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than the quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as significant unobservable inputs (entity developed assumptions) in which little or no market data exists.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">As of March 31, 2018, the Company held certain investments that are required to be measured at fair value on a recurring basis. The following tables present the Company’s fair value hierarchy for these financial assets as of March 31, 2018 and December 31, 2017:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 90%;"><tr><td valign="bottom" style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; width: 21%; vertical-align: top; font-weight: bold; padding-bottom: 2px; font-style: normal;"><div style="text-align: left;"><u>March 31, 2018</u></div></td><td valign="bottom" style="width: 1%; vertical-align: top; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; width: 20%; vertical-align: top; font-weight: bold; padding-bottom: 2px; font-style: normal;"><div style="text-align: left;"><u>Type of Instrument</u></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Fair Value</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Level 1</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Level 2</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Level 3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: top;"> </td><td valign="bottom" style="width: 1%; vertical-align: top;"> </td><td valign="bottom" style="width: 20%; vertical-align: top;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Cash equivalents</div></td><td valign="bottom" style="width: 1%; vertical-align: top; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Institutional Money Market</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,432,432</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,432,432</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Cash equivalents</div></td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Certificates of Deposit</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">250,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">250,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Cash equivalents</div></td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Corporate Bonds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,585,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,585,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: top; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: top; background-color: #ffffff;"> </td><td valign="bottom" style="width: 20%; vertical-align: top; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Investments</div></td><td valign="bottom" style="width: 1%; vertical-align: top; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Municipal Bonds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,525,134</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,525,134</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: top; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: top; background-color: #ffffff;"> </td><td valign="bottom" style="width: 20%; vertical-align: top; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Investments</div></td><td valign="bottom" style="width: 1%; vertical-align: top; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Corporate Bonds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">42,328,363</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">42,328,363</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: top; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: top; background-color: #ffffff;"> </td><td valign="bottom" style="width: 20%; vertical-align: top; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Investments</div></td><td valign="bottom" style="width: 1%; vertical-align: top; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Certificates of Deposit</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,737,900</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,737,900</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr></table><div> </div><table align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 90%;"><tr><td valign="bottom" style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; width: 21%; vertical-align: top; font-weight: bold; padding-bottom: 2px; font-style: normal;"><div style="text-align: left;"><u>December 31, 2017</u></div></td><td valign="bottom" style="width: 1%; vertical-align: top; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; width: 20%; vertical-align: top; font-weight: bold; padding-bottom: 2px; font-style: normal;"><div style="text-align: left;"><u>Type of Instrument</u></div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Fair Value</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Level 1</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Level 2</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Level 3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle;"> </td><td valign="bottom" style="width: 1%; vertical-align: middle;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Cash equivalents</div></td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Institutional Money Market</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,108,549</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,108,549</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Cash equivalents</div></td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Municipal Bonds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">800,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">800,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Investments</div></td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Municipal Bonds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,102,650</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,102,650</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Investments</div></td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Corporate Bonds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">51,299,068</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">51,299,068</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 21%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Investments</div></td><td valign="bottom" style="width: 1%; vertical-align: middle; background-color: #cceeff;"> </td><td valign="bottom" style="width: 20%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Certificates of Deposit</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,318,227</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,318,227</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">Concentration of Credit Risk and Major Customers</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The Company maintains bank account balances, which, at times, may exceed insured limits. The Company has not experienced any losses with these accounts and believes that it is not exposed to any significant credit risk on cash.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The Company maintains investments in FDIC insured certificates of deposits, municipal bonds and corporate bonds.</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The Company is currently dependent on one customer, Endo, who generates almost all its revenues. For the periods ended March 31, 2018 and 2017, the licensing, sublicensing, milestones, royalty and mark-up on cost of goods sold revenues under the License Agreement with Endo were approximately $7.1 and $7.7 million, respectively.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">At March 31, 2018 and December 31, 2017, our accounts receivable balances from Endo were $19.2 million and $4.7 million, respectively.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">Treasury Stock</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The Company accounts for treasury stock under the cost method and includes treasury stock as a component of stockholders’ equity. For the three months ended <font style="font-size: 10pt; font-family: 'Times New Roman';">March 31, 2018</font>, there were no shares repurchased as compared to the repurchase of 4,260 shares at an average price of $52.07 in the corresponding 2017 period.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">Receivables and Doubtful Accounts</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; background-color: #ffffff;">Trade accounts receivable are stated at the amount the Company expects to collect. We may maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. We consider the following factors when determining the collectability of specific customer accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms.  Our accounts receivable balance is typically due from Endo, our one large specialty pharmaceutical customer.  Endo has historically paid timely and has been a financially stable organization.  Due to the nature of the accounts receivable balance, we believe the risk of doubtful accounts is minimal.  If the financial condition of our customer were to deteriorate, adversely affecting its ability to make payments, additional allowances would be required.  We may provide for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. Balances that remain outstanding after we have used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable.<font style="font-size: 10pt; font-family: 'Times New Roman';"> </font>At <font style="font-size: 10pt; font-family: 'Times New Roman';">March 31, 2018</font> and December 31, 2017 our accounts receivable balance was $19.2 million and $4.7 million, respectively, and was from one customer, Endo. With the adoption of ASC 606 as of January 1, 2018, <font style="font-size: 10pt; font-family: 'Times New Roman';">using the modified-retrospective adoption method</font>, <font style="font-size: 10pt; font-family: 'Times New Roman';">we recorded an adjustment to our accounts receivable balance of $7.6 million related to royalties associated with the net sales of XIAFLEX that occurred during the fourth quarter of 2017 thereby eliminating the one quarter lag</font>.<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> (</font>For more a more detailed discussion regarding ASC 606 see <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Note 2</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> - RECENT ACCOUNTING PRONOUNCEMENTS</font> - <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Accounting Pronouncements Adopted.</font></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">Deferred Revenue</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; background-color: #ffffff;">Deferred revenue consists of approximately $35,000 related to nonrefundable upfront product license fees for product candidates for which we are providing continuing services related to product development and $100,000 related to a milestone payment withheld by Endo due to a foreign tax withholding which remains uncollected. Currently, the Company expects to recover the full amount. With the adoption of ASC 606 using the modified retrospective adoption method as of January 1, 2018, the remaining deferred revenue balance associated with the mark-up on cost of goods sold for sales by non-affiliated sublicensees of Endo outside of the U.S. as of December 31, 2017 of $6.3 million <font style="font-size: 10pt; font-family: 'Times New Roman';">was recorded as an adjustment to our retained earnings.</font> As of March 31, 2018 and December 31, 2017, deferred revenue was $135,000 and $6.4 million, respectively. <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(</font>For more a more detailed discussion regarding ASC 606 see <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Note 2</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> - RECENT ACCOUNTING PRONOUNCEMENTS</font> - <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Accounting Pronouncements Adopted.</font></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">Reimbursable Third-Party Patent Costs</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">We accrue patent costs that are reimbursable to Endo by us under the License Agreement. We capitalize certain patent costs related to patent prosecution and maintenance and expense others. As of March 31, 2018<font style="font-size: 10pt; font-family: 'Times New Roman';"> and December 31, 2017,</font> our net reimbursable third party patent expense was $134,000 and zero, respectively.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">Third-Party Royalties</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; background-color: #ffffff;">We have entered into licensing and royalty agreements with third parties and agreed to pay certain royalties on net sales of products for specific indications. The royalty rates differ from agreement to agreement and, in certain cases, have been redacted with the permission of the SEC.  No assumptions should be made that any disclosed royalty rate payable to a particular third party is the same or similar with respect to any royalty rate payable to any other third parties. We accrue third-party royalty expenses on net sales reported to us by Endo. Third-party royalty costs are generally expensed under general and administrative in the quarter that the net sales have occurred. For the three month periods ended March 31, 2018 and 2017, third-party royalty expenses were $0.5 million in each period. With the adoption of ASC 606 as of January 1, 2018 <font style="font-size: 10pt; font-family: 'Times New Roman';">using the modified-retrospective adoption method</font>, <font style="font-size: 10pt; font-family: 'Times New Roman';">we recorded an adjustment to our retained earnings for third party royalties expense of $0.5 million associated with the net sales of XIAFLEX that occurred during the fourth quarter of 2017 thereby eliminating the one quarter lag</font>. Our third-party royalty expense under general and administrative expenses may increase if net sales by Endo and its partners for XIAFLEX and Xiapex increase and potential new indications for XIAFLEX and Xiapex are approved, marketed and sold.<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> (</font>For more a more detailed discussion regarding ASC 606 see <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Note 2</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> - RECENT ACCOUNTING PRONOUNCEMENTS</font> - <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Accounting Pronouncements Adopted.</font></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; background-color: #ffffff;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify; background-color: #ffffff;">Royalty Buy-Down</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; background-color: #ffffff;">On March 31, 2012, we entered into an amendment to our existing agreement with Dr. Martin K. Gelbard, dated August 27, 2008, related to our future royalty obligations in connection with Peyronie’s disease. The amendment enables us to buy down a portion of our future royalty obligations in exchange for an initial cash payment of $1.5 million and five additional cash payments of $600,000, all of which have been paid as of March 31, 2018.  Royalty obligations terminate five years after first commercial sale which occurred in January 2014. The Company amortizes long-term contracts with finite lives in a manner that reflects the pattern in which the economic benefits of the assets are consumed or otherwise used up. Dr. Gelbard’s agreement is amortized based on an income forecast method by estimating sales of XIAFLEX and Xiapex for Peyronie’s disease on an annual basis as measured by the proportion of the total estimated sales over the five year period. For the three months ended March 31, 2018 and 2017, we amortized approximately $0.5 million and $0.4 million related to this agreement, respectively. With the adoption of ASC 606 as of January 1, 2018 <font style="font-size: 10pt; font-family: 'Times New Roman';">using the modified-retrospective adoption method</font>, <font style="font-size: 10pt; font-family: 'Times New Roman';">we recorded an adjustment to our capitalized balance of $0.4 million related to royalties associated with the net sales of XIAFLEX that occurred during the fourth quarter of 2017 thereby eliminating the one quarter lag</font>. As of March 31, 2018 and December 31, 2017, the remaining capitalized balances were approximately $1.6 million and $2.5 million, respectively. We perform an evaluation of the recoverability of the carrying value to determine if facts and circumstances indicate that the carrying value of the assets may be impaired and if any adjustment is warranted.  As of March 31, 2018, there was no indicator that an impairment existed. <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(</font>For more a more detailed discussion regarding ASC 606 see <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Note 2</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> - RECENT ACCOUNTING PRONOUNCEMENTS</font> - <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Accounting Pronouncements Adopted.</font></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">Research and Development Expenses</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">R&D expenses </font>include, but are not limited to, internal costs, such as salaries and benefits, costs of materials, lab expense, facility costs and overhead. R&D expenses also consist of third party costs, such as medical professional fees, product costs used in clinical trials, consulting fees and costs associated with clinical study arrangements. We may fund R&D at medical research institutions under agreements that are generally cancelable. All of these costs are charged to R&D as incurred, which may be measured by percentage of completion, contract milestones, patient enrollment, or the passage of time.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Clinical Trial Expenses</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Our cost accruals for clinical trials are based on estimates of the services received and efforts expended pursuant to contracts with various clinical trial centers and clinical research consultants. In the normal course of business, we contract with third parties to perform various clinical trial activities in the ongoing development of potential drugs. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events, the successful enrollment of patients, the completion of portions of the clinical trial, or similar conditions. The objective of our accrual policy is to match the recording of expenses in our financial statements to the actual cost of services received and efforts expended. As such, expenses related to each patient enrolled in a clinical trial are recognized ratably beginning upon entry into the trial and over the course of the patient’s continued participation in the trial. In the event of early termination of a clinical trial, we accrue an amount based on our estimate of the remaining non-cancelable obligations associated with the winding down of the clinical trial. Our estimates and assumptions could differ significantly from the amounts that may actually be incurred.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">Stock-Based Compensation</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The Company has one stock-based compensation plan in effect. Accounting Standards Codification 718, <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Compensation - Stock Compensation </font>(“ASC 718”), requires the recognition of compensation expense, using a fair-value based method, for costs related to all stock options including stock options and common stock issued to our employees and directors under our stock plans. ASC 718 requires companies to estimate the fair value of stock option awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service periods in our condensed<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> </font>consolidated statements of operations.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> </div><div style="background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Under ASC 718, we estimate the fair value of our employee stock option awards at the date of grant using the Black-Scholes option-pricing model, which requires the use of certain subjective assumptions. The most significant of these assumptions are our estimates of the expected volatility of the market price of our stock and the expected term of an award. When establishing an estimate of the expected term of an option award, we consider the vesting period for the award, our recent historical experience of employee stock option exercises (including forfeitures) and the expected volatility of our common stock.  As required under the accounting rules, we review our estimates at each grant date and, as a result, the valuation assumptions that we use to value employee stock-based awards granted in future periods may change. On March 15, 2018, we granted a total of 30,000 stock options to two members of our Board of Directors, valued at approximately $540,000. We used the Black-Scholes valuation model to estimate the value of options using 39.6% volatility, a risk free rate of 2.62% and an expected term of 6.25 years.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Further, ASC 718 requires that employee stock-based compensation costs be recognized over the requisite service period, or the vesting period, in a manner similar to all other forms of compensation paid to employees. The allocation of employee stock-based compensation costs to each operating expense line are estimated based on specific employee headcount information at each grant date and estimated stock option forfeiture rates and revised, if necessary, in future periods if actual employee headcount information or forfeitures differ materially from those estimates. As a result, the amount of employee stock-based compensation costs we recognize in each operating expense category in future periods may differ significantly from what we have recorded in the current period.</div></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Stock-based compensation expense recognized in general and administrative expenses was approximately $33,000 for each three month period ended March 31, 2018 and 2017.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify;">Stock Option Activity</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">A summary of our stock option activity during the three months ended March 31, 2018 is presented below:</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> </div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 95%;"><tr><td valign="bottom" style="width: 47%; vertical-align: middle; padding-bottom: 2px;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Shares</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Weighted</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Average</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Exercise</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Price</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Weighted</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Average</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Remaining</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Contractual</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Term</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Aggregate</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Intrinsic</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Value</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 47%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Outstanding at December 31, 2017</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">232,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">21.56</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2.52</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,050,990</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 47%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Grants</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">30,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">41.82</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 47%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Exercised</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(10,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">13.24</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 47%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Forfeitures or expirations</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 47%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Outstanding at March 31, 2018</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">252,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">24.30</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">3.29</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">5,049,910</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 47%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Exercisable at March 31, 2018</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">207,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">20.80</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">2.04</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">4,873,810</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">During the three months ended March 31, 2018 and 2017, the Company received approximately $132,000 and $258,000, respectively, from stock options exercised by option holders.</div><div style="text-align: left;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Aggregate intrinsic value represents the total pre-tax intrinsic value based on the closing price of our common stock of $44.34 on March 29, 2018, which would have been received by the option holders had all option holders exercised their options as of that date. We have approximately $648,000 in unrecognized compensation cost related to stock options outstanding as of March 31, 2018, which we expect to recognize over the next 3.45 years.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">Property and Equipment</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Property and equipment are stated at cost, less accumulated depreciation. Machinery and equipment, furniture and fixtures, and autos are depreciated on a straight-line basis over their estimated useful lives of five to ten years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the remaining life of the lease. At each of March 31, 2018 and December 31, 2017, property and equipment were fully depreciated.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">Comprehensive Income</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">For each of the three month periods ended March 31, 2018 and 2017, we had no components of other comprehensive income other than net income itself.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">Provision for Income Taxes</div><div style="text-align: left;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Deferred tax assets and liabilities are recognized based on the expected future tax consequences, using current tax rates, of temporary differences between the financial statement carrying amounts and the income tax basis of assets and liabilities. A valuation allowance is applied against any net deferred tax asset if, based on the weighted available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">We use the asset and liability method of accounting for income taxes, as set forth in Accounting Standards Codification 740-10-25-2. Under this method, deferred income taxes, when required, are provided on the basis of the difference between the financial reporting and income tax basis of assets and liabilities at the statutory rates enacted for future periods. </font>In accordance with Accounting Standards Codification 740-10-45-25, <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Income Statement Classification of Interest and Penalties</font>, we classify interest associated with income taxes under interest expense and tax penalties under other.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon the ultimate settlement. As of March 31, 2018 and December 31, 2017, the Company has not recorded any unrecognized tax benefits.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Commitments and Contingencies</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">On November 6, 2017, the Company entered into an agreement with the Landlord to extend the term of the lease to the Headquarters for an additional one year period (the “Extended Lease Agreement”). The one year extension will end on November 30, 2018. Pursuant to the Extended Lease Agreement, the base rent is $11,165 per month and the Company may cancel the lease with three months’ prior written notice to the Landlord at any time during the term.</div></div>

10000

67516838

81844689

2535676

68733

-1400000

1288977

1246699

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">Receivables and Doubtful Accounts</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; background-color: #ffffff;">Trade accounts receivable are stated at the amount the Company expects to collect. We may maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. We consider the following factors when determining the collectability of specific customer accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms.  Our accounts receivable balance is typically due from Endo, our one large specialty pharmaceutical customer.  Endo has historically paid timely and has been a financially stable organization.  Due to the nature of the accounts receivable balance, we believe the risk of doubtful accounts is minimal.  If the financial condition of our customer were to deteriorate, adversely affecting its ability to make payments, additional allowances would be required.  We may provide for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. Balances that remain outstanding after we have used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable.<font style="font-size: 10pt; font-family: 'Times New Roman';"> </font>At <font style="font-size: 10pt; font-family: 'Times New Roman';">March 31, 2018</font> and December 31, 2017 our accounts receivable balance was $19.2 million and $4.7 million, respectively, and was from one customer, Endo. With the adoption of ASC 606 as of January 1, 2018, <font style="font-size: 10pt; font-family: 'Times New Roman';">using the modified-retrospective adoption method</font>, <font style="font-size: 10pt; font-family: 'Times New Roman';">we recorded an adjustment to our accounts receivable balance of $7.6 million related to royalties associated with the net sales of XIAFLEX that occurred during the fourth quarter of 2017 thereby eliminating the one quarter lag</font>.<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> (</font>For more a more detailed discussion regarding ASC 606 see <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Note 2</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> - RECENT ACCOUNTING PRONOUNCEMENTS</font> - <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Accounting Pronouncements Adopted.</font></div></div>

7898200

410934

4260

52.07

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">Critical Accounting Policies, Estimates and Assumptions</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The preparation of condensed<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> </font>consolidated financial statements in conformity with U.S. GAAP requires the use of management’s estimates and assumptions that affect the amounts reported in the condensed<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> </font>consolidated financial statements and accompanying notes. The Company makes certain assumptions and estimates for its revenues, deferred tax assets, third party royalties and deferred royalty buy-down. <font style="font-size: 10pt; font-family: 'Times New Roman';">We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions. </font>For further details, see notes “Revenue Recognition”, “Provision for Income Taxes” and “Third-Party Royalties and Royalty Buy-Down.” Actual results may differ from those estimates.</div></div>

7164248

7192900

7303336

7332736

-400000 -500000 -900000 P3M 11165 0 0 1 P0Y P0Y P0Y 2 5 5 P5Y 600000 1500000 134000 0 1 <div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">Reimbursable Third-Party Patent Costs</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">We accrue patent costs that are reimbursable to Endo by us under the License Agreement. We capitalize certain patent costs related to patent prosecution and maintenance and expense others. As of March 31, 2018<font style="font-size: 10pt; font-family: 'Times New Roman';"> and December 31, 2017,</font> our net reimbursable third party patent expense was $134,000 and zero, respectively.</div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify; background-color: #ffffff;">Royalty Buy-Down</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; background-color: #ffffff;">On March 31, 2012, we entered into an amendment to our existing agreement with Dr. Martin K. Gelbard, dated August 27, 2008, related to our future royalty obligations in connection with Peyronie’s disease. The amendment enables us to buy down a portion of our future royalty obligations in exchange for an initial cash payment of $1.5 million and five additional cash payments of $600,000, all of which have been paid as of March 31, 2018.  Royalty obligations terminate five years after first commercial sale which occurred in January 2014. The Company amortizes long-term contracts with finite lives in a manner that reflects the pattern in which the economic benefits of the assets are consumed or otherwise used up. Dr. Gelbard’s agreement is amortized based on an income forecast method by estimating sales of XIAFLEX and Xiapex for Peyronie’s disease on an annual basis as measured by the proportion of the total estimated sales over the five year period. For the three months ended March 31, 2018 and 2017, we amortized approximately $0.5 million and $0.4 million related to this agreement, respectively. With the adoption of ASC 606 as of January 1, 2018 <font style="font-size: 10pt; font-family: 'Times New Roman';">using the modified-retrospective adoption method</font>, <font style="font-size: 10pt; font-family: 'Times New Roman';">we recorded an adjustment to our capitalized balance of $0.4 million related to royalties associated with the net sales of XIAFLEX that occurred during the fourth quarter of 2017 thereby eliminating the one quarter lag</font>. As of March 31, 2018 and December 31, 2017, the remaining capitalized balances were approximately $1.6 million and $2.5 million, respectively. We perform an evaluation of the recoverability of the carrying value to determine if facts and circumstances indicate that the carrying value of the assets may be impaired and if any adjustment is warranted.  As of March 31, 2018, there was no indicator that an impairment existed. <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(</font>For more a more detailed discussion regarding ASC 606 see <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Note 2</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> - RECENT ACCOUNTING PRONOUNCEMENTS</font> - <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Accounting Pronouncements Adopted.</font></div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">Third-Party Royalties</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; background-color: #ffffff;">We have entered into licensing and royalty agreements with third parties and agreed to pay certain royalties on net sales of products for specific indications. The royalty rates differ from agreement to agreement and, in certain cases, have been redacted with the permission of the SEC.  No assumptions should be made that any disclosed royalty rate payable to a particular third party is the same or similar with respect to any royalty rate payable to any other third parties. We accrue third-party royalty expenses on net sales reported to us by Endo. Third-party royalty costs are generally expensed under general and administrative in the quarter that the net sales have occurred. For the three month periods ended March 31, 2018 and 2017, third-party royalty expenses were $0.5 million in each period. With the adoption of ASC 606 as of January 1, 2018 <font style="font-size: 10pt; font-family: 'Times New Roman';">using the modified-retrospective adoption method</font>, <font style="font-size: 10pt; font-family: 'Times New Roman';">we recorded an adjustment to our retained earnings for third party royalties expense of $0.5 million associated with the net sales of XIAFLEX that occurred during the fourth quarter of 2017 thereby eliminating the one quarter lag</font>. Our third-party royalty expense under general and administrative expenses may increase if net sales by Endo and its partners for XIAFLEX and Xiapex increase and potential new indications for XIAFLEX and Xiapex are approved, marketed and sold.<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> (</font>For more a more detailed discussion regarding ASC 606 see <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Note 2</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> - RECENT ACCOUNTING PRONOUNCEMENTS</font> - <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Accounting Pronouncements Adopted.</font></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; background-color: #ffffff;"> </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Clinical Trial Expenses</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Our cost accruals for clinical trials are based on estimates of the services received and efforts expended pursuant to contracts with various clinical trial centers and clinical research consultants. In the normal course of business, we contract with third parties to perform various clinical trial activities in the ongoing development of potential drugs. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events, the successful enrollment of patients, the completion of portions of the clinical trial, or similar conditions. The objective of our accrual policy is to match the recording of expenses in our financial statements to the actual cost of services received and efforts expended. As such, expenses related to each patient enrolled in a clinical trial are recognized ratably beginning upon entry into the trial and over the course of the patient’s continued participation in the trial. In the event of early termination of a clinical trial, we accrue an amount based on our estimate of the remaining non-cancelable obligations associated with the winding down of the clinical trial. Our estimates and assumptions could differ significantly from the amounts that may actually be incurred.</div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">Treasury Stock</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The Company accounts for treasury stock under the cost method and includes treasury stock as a component of stockholders’ equity. For the three months ended <font style="font-size: 10pt; font-family: 'Times New Roman';">March 31, 2018</font>, there were no shares repurchased as compared to the repurchase of 4,260 shares at an average price of $52.07 in the corresponding 2017 period.</div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">Revenue Recognition</div><div style="background-color: #ffffff;"><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Beginning in 2014, Financial Accounting Standards Board (“FASB”) issued several Accounting Standards Updates establishing ASC Topic 606, “Revenue from Contracts with Customers” (“ASC 606”).  ASC 606 requires retrospective implementation, and replaces most industry-specific revenue recognition guidance in U.S. GAAP with a new principles-based, five-step revenue recognition model.  The Company adopted ASC 606 effective January 1, 2018. Under ASC 606, we recognize revenues when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation(s).</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Revenues, and their respective treatment for financial reporting purposes under ASC 606 and our license agreement with Endo, are as follows:</div><div style="text-align: justify;"><br /></div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify; background-color: #ffffff; text-indent: 36pt;">Royalty / Mark-Up on Cost of Goods Sold</div><div style="background-color: #ffffff;"><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">We receive royalty revenues on net sales and mark-up on cost of goods sold revenue in the U.S. under our License Agreement with Endo. These are presented in “Royalties” in our condensed consolidated statements of income.  We do not have future performance obligations under this revenue stream. In accordance with ASC 606, we record these revenues based on estimates of the net sales that occurred during the relevant period, thereby eliminating the one quarter lag convention in previous periods. The relevant period estimates of these royalties are based on interim data provided by Endo and analysis of historical royalties and mark-up on cost of goods sold revenue that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. The royalties payable by Endo to us are subject to set-off for certain patent costs.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> </div></div><div style="background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify; margin-left: 36pt;">Licensing Revenue</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">We include revenue recognized from upfront licensing, sublicensing and milestone payments in “License Revenues” in our condensed consolidated statements of income.</div></div><div style="text-align: left; background-color: #ffffff;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; background-color: #ffffff;">The Company recognizes licensing revenues generated through development and/or commercialization agreements. The terms of these agreements typically include payment to the Company of one or more of the following: nonrefundable, upfront license fees; sublicensing; development and commercial milestone payments; development activities; and royalties on net sales of licensed products. Each of these types of payments results in licensing revenues except for revenues from royalties on net sales of licensed products and the mark-up of cost of goods sold revenues which are classified as royalty revenues. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the customer.</div><div style="text-align: left; background-color: #ffffff; text-indent: 18pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; background-color: #ffffff;">For each development and/or commercialization agreement that result in revenues, the Company identifies all material performance obligations, which may include a license to intellectual property and know-how, development activities and/or transition activities. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company’s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required.</div><div style="text-align: left; background-color: #ffffff;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; background-color: #ffffff;">If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, upfront license fees based on the relative standalone selling price prescribed to the license compared to the total value of the arrangement. The revenue is recognized when the license is transferred to the collaborator and the collaborator is able to use and benefit from the license.  For licenses that are not distinct from other obligations identified in the arrangement, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the combined performance obligation is satisfied over time, the Company applies an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees.  The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</div><div style="text-align: left; background-color: #ffffff; text-indent: 18pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left; background-color: #ffffff; text-indent: 36pt;">Development and Regulatory Milestone Payments</div><div style="text-align: left; background-color: #ffffff;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; background-color: #ffffff;">Depending on facts and circumstances, the Company may conclude that it is appropriate to include the milestone, representing variable consideration, in the estimated total transaction price, or that it is appropriate to fully constrain the milestone. The Company may include revenues from certain milestones in the total transaction price in a reporting period before the milestone is achieved if the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods. The Company records a corresponding contract asset when this conclusion is reached. Milestone payments that have not been included in the transaction price to date are fully constrained. The Company re-evaluates the probability of achievement of such development milestones and any related constraint each reporting period. The Company adjusts its estimate of the total transaction price, including the amount of revenue that it has recorded, if necessary.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; background-color: #ffffff;"> </div></div> -259713 -4409 750000 500000 As of January 1, 2018, the Company adopted the requirements of ASC 606 using the modified retrospective adoption method, and as a result, there is a lack of comparability of certain amounts to the prior periods presented. See Note 2 for additional discussion. This adjustment represents the elimination of the one quarter lag by recognizing royalty revenues based on of XIALFLEX net sales and mark-up on cost of goods sold revenues reported to us by Endo for the fourth quarter of 2017. Represents the remaining deferred revenue balance of the prepaid mark-up on cost of goods sold based on sales by non-affiliated sublicensees of Endo outside of the U.S. Represents the amortization of the royalty buy-down and third party royalties expense associated royalty revenues based on XIALFLEX net sales reported to us by Endo for the fourth quarter of 2017. To reverse a deferred tax asset associated with the deferred revenue balance of the prepaid mark-up on cost of goods sold by non-affiliated sublicensees of Endo outside of the U.S. To create a tax liability associated the elimination of the one quarter lag by recognizing royalty revenues based on of XIALFLEX net sales and mark-up on cost of goods sold revenues reported to us by Endo for the fourth quarter of 2017. EX-101.SCH 5 bstc-20180331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 010000 - Statement - Condensed Consolidated Balance Sheets (unaudited) link:presentationLink link:calculationLink link:definitionLink 010100 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 020000 - Statement - Condensed Consolidated Income Statements (unaudited) link:presentationLink link:calculationLink link:definitionLink 030000 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 060100 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 060200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 060300 - Disclosure - NET INCOME PER SHARE link:presentationLink link:calculationLink link:definitionLink 060400 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES link:presentationLink link:calculationLink link:definitionLink 060500 - Disclosure - PATENT COSTS link:presentationLink link:calculationLink link:definitionLink 060600 - Disclosure - PROVISION FOR INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 070200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 080200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 080300 - Disclosure - NET INCOME PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 080400 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 080500 - Disclosure - PATENT COSTS (Tables) link:presentationLink link:calculationLink link:definitionLink 090100 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details) link:presentationLink link:calculationLink link:definitionLink 090200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Recent Accounting Pronouncements (Details) link:presentationLink link:calculationLink link:definitionLink 090202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Cash, Cash Equivalents and Investments (Details) link:presentationLink link:calculationLink link:definitionLink 090204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 090206 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Concentration of Credit Risk and Major Customers and Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 090208 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Treasury Stock, Receivables and Doubtful Accounts and Deferred Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 090210 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Reimbursable Third-Party Patent Costs, Third party Royalties and Royalty Buy-Down (Details) link:presentationLink link:calculationLink link:definitionLink 090212 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 090214 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Property and Equipment, Comprehensive Income, Provision for Income Taxes and Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 090300 - Disclosure - NET INCOME PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 090400 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 090500 - Disclosure - PATENT COSTS (Details) link:presentationLink link:calculationLink link:definitionLink 090600 - Disclosure - PROVISION FOR INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 bstc-20180331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 bstc-20180331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 bstc-20180331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Amendment Flag Current Fiscal Year End Date Document Period End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Public Float Entity Registrant Name Entity Central Index Key Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Document Type Award Type [Axis] ASU 2014-09 [Member] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract] Trade accounts payable Accounts Payable, Trade, Current ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accounts payable and accrued expenses [Abstract] Accounts Payable and Accrued Liabilities, Current [Abstract] Accounts payable and accrued expenses Total Accounts Payable and Accrued Liabilities, Current Accounts Receivable and Allowance For Doubtful Accounts [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts receivable Accounts receivable Third party royalties Accrued legal and other professional fees Fair Value Measurements [Abstract] Additional Fair Value Elements [Abstract] Additional paid-in capital Amount amortized related to agreement Adjustments to reconcile net income to net cash provided by operating activities: Adjustments for New Accounting Pronouncements [Axis] Stock-based compensation expense Allocated Share-based Compensation Expense Amortized premium included in interest income Amortization expense for patents Amortization of Intangible Assets Antidilutive Securities [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities, Name [Domain] Antidilutive securities excluded from earnings per share calculation (in shares) Assets Assets [Abstract] Assets [Abstract] Total assets Assets Current assets: Total current assets Assets, Current Basis of Presentation Adjusted / Balances Without Adoption of New Revenue Standard [Member] Cash, Cash Equivalents and Investments Cash and cash equivalents Cash and cash equivalents at end of period Cash and cash equivalents at beginning of year Cash, Cash Equivalents and Investments [Abstract] Increase in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Certificates of Deposit [Member] Class of Stock [Domain] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Commitments and Contingencies Commitments and Contingencies, Policy [Policy Text Block] Common stock, authorized (in shares) Common stock, issued (in shares) Common stock, par value (in dollars per share) Common stock, $.001 par value; 10,000,000 shares authorized; 7,610,167 and 7,600,167 shares issued, 7,199,233 and 7,189,233 shares outstanding as of March 31, 2018 and December 31, 2017, respectively Common Stock, Value, Issued Common stock, outstanding (in shares) Common Stock, Shares, Outstanding Comprehensive Income [Abstract] Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Comprehensive Income Concentration Risk [Line Items] Concentration of Credit Risk and Major Customers Concentration Risk [Table] Principles of Consolidation Long-term deferred revenue Deferred revenue, long term Deferred revenue Contract with Customer, Liability Deferred revenue Contract with Customer, Liability, Current Contract assets Corporate Bonds [Member] Costs and expenses: Costs and expenses [Abstract] Total costs and expenses Costs and Expenses Deferred royalty buy-down Deferred royalty buy-down Deferred Costs, Current Deferred royalty buy-down - long term, net Deferred revenue on licensing agreements Deferred Revenue [Abstract] Deferred tax assets, net Deferred tax assets, net Deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Amortization Adjustments / Effect of Change Higher / (Lower) [Member] Accrued liabilities of discontinued operations Diluted net income per share (in dollars per share) NET INCOME PER SHARE Earnings Per Share [Text Block] Basic net income per share (in dollars per share) NET INCOME PER SHARE [Abstract] Unrecognized compensation cost Stock Options [Member] Employee Stock Option [Member] Options grant date fair value Recognized compensation period Accrued payroll and related costs Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Fair Value Measurements Fair Value, Hierarchy [Axis] Measurement Frequency [Axis] Asset Class [Axis] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Measurement Frequency [Domain] Asset Class [Domain] Asset Class [Domain] Recurring [Member] Fair Value, Measurements, Recurring [Member] Fair Value Hierarchy [Domain] Fair Value Assets Measured on Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Level 3 [Member] Fair Value, Inputs, Level 3 [Member] April 1, 2018 - December 31, 2018 Finite-Lived Intangible Assets [Line Items] 2022 Finite-Lived Intangible Assets, Amortization Expense, Year Five Net Patent Costs [Abstract] Finite-Lived Intangible Assets, Net [Abstract] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Thereafter Finite-Lived Intangible Assets by Major Class [Axis] Estimated aggregate amortization expense [Abstract] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] 2020 Estimated useful lives Finite-Lived Intangible Asset, Useful Life 2021 Patents 2019 Finite-Lived Intangible Assets, Amortization Expense, Year Two Finite-Lived Intangible Assets, Major Class Name [Domain] General and Administrative [Member] General and administrative PATENT COSTS [Abstract] Held-to-maturity securities, unrecognized gain Held-to-maturity securities, current Schedule of Maturities Held-to-maturity Securities [Table Text Block] Held-to-maturity securities, unrecognized loss Aggregate fair value of investments Held-to-maturity Securities Held-to-maturity securities, noncurrent PROVISION FOR INCOME TAXES [Abstract] Income before income tax expense Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Condensed Consolidated Income Statements (unaudited) [Abstract] Income Statements [Abstract] PROVISION FOR INCOME TAXES Income Tax Disclosure [Text Block] Income Taxes [Abstract] Income Tax Expense (Benefit), Continuing Operations [Abstract] Provision for income tax expense Provision for income taxes Income Tax Expense (Benefit) Provision for Income Taxes Taxes Accounts receivable Increase (Decrease) in Accounts Receivable Accounts payable and accrued expenses Income tax receivable Increase (Decrease) in Income Taxes Receivable Deferred tax expense Increase (Decrease) in Deferred Income Taxes Patent costs Increase (Decrease) in Intangible Assets, Current Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Changes in operating assets and liabilities: Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Domain] Patent costs, net Net Patent Costs PATENT COSTS Intangible Assets Disclosure [Text Block] Interest Investments [Domain] Interest income Investment Income, Interest Investment Type [Axis] Investments Investments, Fair Value Disclosure Additional lease term extension period Lessee, Operating Lease, Renewal Term Total liabilities and stockholders' equity Liabilities and Equity Liabilities [Abstract] Liabilities [Abstract] Liabilities and stockholders' equity Total current liabilities Liabilities, Current EX-101.PRE 9 bstc-20180331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2018	May 09, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	BIOSPECIFICS TECHNOLOGIES CORP
Entity Central Index Key	0000875622
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		7,214,233
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q1
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2018

XML 11 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (unaudited) - USD ($)

Mar. 31, 2018

Dec. 31, 2017

Current assets:

Cash and cash equivalents

^[1]

$ 12,558,901

$ 7,333,810

Short term investments

48,751,206

^[1]

51,973,971

Accounts receivable

19,165,670

^[1]

4,655,105

Deferred royalty buy-down

1,648,319

^[1]

1,794,126

Prepaid expenses and other current assets

580,920

^[1]

623,503

Total current assets

82,705,016

^[1]

66,380,515

Long-term investments

2,840,191

^[1]

5,745,974

Deferred royalty buy-down - long term, net

^[1]

732,206

Deferred tax assets, net

403,944

^[1]

1,739,706

Patent costs, net

425,785

^[1]

397,993

Total assets

86,374,936

^[1]

74,996,394

Current liabilities:

Accounts payable and accrued expenses

1,781,163

^[1]

933,998

Income tax payable

2,535,676

^[1]

68,733

Deferred revenue

117,635

^[1]

1,057,979

Accrued liabilities of discontinued operations

78,138

^[1]

78,138

Total current liabilities

4,512,612

^[1]

2,138,848

Long-term deferred revenue

17,635

^[1]

5,340,708

Stockholders' equity:

Series A Preferred stock, $.50 par value, 700,000 shares authorized; none outstanding

^[1]

Common stock, $.001 par value; 10,000,000 shares authorized; 7,610,167 and 7,600,167 shares issued, 7,199,233 and 7,189,233 shares outstanding as of March 31, 2018 and December 31, 2017, respectively

7,610

^[1]

7,600

Additional paid-in capital

33,633,225

^[1]

33,468,323

Retained earnings

56,102,054

^[1]

41,939,115

Treasury stock, 410,934 shares at cost as of each period ended March 31, 2018 and December 31, 2017

(7,898,200)

^[1]

(7,898,200)

Total stockholders' equity

81,844,689

^[1]

67,516,838

Total liabilities and stockholders' equity

$ 86,374,936

^[1]

$ 74,996,394

[1]	As of January 1, 2018, the Company adopted the requirements of ASC 606 using the modified retrospective adoption method, and as a result, there is a lack of comparability of certain amounts to the prior periods presented. See Note 2 for additional discussion.

XML 12 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Stockholders' equity:
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	10,000,000	10,000,000
Common stock, issued (in shares)	7,610,167	7,600,167
Common stock, outstanding (in shares)	7,199,233	7,189,233
Treasury stock, shares (in shares)	410,934	410,934
Series A Preferred Stock [Member]
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.50	$ 0.50
Preferred stock, authorized (in shares)	700,000	700,000
Preferred stock, outstanding (in shares)	0	0

XML 13 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Income Statements (unaudited) - USD ($)

3 Months Ended

Mar. 31, 2018

^[1]

Mar. 31, 2017

Revenue:

Total Revenues

$ 7,089,409

$ 7,690,619

Costs and expenses:

Research and development

195,227

254,781

General and administrative

2,069,633

2,425,717

Total costs and expenses

2,264,860

2,680,498

Operating income

4,824,549

5,010,121

Other income:

Interest income

217,951

101,753

Other income

14,678

2,562

Total other income

232,629

104,315

Income before income tax expense

5,057,178

5,114,436

Provision for income tax expense

(1,078,574)

(1,769,683)

Net income

$ 3,978,604

$ 3,344,753

Basic net income per share (in dollars per share)

$ 0.55

$ 0.47

Diluted net income per share (in dollars per share)

$ 0.54

$ 0.46

Shares used in computation of basic net income per share (in shares)

7,192,900

7,164,248

Shares used in computation of diluted net income per share (in shares)

7,303,336

7,332,736

Royalties [Member]

Revenue:

Total Revenues

$ 7,085,000

$ 7,686,210

Licensing Revenues [Member]

Revenue:

Total Revenues

$ 4,409

[1]	As of January 1, 2018, the Company adopted the requirements of ASC 606 using the modified retrospective adoption method, and as a result, there is a lack of comparability of certain amounts to the prior periods presented. See Note 2 for additional discussion.

XML 14 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)

3 Months Ended

Mar. 31, 2018

^[1]

Mar. 31, 2017

Cash flows from operating activities:

Net income

$ 3,978,604

$ 3,344,753

Adjustments to reconcile net income to net cash provided by operating activities:

Amortization

699,703

545,067

Stock-based compensation expense

32,512

33,476

Deferred tax expense

97,508

Changes in operating assets and liabilities:

Accounts receivable

(6,955,839)

(1,117,501)

Income tax receivable

1,067,002

212,174

Prepaid expenses and other current assets

42,582

40,709

Patent costs

(44,598)

Accounts payable and accrued expenses

308,152

422,793

Deferred revenue

(4,409)

(259,713)

Net cash (used in) provided by operating activities

(876,291)

3,319,266

Cash flows from investing activities:

Maturity of marketable investments

20,287,000

18,217,000

Purchases of marketable investments

(14,318,018)

(17,304,251)

Net cash provided by investing activities

5,968,982

912,749

Cash flows from financing activities:

Proceeds from stock option exercises

132,400

258,250

Payments for repurchase of common stock

(221,821)

Net cash provided by financing activities

132,400

36,429

Increase in cash and cash equivalents

5,225,091

4,268,444

Cash and cash equivalents at beginning of year

7,333,810

4,763,364

Cash and cash equivalents at end of period

12,558,901

9,031,808

Cash paid during the period for:

Interest

Taxes

$ 0

$ 1,460,000

[1]	As of January 1, 2018, the Company adopted the requirements of ASC 606 using the modified retrospective adoption method, and as a result, there is a lack of comparability of certain amounts to the prior periods presented. See Note 2 for additional discussion.

XML 15 R6.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND DESCRIPTION OF BUSINESS	3 Months Ended
ORGANIZATION AND DESCRIPTION OF BUSINESS	Mar. 31, 2018
ORGANIZATION AND DESCRIPTION OF BUSINESS [Abstract]
ORGANIZATION AND DESCRIPTION OF BUSINESS	1. ORGANIZATION AND DESCRIPTION OF BUSINESS We are a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. We currently have a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (“Endo Global Ventures”), an affiliate of Endo International plc (“Endo”), for injectable collagenase for marketed indications and indications in development. Endo assumed this agreement when Endo acquired Auxilium Pharmaceuticals, Inc. (“Auxilium”) on January 29, 2015 (the “Acquisition”). Injectable collagenase clostridium histolyticum is marketed as XIAFLEX® (or Xiapex® in Europe). On February 1, 2016, we entered into with Endo the First Amendment (the “First Amendment”) to the Second Amended and Restated Development and Licensing Agreement (the “Auxilium Agreement”), by and between us and Auxilium, now a wholly-owned subsidiary of Endo, to amend certain provisions of the Auxilium Agreement (as amended by the First Amendment, the “License Agreement”). The effective date of the First Amendment was January 1, 2016. Pursuant to the First Amendment, we and Endo mutually agreed that in exchange for a $8.25 million lump sum payment, we will not receive future additional mark-up on cost of goods sold for sales by non-affiliated sublicensees of Endo outside of the U.S.; provided, however, that Endo will still be required to pay a mark-up on cost of goods sold for sales made in the “Endo Territory,” which includes sales made in the U.S. and sales made in any other country where Endo sells the product directly or through affiliated sublicensees. We received this $8.25 million lump sum payment in February 2016 and began recognizing this income over time based on sales by non-affiliated sublicensees of Endo outside of the U.S. according to our previous revenue recognition policy in the second quarter of 2016. Additionally, we agreed that Endo may opt-in early to indications, prior to our submission of a clinical trial report, with our consent, such consent not to be unreasonably withheld. For early opt-ins, Endo will be required to make an opt-in payment of $0.5 million on a per indication basis. For regular opt-ins, following our submission of a clinical trial report, Endo will be required to make an opt-in payment of $0.75 million on a per indication basis. The two marketed indications involving our injectable collagenase are Dupuytren’s contracture and Peyronie’s disease. Prior to the Acquisition, Auxilium had, and after the Acquisition, Endo has, opted-in to the following indications: frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis and human lipoma. Endo exercised, with our consent, an early opt-in for lateral hip fat and plantar fibromatosis in November 2015. Endo opted-in for human lipoma in July 2016. We manage the development of XIAFLEX for uterine fibroids and initiate the development of XIAFLEX in new potential indications, not licensed by Endo. On November 8, 2016, following a change in Endo management, Endo announced that a commercial review is ongoing of the XIAFLEX exercised but non-marketed indications, including frozen shoulder, cellulite, lateral hip fat, plantar fibromatosis and human lipoma, so that Endo can best prioritize its R&D efforts and determine clinical trial timelines moving forward. Endo is currently selling XIAFLEX in the U.S. for the treatment of Dupuytren’s contracture and Peyronie’s disease and has an agreement with Swedish Orphan Biovitrum AB (“Sobi”), pursuant to which Sobi has marketing rights for Xiapex for Dupuytren’s contracture and Peyronie’s disease in Europe and certain Eurasian countries. Sobi is currently selling Xiapex in Europe and certain Eurasian countries for the treatment of Dupuytren’s contracture and Peyronie’s disease. In addition, Endo has an agreement with Asahi Kasei Pharma Corporation (“Asahi”) pursuant to which Asahi has the right to commercialize XIAFLEX for the treatment of Dupuytren’s contracture and Peyronie’s disease in Japan. Asahi is selling XIAFLEX for the treatment of Dupuytren’s contracture in Japan. Endo is currently distributing XIAFLEX in Canada through Paladin Labs Inc, an operating company of Endo. In December 2016, Endo entered into a new out-licensing agreement with Actelion Pharmaceuticals Ltd. (“Actelion”), pursuant to which Actelion obtained marketing and commercial rights for XIAFLEX in Australia and New Zealand.

XML 16 R7.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2018

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its subsidiary, Advance Biofactures Corp. All intercompany balances and transactions have been eliminated.

Critical Accounting Policies, Estimates and Assumptions

Revenue Recognition

Revenues, and their respective treatment for financial reporting purposes under ASC 606 and our license agreement with Endo, are as follows:

Royalty / Mark-Up on Cost of Goods Sold

Licensing Revenue

We include revenue recognized from upfront licensing, sublicensing and milestone payments in “License Revenues” in our condensed consolidated statements of income.

Development and Regulatory Milestone Payments

Recent Accounting Prnouncements

Accounting Pronouncements Adopted

The Company recorded the following cumulative effect as of January 1, 2018, itemized here (in millions):

	As reported December 31, 2017			Adjustments			Adjusted January 1, 2018
Accounts receivable	$	4.7		$	7.6	⁽¹⁾	$	12.3
Deferred revenue		(6.4	)		6.3	⁽²⁾		(0.1	)
Deferred royalty buy-down		(2.5	)		(0.4	)⁽³⁾		(2.9	)
Accounts payable and accrued expenses -third party royalties		(0.4	)		(0.5	)⁽³⁾		(0.9	)
Deferred tax assets, net		1.7			(1.3	)⁽⁴⁾		0.4
Income tax payable		-			(1.4	)⁽⁵⁾		(1.4	)

Retained earnings adjustment	$	(2.9	)	$	10.3		$	7.4

(1)	This adjustment represents the elimination of the one quarter lag by recognizing royalty revenues based on of XIALFLEX net sales and mark-up on cost of goods sold revenues reported to us by Endo for the fourth quarter of 2017.

(2)	Represents the remaining deferred revenue balance of the prepaid mark-up on cost of goods sold based on sales by non-affiliated sublicensees of Endo outside of the U.S.

(3)	Represents the amortization of the royalty buy-down and third party royalties expense associated royalty revenues based on XIALFLEX net sales reported to us by Endo for the fourth quarter of 2017.

(4)	To reverse a deferred tax asset associated with the deferred revenue balance of the prepaid mark-up on cost of goods sold by non-affiliated sublicensees of Endo outside of the U.S.

(5)	To create a tax liability associated the elimination of the one quarter lag by recognizing royalty revenues based on of XIALFLEX net sales and mark-up on cost of goods sold revenues reported to us by Endo for the fourth quarter of 2017.

At March 31, 2018, contract assets of $7.0 million for which there’s an unconditional right to receive payment was included in accounts receivable on the condensed consolidated balance sheet.

In accordance with the new revenue standard requirements, the impact of adoption on our condensed consolidated balance sheet was as follows:

	March 31, 2018
	As Reported		Balances Without Adoption of New Revenue Standard		Effect of Change Higher / (Lower)
Assets
Accounts receivable	$	19,165,670	$	12,120,670	$	7,045,000
Deferred royalty buy-down		1,648,319		2,014,598		(366,279	)
Deferred tax assets		403,944		1,696,932		(1,292,988	)
Liabilities
Accounts payable and accrued expenses		1,781,163		1,271,163		510,000
Deferred revenue		117,635		1,023,854		(906,219	)
Income tax payable		2,535,676		1,288,977		1,246,699
Deferred revenue, long term		17,635		5,173,564		(5,155,930	)
Equity
Retained earnings		56,102,054		46,440,716		9,661,338

In accordance with the new revenue standard requirements, the impact of adoption on our condensed consolidated statement of operations was as follows:

	Three Months Ended March 31, 2018
	As Reported		Balances Without Adoption of New Revenue Standard		Effect of Change Higher / (Lower)
Revenues
Royalties	$	7,085,000	$	7,731,566	$	(646,566	)
Costs and expenses
General and administrative	$	2,069,633	$	2,087,921	$	(17,418	)
Provision for income taxes		1,078,574		1,220,244		(141,670	)
Net income		3,978,604		4,500,918		(522,314	)

Accounting Pronouncements Not Yet Adopted

Cash, Cash Equivalents and Investments

Fair Value Measurements

The following table presents the Company’s schedule of maturities at March 31, 2018 and December 31, 2017:

	Maturities as of March 31, 2018				Maturities as of December 31, 2017
	1 Year or Less		Greater than 1 Year		1 Year or Less		Greater than 1 Year
Municipal bonds	$	3,425,134	$	100,000	$	1,002,650	$	100,000
Corporate bonds		41,828,133		500,230		48,143,495		3,155,573
Certificates of deposit		3,497,939		2,239,961		2,827,826		2,490,401
Total	$	48,751,206	$	2,840,191	$	51,973,971	$	5,745,974

March 31, 2018	Type of Instrument	Fair Value		Level 1		Level 2		Level 3

Cash equivalents	Institutional Money Market	$	7,432,432	$	7,432,432	$	-	$	-

Cash equivalents	Certificates of Deposit		250,000		250,000		-		-

Cash equivalents	Corporate Bonds		2,585,000		2,585,000		-		-

Investments	Municipal Bonds		3,525,134		-		3,525,134		-

Investments	Corporate Bonds		42,328,363		-		42,328,363		-

Investments	Certificates of Deposit		5,737,900		5,737,900		-		-

December 31, 2017	Type of Instrument	Fair Value		Level 1		Level 2		Level 3

Cash equivalents	Institutional Money Market	$	3,108,549	$	3,108,549	$	-	$	-

Cash equivalents	Municipal Bonds		800,000		-		800,000		-

Investments	Municipal Bonds		1,102,650		-		1,102,650		-

Investments	Corporate Bonds		51,299,068		-		51,299,068		-

Investments	Certificates of Deposit		5,318,227		5,318,227		-		-

Concentration of Credit Risk and Major Customers

The Company maintains investments in FDIC insured certificates of deposits, municipal bonds and corporate bonds.

At March 31, 2018 and December 31, 2017, our accounts receivable balances from Endo were $19.2 million and $4.7 million, respectively.

Treasury Stock

Receivables and Doubtful Accounts

Deferred Revenue

Reimbursable Third-Party Patent Costs

Third-Party Royalties

Royalty Buy-Down

Research and Development Expenses

Clinical Trial Expenses

Stock-Based Compensation

Stock-based compensation expense recognized in general and administrative expenses was approximately $33,000 for each three month period ended March 31, 2018 and 2017.

Stock Option Activity

A summary of our stock option activity during the three months ended March 31, 2018 is presented below:

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding at December 31, 2017		232,000		$	21.56		2.52	$	5,050,990
Grants		30,000			41.82		-		-
Exercised		(10,000	)		13.24		-		-
Forfeitures or expirations		-			-		-		-
Outstanding at March 31, 2018		252,000		$	24.30		3.29	$	5,049,910
Exercisable at March 31, 2018		207,000		$	20.80		2.04	$	4,873,810

During the three months ended March 31, 2018 and 2017, the Company received approximately $132,000 and $258,000, respectively, from stock options exercised by option holders.

Property and Equipment

Comprehensive Income

For each of the three month periods ended March 31, 2018 and 2017, we had no components of other comprehensive income other than net income itself.

Provision for Income Taxes

Commitments and Contingencies

XML 17 R8.htm IDEA: XBRL DOCUMENT

NET INCOME PER SHARE

3 Months Ended

Mar. 31, 2018

NET INCOME PER SHARE [Abstract]

NET INCOME PER SHARE

3. NET INCOME PER SHARE

	Three Months Ended March 31,
	2018		2017
Stock options		-		20,000

XML 18 R9.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

3 Months Ended

Mar. 31, 2018

ACCOUNTS PAYABLE AND ACCRUED EXPENSES [Abstract]

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

4. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses consisted of the following:

	March 31, 2018		December 31, 2017
Trade accounts payable	$	215,639	$	152,542
Accrued legal and other professional fees		194,565		150,691
Accrued payroll and related costs		204,311		215,322
Third party royalties		1,049,013		329,211
Other accruals		117,635		86,232
Total	$	1,781,163	$	933,998

XML 19 R10.htm IDEA: XBRL DOCUMENT

PATENT COSTS

3 Months Ended

Mar. 31, 2018

PATENT COSTS [Abstract]

PATENT COSTS

5. PATENT COSTS

	March 31, 2018			December 31, 2017
Patents		969,614		$	925,016
Accumulated amortization		(543,829	)		(527,023	)
	$	425,785		$	397,993

April 1, 2018 - December 31, 2018	$	51,000
2019		66,200
2020		50,400
2021		34,500
2022		34,500
Thereafter		189,185

XML 20 R11.htm IDEA: XBRL DOCUMENT

PROVISION FOR INCOME TAXES	3 Months Ended
PROVISION FOR INCOME TAXES	Mar. 31, 2018
PROVISION FOR INCOME TAXES [Abstract]
PROVISION FOR INCOME TAXES	6. PROVISION FOR INCOME TAXES Our deferred tax liabilities and deferred tax assets are impacted by events and transactions arising in the ordinary course of business, R&D activities, vesting of nonqualified options and other items. The provision for income taxes is based on an estimated effective tax rate derived from our consolidated earnings before taxes, adjusted for nondeductible expenses and other permanent differences for the fiscal year. For the three months ended March 31, 2018 and 2017, the provision for income taxes was $1.1 million and $1.8 million, respectively. As of March 31, 2018 and December 31, 2017, our remaining deferred tax assets were approximately $0.4 million and $1.7 million, respectively. As of March 31, 2018, the Company has no unrecognized tax benefits or related interest and penalties. Management does not believe that there is any tax position which it is reasonably possible that will result in unrecognized tax benefit within the next 12 months.

XML 21 R12.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Mar. 31, 2018

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]

Basis of Presentation

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its subsidiary, Advance Biofactures Corp. All intercompany balances and transactions have been eliminated.

Critical Accounting Policies, Estimates and Assumptions

Revenue Recognition

Revenues, and their respective treatment for financial reporting purposes under ASC 606 and our license agreement with Endo, are as follows:

Royalty / Mark-Up on Cost of Goods Sold

Licensing Revenue

We include revenue recognized from upfront licensing, sublicensing and milestone payments in “License Revenues” in our condensed consolidated statements of income.

Development and Regulatory Milestone Payments

Recent Accounting Pronouncements

Recent Accounting Prnouncements

Accounting Pronouncements Adopted

The Company recorded the following cumulative effect as of January 1, 2018, itemized here (in millions):

	As reported December 31, 2017			Adjustments			Adjusted January 1, 2018
Accounts receivable	$	4.7		$	7.6	⁽¹⁾	$	12.3
Deferred revenue		(6.4	)		6.3	⁽²⁾		(0.1	)
Deferred royalty buy-down		(2.5	)		(0.4	)⁽³⁾		(2.9	)
Accounts payable and accrued expenses -third party royalties		(0.4	)		(0.5	)⁽³⁾		(0.9	)
Deferred tax assets, net		1.7			(1.3	)⁽⁴⁾		0.4
Income tax payable		-			(1.4	)⁽⁵⁾		(1.4	)

Retained earnings adjustment	$	(2.9	)	$	10.3		$	7.4

(1)	This adjustment represents the elimination of the one quarter lag by recognizing royalty revenues based on of XIALFLEX net sales and mark-up on cost of goods sold revenues reported to us by Endo for the fourth quarter of 2017.

(2)	Represents the remaining deferred revenue balance of the prepaid mark-up on cost of goods sold based on sales by non-affiliated sublicensees of Endo outside of the U.S.

(3)	Represents the amortization of the royalty buy-down and third party royalties expense associated royalty revenues based on XIALFLEX net sales reported to us by Endo for the fourth quarter of 2017.

(4)	To reverse a deferred tax asset associated with the deferred revenue balance of the prepaid mark-up on cost of goods sold by non-affiliated sublicensees of Endo outside of the U.S.

(5)	To create a tax liability associated the elimination of the one quarter lag by recognizing royalty revenues based on of XIALFLEX net sales and mark-up on cost of goods sold revenues reported to us by Endo for the fourth quarter of 2017.

At March 31, 2018, contract assets of $7.0 million for which there’s an unconditional right to receive payment was included in accounts receivable on the condensed consolidated balance sheet.

In accordance with the new revenue standard requirements, the impact of adoption on our condensed consolidated balance sheet was as follows:

	March 31, 2018
	As Reported		Balances Without Adoption of New Revenue Standard		Effect of Change Higher / (Lower)
Assets
Accounts receivable	$	19,165,670	$	12,120,670	$	7,045,000
Deferred royalty buy-down		1,648,319		2,014,598		(366,279	)
Deferred tax assets		403,944		1,696,932		(1,292,988	)
Liabilities
Accounts payable and accrued expenses		1,781,163		1,271,163		510,000
Deferred revenue		117,635		1,023,854		(906,219	)
Income tax payable		2,535,676		1,288,977		1,246,699
Deferred revenue, long term		17,635		5,173,564		(5,155,930	)
Equity
Retained earnings		56,102,054		46,440,716		9,661,338

In accordance with the new revenue standard requirements, the impact of adoption on our condensed consolidated statement of operations was as follows:

	Three Months Ended March 31, 2018
	As Reported		Balances Without Adoption of New Revenue Standard		Effect of Change Higher / (Lower)
Revenues
Royalties	$	7,085,000	$	7,731,566	$	(646,566	)
Costs and expenses
General and administrative	$	2,069,633	$	2,087,921	$	(17,418	)
Provision for income taxes		1,078,574		1,220,244		(141,670	)
Net income		3,978,604		4,500,918		(522,314	)

Accounting Pronouncements Not Yet Adopted

Cash, Cash Equivalents and Investments

Fair Value Measurements

The following table presents the Company’s schedule of maturities at March 31, 2018 and December 31, 2017:

	Maturities as of March 31, 2018				Maturities as of December 31, 2017
	1 Year or Less		Greater than 1 Year		1 Year or Less		Greater than 1 Year
Municipal bonds	$	3,425,134	$	100,000	$	1,002,650	$	100,000
Corporate bonds		41,828,133		500,230		48,143,495		3,155,573
Certificates of deposit		3,497,939		2,239,961		2,827,826		2,490,401
Total	$	48,751,206	$	2,840,191	$	51,973,971	$	5,745,974

March 31, 2018	Type of Instrument	Fair Value		Level 1		Level 2		Level 3

Cash equivalents	Institutional Money Market	$	7,432,432	$	7,432,432	$	-	$	-

Cash equivalents	Certificates of Deposit		250,000		250,000		-		-

Cash equivalents	Corporate Bonds		2,585,000		2,585,000		-		-

Investments	Municipal Bonds		3,525,134		-		3,525,134		-

Investments	Corporate Bonds		42,328,363		-		42,328,363		-

Investments	Certificates of Deposit		5,737,900		5,737,900		-		-

December 31, 2017	Type of Instrument	Fair Value		Level 1		Level 2		Level 3

Cash equivalents	Institutional Money Market	$	3,108,549	$	3,108,549	$	-	$	-

Cash equivalents	Municipal Bonds		800,000		-		800,000		-

Investments	Municipal Bonds		1,102,650		-		1,102,650		-

Investments	Corporate Bonds		51,299,068		-		51,299,068		-

Investments	Certificates of Deposit		5,318,227		5,318,227		-		-

Concentration of Credit Risk and Major Customers

The Company maintains investments in FDIC insured certificates of deposits, municipal bonds and corporate bonds.

At March 31, 2018 and December 31, 2017, our accounts receivable balances from Endo were $19.2 million and $4.7 million, respectively.

Treasury Stock

Receivables and Doubtful Accounts

Deferred Revenue

Reimbursable Third-Party Patent Costs

Third-Party Royalties

Royalty Buy-Down

Research and Development Expenses

Clinical Trial Expenses

Stock-Based Compensation

Stock-based compensation expense recognized in general and administrative expenses was approximately $33,000 for each three month period ended March 31, 2018 and 2017.

Stock Option Activity

A summary of our stock option activity during the three months ended March 31, 2018 is presented below:

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding at December 31, 2017		232,000		$	21.56		2.52	$	5,050,990
Grants		30,000			41.82		-		-
Exercised		(10,000	)		13.24		-		-
Forfeitures or expirations		-			-		-		-
Outstanding at March 31, 2018		252,000		$	24.30		3.29	$	5,049,910
Exercisable at March 31, 2018		207,000		$	20.80		2.04	$	4,873,810

During the three months ended March 31, 2018 and 2017, the Company received approximately $132,000 and $258,000, respectively, from stock options exercised by option holders.

Property and Equipment

Comprehensive Income

For each of the three month periods ended March 31, 2018 and 2017, we had no components of other comprehensive income other than net income itself.

Provision for Income Taxes

Commitments and Contingencies

XML 22 R13.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Mar. 31, 2018

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]

Schedule of New Accounting Pronouncements and Impact of Adoption on Financial Statements

The Company recorded the following cumulative effect as of January 1, 2018, itemized here (in millions):

	As reported December 31, 2017			Adjustments			Adjusted January 1, 2018
Accounts receivable	$	4.7		$	7.6	⁽¹⁾	$	12.3
Deferred revenue		(6.4	)		6.3	⁽²⁾		(0.1	)
Deferred royalty buy-down		(2.5	)		(0.4	)⁽³⁾		(2.9	)
Accounts payable and accrued expenses -third party royalties		(0.4	)		(0.5	)⁽³⁾		(0.9	)
Deferred tax assets, net		1.7			(1.3	)⁽⁴⁾		0.4
Income tax payable		-			(1.4	)⁽⁵⁾		(1.4	)

Retained earnings adjustment	$	(2.9	)	$	10.3		$	7.4

(1)	This adjustment represents the elimination of the one quarter lag by recognizing royalty revenues based on of XIALFLEX net sales and mark-up on cost of goods sold revenues reported to us by Endo for the fourth quarter of 2017.

(2)	Represents the remaining deferred revenue balance of the prepaid mark-up on cost of goods sold based on sales by non-affiliated sublicensees of Endo outside of the U.S.

(3)	Represents the amortization of the royalty buy-down and third party royalties expense associated royalty revenues based on XIALFLEX net sales reported to us by Endo for the fourth quarter of 2017.

(4)	To reverse a deferred tax asset associated with the deferred revenue balance of the prepaid mark-up on cost of goods sold by non-affiliated sublicensees of Endo outside of the U.S.

(5)	To create a tax liability associated the elimination of the one quarter lag by recognizing royalty revenues based on of XIALFLEX net sales and mark-up on cost of goods sold revenues reported to us by Endo for the fourth quarter of 2017.

In accordance with the new revenue standard requirements, the impact of adoption on our condensed consolidated balance sheet was as follows:

	March 31, 2018
	As Reported		Balances Without Adoption of New Revenue Standard		Effect of Change Higher / (Lower)
Assets
Accounts receivable	$	19,165,670	$	12,120,670	$	7,045,000
Deferred royalty buy-down		1,648,319		2,014,598		(366,279	)
Deferred tax assets		403,944		1,696,932		(1,292,988	)
Liabilities
Accounts payable and accrued expenses		1,781,163		1,271,163		510,000
Deferred revenue		117,635		1,023,854		(906,219	)
Income tax payable		2,535,676		1,288,977		1,246,699
Deferred revenue, long term		17,635		5,173,564		(5,155,930	)
Equity
Retained earnings		56,102,054		46,440,716		9,661,338

In accordance with the new revenue standard requirements, the impact of adoption on our condensed consolidated statement of operations was as follows:

	Three Months Ended March 31, 2018
	As Reported		Balances Without Adoption of New Revenue Standard		Effect of Change Higher / (Lower)
Revenues
Royalties	$	7,085,000	$	7,731,566	$	(646,566	)
Costs and expenses
General and administrative	$	2,069,633	$	2,087,921	$	(17,418	)
Provision for income taxes		1,078,574		1,220,244		(141,670	)
Net income		3,978,604		4,500,918		(522,314	)

Schedule of Maturities

The following table presents the Company’s schedule of maturities at March 31, 2018 and December 31, 2017:

	Maturities as of March 31, 2018				Maturities as of December 31, 2017
	1 Year or Less		Greater than 1 Year		1 Year or Less		Greater than 1 Year
Municipal bonds	$	3,425,134	$	100,000	$	1,002,650	$	100,000
Corporate bonds		41,828,133		500,230		48,143,495		3,155,573
Certificates of deposit		3,497,939		2,239,961		2,827,826		2,490,401
Total	$	48,751,206	$	2,840,191	$	51,973,971	$	5,745,974

Fair Value Assets Measured on Recurring Basis

March 31, 2018	Type of Instrument	Fair Value		Level 1		Level 2		Level 3

Cash equivalents	Institutional Money Market	$	7,432,432	$	7,432,432	$	-	$	-

Cash equivalents	Certificates of Deposit		250,000		250,000		-		-

Cash equivalents	Corporate Bonds		2,585,000		2,585,000		-		-

Investments	Municipal Bonds		3,525,134		-		3,525,134		-

Investments	Corporate Bonds		42,328,363		-		42,328,363		-

Investments	Certificates of Deposit		5,737,900		5,737,900		-		-

December 31, 2017	Type of Instrument	Fair Value		Level 1		Level 2		Level 3

Cash equivalents	Institutional Money Market	$	3,108,549	$	3,108,549	$	-	$	-

Cash equivalents	Municipal Bonds		800,000		-		800,000		-

Investments	Municipal Bonds		1,102,650		-		1,102,650		-

Investments	Corporate Bonds		51,299,068		-		51,299,068		-

Investments	Certificates of Deposit		5,318,227		5,318,227		-		-

Summary of Stock Option Activity

A summary of our stock option activity during the three months ended March 31, 2018 is presented below:

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding at December 31, 2017		232,000		$	21.56		2.52	$	5,050,990
Grants		30,000			41.82		-		-
Exercised		(10,000	)		13.24		-		-
Forfeitures or expirations		-			-		-		-
Outstanding at March 31, 2018		252,000		$	24.30		3.29	$	5,049,910
Exercisable at March 31, 2018		207,000		$	20.80		2.04	$	4,873,810

- Definition

Tabular disclosure of all investments in certain debt and equity securities for which the entity has the positive intent and ability to hold until maturity.

+ References + Details

XML 23 R14.htm IDEA: XBRL DOCUMENT

NET INCOME PER SHARE (Tables)

3 Months Ended

Mar. 31, 2018

NET INCOME PER SHARE [Abstract]

Number of Common Equivalent Shares Excluded from the Calculation of Diluted Net Income Per Share

	Three Months Ended March 31,
	2018		2017
Stock options		-		20,000

XML 24 R15.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)

3 Months Ended

Mar. 31, 2018

ACCOUNTS PAYABLE AND ACCRUED EXPENSES [Abstract]

Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consisted of the following:

	March 31, 2018		December 31, 2017
Trade accounts payable	$	215,639	$	152,542
Accrued legal and other professional fees		194,565		150,691
Accrued payroll and related costs		204,311		215,322
Third party royalties		1,049,013		329,211
Other accruals		117,635		86,232
Total	$	1,781,163	$	933,998

XML 25 R16.htm IDEA: XBRL DOCUMENT

PATENT COSTS (Tables)

3 Months Ended

Mar. 31, 2018

PATENT COSTS [Abstract]

Net Patent Costs

For each period presented below, net patent costs consisted of:

	March 31, 2018			December 31, 2017
Patents		969,614		$	925,016
Accumulated amortization		(543,829	)		(527,023	)
	$	425,785		$	397,993

Estimated Aggregate Future Amortization Expense

The estimated aggregate amortization expense for the remaining nine months of 2018 and each of the years below is approximately as follows:

April 1, 2018 - December 31, 2018	$	51,000
2019		66,200
2020		50,400
2021		34,500
2022		34,500
Thereafter		189,185

XML 26 R17.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND DESCRIPTION OF BUSINESS (Details) - Endo [Member] - Licensing Revenues [Member] - USD ($) $ in Thousands	1 Months Ended
	Feb. 29, 2016	Mar. 31, 2018
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue on licensing agreements		$ 8,250
Proceeds from licensing agreement	$ 8,250
Opt-in fee receivable for each indication		500
Regular opt-in fee receivable for each indication		$ 750

XML 27 R18.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Recent Accounting Pronouncements (Details) - USD ($)

3 Months Ended

Mar. 31, 2018

Mar. 31, 2017

Dec. 31, 2017

Assets [Abstract]

Accounts receivable

$ 19,165,670

^[1]

$ 4,655,105

Deferred royalty buy-down

1,648,319

^[1]

1,794,126

Deferred royalty buy-down

1,600,000

2,500,000

Deferred tax assets, net

403,944

^[1]

1,739,706

Liabilities [Abstract]

Accounts payable and accrued expenses

1,781,163

^[1]

933,998

Deferred revenue

135,000

6,400,000

Deferred revenue

117,635

^[1]

1,057,979

Income tax payable

2,535,676

^[1]

68,733

Deferred revenue, long term

17,635

^[1]

5,340,708

Equity [Abstract]

Retained earnings adjustment

56,102,054

^[1]

41,939,115

Contract assets

7,000,000

Revenues [Abstract]

Total revenues

7,089,409

^[1]

$ 7,690,619

Costs and expenses [Abstract]

General and administrative

2,069,633

^[1]

2,425,717

Provision for income taxes

1,078,574

^[1]

1,769,683

Net income

3,978,604

^[1]

3,344,753

Endo [Member]

Assets [Abstract]

Accounts receivable

19,165,670

4,655,105

Deferred royalty buy-down

(2,500,000)

Deferred tax assets, net

1,739,706

Liabilities [Abstract]

Accounts payable and accrued expenses -third party royalties

(400,000)

Deferred revenue

(6,400,000)

Income tax payable

Equity [Abstract]

Retained earnings adjustment

(2,900,000)

Revenues [Abstract]

Total revenues

7,089,409

7,690,619

Royalties [Member]

Revenues [Abstract]

Total revenues

7,085,000

^[1]

$ 7,686,210

ASU 2014-09 [Member] | Endo [Member]

Assets [Abstract]

Accounts receivable

12,300,000

Deferred royalty buy-down

(2,900,000)

Deferred tax assets, net

400,000

Liabilities [Abstract]

Accounts payable and accrued expenses -third party royalties

(900,000)

Deferred revenue

(100,000)

Income tax payable

(1,400,000)

Equity [Abstract]

Retained earnings adjustment

7,400,000

Adjustments / Effect of Change Higher / (Lower) [Member] | ASU 2014-09 [Member]

Assets [Abstract]

Accounts receivable

7,045,000

Deferred royalty buy-down

(366,279)

Deferred tax assets, net

(1,292,988)

Liabilities [Abstract]

Accounts payable and accrued expenses

510,000

Deferred revenue

(906,219)

Income tax payable

1,246,699

Deferred revenue, long term

(5,155,930)

Equity [Abstract]

Retained earnings adjustment

9,661,338

Costs and expenses [Abstract]

General and administrative

(17,418)

Provision for income taxes

(141,670)

Net income

(522,314)

Adjustments / Effect of Change Higher / (Lower) [Member] | ASU 2014-09 [Member] | Endo [Member]

Assets [Abstract]

Accounts receivable

^[2]

7,600,000

Deferred royalty buy-down

^[3]

(400,000)

Deferred tax assets, net

^[4]

(1,300,000)

Liabilities [Abstract]

Accounts payable and accrued expenses -third party royalties

^[3]

(500,000)

Deferred revenue

^[5]

6,300,000

Income tax payable

^[6]

(1,400,000)

Equity [Abstract]

Retained earnings adjustment

$ 10,300,000

Adjustments / Effect of Change Higher / (Lower) [Member] | ASU 2014-09 [Member] | Royalties [Member]

Revenues [Abstract]

Total revenues

(646,566)

Adjusted / Balances Without Adoption of New Revenue Standard [Member] | ASU 2014-09 [Member]

Assets [Abstract]

Accounts receivable

12,120,670

Deferred royalty buy-down

2,014,598

Deferred tax assets, net

1,696,932

Liabilities [Abstract]

Accounts payable and accrued expenses

1,271,163

Deferred revenue

1,023,854

Income tax payable

1,288,977

Deferred revenue, long term

5,173,564

Equity [Abstract]

Retained earnings adjustment

46,440,716

Costs and expenses [Abstract]

General and administrative

2,087,921

Provision for income taxes

1,220,244

Net income

4,500,918

Adjusted / Balances Without Adoption of New Revenue Standard [Member] | ASU 2014-09 [Member] | Royalties [Member]

Revenues [Abstract]

Total revenues

$ 7,731,566

[1]	As of January 1, 2018, the Company adopted the requirements of ASC 606 using the modified retrospective adoption method, and as a result, there is a lack of comparability of certain amounts to the prior periods presented. See Note 2 for additional discussion.
[2]	This adjustment represents the elimination of the one quarter lag by recognizing royalty revenues based on of XIALFLEX net sales and mark-up on cost of goods sold revenues reported to us by Endo for the fourth quarter of 2017.
[3]	Represents the amortization of the royalty buy-down and third party royalties expense associated royalty revenues based on XIALFLEX net sales reported to us by Endo for the fourth quarter of 2017.
[4]	To reverse a deferred tax asset associated with the deferred revenue balance of the prepaid mark-up on cost of goods sold by non-affiliated sublicensees of Endo outside of the U.S.
[5]	Represents the remaining deferred revenue balance of the prepaid mark-up on cost of goods sold based on sales by non-affiliated sublicensees of Endo outside of the U.S.
[6]	To create a tax liability associated the elimination of the one quarter lag by recognizing royalty revenues based on of XIALFLEX net sales and mark-up on cost of goods sold revenues reported to us by Endo for the fourth quarter of 2017.

XML 28 R19.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Cash, Cash Equivalents and Investments (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Cash, Cash Equivalents and Investments [Abstract]
Aggregate fair value of investments	$ 51,600,000	$ 57,700,000
Held-to-maturity securities, unrecognized gain	0	0
Held-to-maturity securities, unrecognized loss	$ 0	$ 0

XML 29 R20.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Fair Value Measurements (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Fair Value Measurements [Abstract]
Held-to-maturity securities, unrecognized loss	$ 0	$ 0
Amortized premium included in interest income	(160,000)	(673,000)
Schedule of Held-to-maturity Securities [Line Items]
Held-to-maturity securities, current	48,751,206	51,973,971
Held-to-maturity securities, noncurrent	2,840,191	5,745,974
Recurring [Member] \| Institutional Money Market [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	7,432,432	3,108,549
Recurring [Member] \| Municipal Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents		800,000
Investments	3,525,134	1,102,650
Recurring [Member] \| Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	2,585,000
Investments	42,328,363	51,299,068
Recurring [Member] \| Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	250,000
Investments	5,737,900	5,318,227
Recurring [Member] \| Level 1 [Member] \| Institutional Money Market [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	7,432,432	3,108,549
Recurring [Member] \| Level 1 [Member] \| Municipal Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents		0
Investments	0	0
Recurring [Member] \| Level 1 [Member] \| Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	2,585,000
Investments	0	0
Recurring [Member] \| Level 1 [Member] \| Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	250,000
Investments	5,737,900	5,318,227
Recurring [Member] \| Level 2 [Member] \| Institutional Money Market [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Recurring [Member] \| Level 2 [Member] \| Municipal Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents		800,000
Investments	3,525,134	1,102,650
Recurring [Member] \| Level 2 [Member] \| Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0
Investments	42,328,363	51,299,068
Recurring [Member] \| Level 2 [Member] \| Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0
Investments	0	0
Recurring [Member] \| Level 3 [Member] \| Institutional Money Market [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Recurring [Member] \| Level 3 [Member] \| Municipal Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents		0
Investments	0	0
Recurring [Member] \| Level 3 [Member] \| Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0
Investments	0	0
Recurring [Member] \| Level 3 [Member] \| Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0
Investments	0	0
Municipal Bonds [Member]
Schedule of Held-to-maturity Securities [Line Items]
Held-to-maturity securities, current	3,425,134	1,002,650
Held-to-maturity securities, noncurrent	100,000	100,000
Corporate Bonds [Member]
Schedule of Held-to-maturity Securities [Line Items]
Held-to-maturity securities, current	41,828,133	48,143,495
Held-to-maturity securities, noncurrent	500,230	3,155,573
Certificates of Deposit [Member]
Schedule of Held-to-maturity Securities [Line Items]
Held-to-maturity securities, current	3,497,939	2,827,826
Held-to-maturity securities, noncurrent	$ 2,239,961	$ 2,490,401

XML 30 R21.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Concentration of Credit Risk and Major Customers and Revenue Recognition (Details)

3 Months Ended

Mar. 31, 2018

USD ($)

Customer

Mar. 31, 2017

USD ($)

Dec. 31, 2017

USD ($)

Concentration Risk [Line Items]

Total revenues

$ 7,089,409

^[1]

$ 7,690,619

Accounts receivable

19,165,670

^[1]

$ 4,655,105

Royalties [Member]

Concentration Risk [Line Items]

Total revenues

7,085,000

^[1]

7,686,210

Licensing Revenues [Member]

Concentration Risk [Line Items]

Total revenues

$ 4,409

^[1]

4,409

Endo [Member]

Concentration Risk [Line Items]

Number of customers | Customer

Total revenues

$ 7,089,409

$ 7,690,619

Accounts receivable

$ 19,165,670

$ 4,655,105

[1]	As of January 1, 2018, the Company adopted the requirements of ASC 606 using the modified retrospective adoption method, and as a result, there is a lack of comparability of certain amounts to the prior periods presented. See Note 2 for additional discussion.

XML 31 R22.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Treasury Stock, Receivables and Doubtful Accounts and Deferred Revenue (Details) - USD ($)

3 Months Ended

Mar. 31, 2018

Mar. 31, 2017

Dec. 31, 2017

Treasury Stock [Abstract]

Treasury stock purchased (in shares)

4,260

Average price of share (in dollars per share)

$ 52.07

Receivables and Doubtful Accounts [Abstract]

Accounts receivable

$ 19,165,670

^[1]

$ 4,655,105

Deferred Revenue [Abstract]

Deferred revenue

135,000

6,400,000

Adjustments / Effect of Change Higher / (Lower) [Member] | ASU 2014-09 [Member]

Receivables and Doubtful Accounts [Abstract]

Accounts receivable

7,045,000

Nonrefundable Upfront Product License Fees [Member]

Deferred Revenue [Abstract]

Deferred revenue

35,000

Milestone Payment Due Foreign Tax Withholding [Member]

Deferred Revenue [Abstract]

Deferred revenue

100,000

Endo [Member]

Receivables and Doubtful Accounts [Abstract]

Accounts receivable

$ 19,165,670

4,655,105

Deferred Revenue [Abstract]

Deferred revenue

(6,400,000)

Endo [Member] | ASU 2014-09 [Member]

Receivables and Doubtful Accounts [Abstract]

Accounts receivable

12,300,000

Deferred Revenue [Abstract]

Deferred revenue

(100,000)

Endo [Member] | Adjustments / Effect of Change Higher / (Lower) [Member] | ASU 2014-09 [Member]

Receivables and Doubtful Accounts [Abstract]

Accounts receivable

^[2]

7,600,000

Deferred Revenue [Abstract]

Deferred revenue

^[3]

$ 6,300,000

[1]	As of January 1, 2018, the Company adopted the requirements of ASC 606 using the modified retrospective adoption method, and as a result, there is a lack of comparability of certain amounts to the prior periods presented. See Note 2 for additional discussion.
[2]	This adjustment represents the elimination of the one quarter lag by recognizing royalty revenues based on of XIALFLEX net sales and mark-up on cost of goods sold revenues reported to us by Endo for the fourth quarter of 2017.
[3]	Represents the remaining deferred revenue balance of the prepaid mark-up on cost of goods sold based on sales by non-affiliated sublicensees of Endo outside of the U.S.

XML 32 R23.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Reimbursable Third-Party Patent Costs, Third party Royalties and Royalty Buy-Down (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2018 USD ($) Payment	Mar. 31, 2017 USD ($)	Mar. 31, 2012 USD ($) Payment	Dec. 31, 2017 USD ($)
Reimbursable Third-Party Patent Costs [Abstract]
Accrued patent costs	$ 134			$ 0
Third-Party Royalties [Abstract]
Royalty expenses	500	$ 500
Royalty Buy-Down [Abstract]
Initial payment for royalty buy down	$ 600		$ 1,500
Number of additional cash payments for royalty buy-down \| Payment			5
Number of cash payments made for royalty obligation \| Payment	5
Deferred costs, amortization period	5 years
Amount amortized related to agreement	$ 500	$ 400
Deferred royalty buy-down	$ 1,600			$ 2,500

XML 33 R24.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Stock-Based Compensation (Details)

3 Months Ended

12 Months Ended

Mar. 31, 2018

USD ($)

Plan

Director

$ / shares

Mar. 31, 2017

USD ($)

Dec. 31, 2016

Mar. 29, 2018

$ / shares

Share-Based Compensation [Abstract]

Number of stock based compensation plans | Plan

Additional Disclosures [Abstract]

Proceeds from stock option exercises

$ 132,400

^[1]

$ 258,250

Closing price of common stock (in dollars per share) | $ / shares

$ 44.34

General and Administrative [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Stock-based compensation expense

$ 33,000

Stock Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of board of directors granted options | Director

Options grant date fair value

$ 540,000

Volatility rate

39.60%

Risk free rate

2.62%

Expected term

6 years 3 months

Stock Options Activity [Roll Forward]

Outstanding, beginning of period (in shares) | shares

232,000

Grants (in shares) | shares

30,000

Exercised (in shares) | shares

(10,000)

Forfeitures or expirations (in shares) | shares

Outstanding, end of period (in shares) | shares

252,000

Exercisable, end of period (in shares) | shares

207,000

Weighted Average Exercise Price [Roll Forward]

Outstanding, beginning of period (in dollars per share) | $ / shares

$ 21.56

Grants (in dollars per share) | $ / shares

41.82

Exercised (in dollars per share) | $ / shares

13.24

Forfeitures or expirations (in dollars per share) | $ / shares

Outstanding, end of period (in dollars per share) | $ / shares

24.30

Exercisable, end of period (in dollars per share) | $ / shares

$ 20.80

Weighted Average Remaining Contractual Term [Roll Forward]

Outstanding

3 years 3 months 14 days

2 years 6 months 7 days

Grants

0 years

Exercised

0 years

Forfeitures or expirations

0 years

Exercisable

2 years 14 days

Aggregate Intrinsic Value [Roll Forward]

Outstanding, beginning of period

$ 5,050,990

Grants

Exercised

Forfeitures or expirations

Outstanding, end of period

5,049,910

Exercisable, end of period

4,873,810

Additional Disclosures [Abstract]

Proceeds from stock option exercises

132,000

$ 258,000

Unrecognized compensation cost

$ 648,000

Recognized compensation period

3 years 5 months 12 days

[1]	As of January 1, 2018, the Company adopted the requirements of ASC 606 using the modified retrospective adoption method, and as a result, there is a lack of comparability of certain amounts to the prior periods presented. See Note 2 for additional discussion.

XML 34 R25.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Property and Equipment, Comprehensive Income, Provision for Income Taxes and Commitments and Contingencies (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Comprehensive Income [Abstract]
Other comprehensive income	$ 0	$ 0
Income Taxes [Abstract]
Unrecognized tax benefits	$ 0		$ 0
Commitments and Contingencies [Abstract]
Additional lease term extension period	1 year
Monthly base rent	$ 11,165
Notice period to cancel lease agreements	3 months
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	5 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	10 years

XML 35 R26.htm IDEA: XBRL DOCUMENT

NET INCOME PER SHARE (Details) - Stock Options [Member] - $ / shares		3 Months Ended
	Oct. 25, 2017	Mar. 31, 2018	Mar. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from earnings per share calculation (in shares)		0	20,000
Exercise Price of $29.21 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Exercise price (in dollars per share)			$ 29.21
Options cancelled (in shares)	(20,000)

XML 36 R27.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - USD ($)

Mar. 31, 2018

Dec. 31, 2017

Accounts payable and accrued expenses [Abstract]

Trade accounts payable

$ 215,639

$ 152,542

Accrued legal and other professional fees

194,565

150,691

Accrued payroll and related costs

204,311

215,322

Third party royalties

1,049,013

329,211

Other accruals

117,635

86,232

Total

$ 1,781,163

^[1]

$ 933,998

[1]	As of January 1, 2018, the Company adopted the requirements of ASC 606 using the modified retrospective adoption method, and as a result, there is a lack of comparability of certain amounts to the prior periods presented. See Note 2 for additional discussion.

XML 37 R28.htm IDEA: XBRL DOCUMENT

PATENT COSTS (Details) - USD ($)

3 Months Ended

Mar. 31, 2018

Mar. 31, 2017

Dec. 31, 2017

Net Patent Costs [Abstract]

Net Patent Costs

$ 425,785

^[1]

$ 397,993

Patents [Member]

Net Patent Costs [Abstract]

Patents

969,614

925,016

Accumulated Amortization

(543,829)

(527,023)

Net Patent Costs

425,785

$ 397,993

Amortization expense for patents

16,800

$ 10,200

Estimated aggregate amortization expense [Abstract]

April 1, 2018 - December 31, 2018

51,000

66,200

50,400

34,500

34,500

$ 189,185

Patents [Member] | Minimum [Member]

Finite-Lived Intangible Assets [Line Items]

Estimated useful lives

2 years

Patents [Member] | Maximum [Member]

Finite-Lived Intangible Assets [Line Items]

Estimated useful lives

10 years

[1]	As of January 1, 2018, the Company adopted the requirements of ASC 606 using the modified retrospective adoption method, and as a result, there is a lack of comparability of certain amounts to the prior periods presented. See Note 2 for additional discussion.

XML 38 R29.htm IDEA: XBRL DOCUMENT

PROVISION FOR INCOME TAXES (Details) - USD ($)

3 Months Ended

Mar. 31, 2018

Mar. 31, 2017

Dec. 31, 2017

PROVISION FOR INCOME TAXES [Abstract]

Provision for income taxes

$ 1,078,574

^[1]

$ 1,769,683

Deferred tax assets

400,000

$ 1,700,000

Unrecognized tax benefits

$ 0

Interest and penalties

$ 0

[1]	As of January 1, 2018, the Company adopted the requirements of ASC 606 using the modified retrospective adoption method, and as a result, there is a lack of comparability of certain amounts to the prior periods presented. See Note 2 for additional discussion.

XML 39 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; EXCEL 40 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

XML 41 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 43 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 89 195 1 true 27 0 false 8 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://biospecifics.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 010000 - Statement - Condensed Consolidated Balance Sheets (unaudited) Sheet http://biospecifics.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (unaudited) Statements 2 false false R3.htm 010100 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) Sheet http://biospecifics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) Statements 3 false false R4.htm 020000 - Statement - Condensed Consolidated Income Statements (unaudited) Sheet http://biospecifics.com/role/CondensedConsolidatedIncomeStatementsUnaudited Condensed Consolidated Income Statements (unaudited) Statements 4 false false R5.htm 030000 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) Sheet http://biospecifics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (unaudited) Statements 5 false false R6.htm 060100 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS Sheet http://biospecifics.com/role/OrganizationAndDescriptionOfBusiness ORGANIZATION AND DESCRIPTION OF BUSINESS Notes 6 false false R7.htm 060200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://biospecifics.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 7 false false R8.htm 060300 - Disclosure - NET INCOME PER SHARE Sheet http://biospecifics.com/role/NetIncomePerShare NET INCOME PER SHARE Notes 8 false false R9.htm 060400 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES Sheet http://biospecifics.com/role/AccountsPayableAndAccruedExpenses ACCOUNTS PAYABLE AND ACCRUED EXPENSES Notes 9 false false R10.htm 060500 - Disclosure - PATENT COSTS Sheet http://biospecifics.com/role/PatentCosts PATENT COSTS Notes 10 false false R11.htm 060600 - Disclosure - PROVISION FOR INCOME TAXES Sheet http://biospecifics.com/role/ProvisionForIncomeTaxes PROVISION FOR INCOME TAXES Notes 11 false false R12.htm 070200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://biospecifics.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 12 false false R13.htm 080200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://biospecifics.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://biospecifics.com/role/SummaryOfSignificantAccountingPolicies 13 false false R14.htm 080300 - Disclosure - NET INCOME PER SHARE (Tables) Sheet http://biospecifics.com/role/NetIncomePerShareTables NET INCOME PER SHARE (Tables) Tables http://biospecifics.com/role/NetIncomePerShare 14 false false R15.htm 080400 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) Sheet http://biospecifics.com/role/AccountsPayableAndAccruedExpensesTables ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) Tables http://biospecifics.com/role/AccountsPayableAndAccruedExpenses 15 false false R16.htm 080500 - Disclosure - PATENT COSTS (Tables) Sheet http://biospecifics.com/role/PatentCostsTables PATENT COSTS (Tables) Tables http://biospecifics.com/role/PatentCosts 16 false false R17.htm 090100 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details) Sheet http://biospecifics.com/role/OrganizationAndDescriptionOfBusinessDetails ORGANIZATION AND DESCRIPTION OF BUSINESS (Details) Details http://biospecifics.com/role/OrganizationAndDescriptionOfBusiness 17 false false R18.htm 090200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Recent Accounting Pronouncements (Details) Sheet http://biospecifics.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Recent Accounting Pronouncements (Details) Details 18 false false R19.htm 090202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Cash, Cash Equivalents and Investments (Details) Sheet http://biospecifics.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndInvestmentsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Cash, Cash Equivalents and Investments (Details) Details 19 false false R20.htm 090204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Fair Value Measurements (Details) Sheet http://biospecifics.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Fair Value Measurements (Details) Details 20 false false R21.htm 090206 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Concentration of Credit Risk and Major Customers and Revenue Recognition (Details) Sheet http://biospecifics.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskAndMajorCustomersAndRevenueRecognitionDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Concentration of Credit Risk and Major Customers and Revenue Recognition (Details) Details 21 false false R22.htm 090208 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Treasury Stock, Receivables and Doubtful Accounts and Deferred Revenue (Details) Sheet http://biospecifics.com/role/SummaryOfSignificantAccountingPoliciesTreasuryStockReceivablesAndDoubtfulAccountsAndDeferredRevenueDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Treasury Stock, Receivables and Doubtful Accounts and Deferred Revenue (Details) Details 22 false false R23.htm 090210 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Reimbursable Third-Party Patent Costs, Third party Royalties and Royalty Buy-Down (Details) Sheet http://biospecifics.com/role/SummaryOfSignificantAccountingPoliciesReimbursableThirdpartyPatentCostsThirdPartyRoyaltiesAndRoyaltyBuydownDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Reimbursable Third-Party Patent Costs, Third party Royalties and Royalty Buy-Down (Details) Details 23 false false R24.htm 090212 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Stock-Based Compensation (Details) Sheet http://biospecifics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Stock-Based Compensation (Details) Details 24 false false R25.htm 090214 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Property and Equipment, Comprehensive Income, Provision for Income Taxes and Commitments and Contingencies (Details) Sheet http://biospecifics.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentComprehensiveIncomeProvisionForIncomeTaxesAndCommitmentsAndContingenciesDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Property and Equipment, Comprehensive Income, Provision for Income Taxes and Commitments and Contingencies (Details) Details 25 false false R26.htm 090300 - Disclosure - NET INCOME PER SHARE (Details) Sheet http://biospecifics.com/role/NetIncomePerShareDetails NET INCOME PER SHARE (Details) Details http://biospecifics.com/role/NetIncomePerShareTables 26 false false R27.htm 090400 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) Sheet http://biospecifics.com/role/AccountsPayableAndAccruedExpensesDetails ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) Details http://biospecifics.com/role/AccountsPayableAndAccruedExpensesTables 27 false false R28.htm 090500 - Disclosure - PATENT COSTS (Details) Sheet http://biospecifics.com/role/PatentCostsDetails PATENT COSTS (Details) Details http://biospecifics.com/role/PatentCostsTables 28 false false R29.htm 090600 - Disclosure - PROVISION FOR INCOME TAXES (Details) Sheet http://biospecifics.com/role/ProvisionForIncomeTaxesDetails PROVISION FOR INCOME TAXES (Details) Details http://biospecifics.com/role/ProvisionForIncomeTaxes 29 false false All Reports Book All Reports bstc-20180331.xml bstc-20180331.xsd bstc-20180331_cal.xml bstc-20180331_def.xml bstc-20180331_lab.xml bstc-20180331_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2017-01-31 true true ZIP 45 0001140361-18-022751-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-18-022751-xbrl.zip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ÐR.L#('W6,ZYY:'[IDB ^XBO3Z67GA! M]6LM)$I<]ARE/JR9;LK)?[HXW'A/6X"A1( H+6I=]--R&0F,;M"EW ;#9IRA MV9B[%I];TV6HII%Q7:[QUA!XKR&\S>::"OC$L(RK(VM=I^R"@HM&:YU;Y;S! M?*+XL-/Z!3UL("[YI/W+6U/=S@H307;G)9?%<@N1F,0<6[- F#M!@X,%D\ZG2?=7O:D>DY$ P7%8$)IU"9+E&$]T#[[+*%L*4SN M,$2CUL.3OVW@+6?\9.;;PF6%D@L%+45ZZ=6R' G,PHU4T(L3K7GB6,\#O\Z( M:RMSZH_"'<_(D3T;+H:L.-2JECD@0/J:50!5)^R:["#VONH*'! M!4J5#Y R"A(5[UP$,G&I&A=V&V]_T_'EKHC[3NB68.8SO/70S;))(8YEJ+(( MQ_CY>Q=FV;@>3WV*)Q? VDPN#F2D1\Q&@++@I-5)T?94!3)#4&&5;)&=U'3- M:$LT4/RIO,L-"GDNH ?C#>L!=WJ M=<*I9.ME\Z'H^>SR*K<@OQ\E.-[V4,K(9'JI(L'224:_1R^FF N%=589+ET0XK45/97RN22+.;<[ M:@[^DME@$]<9+X]/\$0PD CN- >=O[!=ZJU">=#L]/D0N48RM[SA/N*I%]X) M7K$*"&Z%\,H906S6W.;\IHU*-HDOY>6 F3LO5[ZH-)4X[Q1#!^&*)<;%"?S4 M$I+I$*[KCQ,_:=NY*(]1:EN@3ED59$>@"$Y/H1.W*DDO3H;!B"C7=G,\)%MR M=*$0R)YK9^59*KID=C(E3(-P"3$ 2%E^& >P@H59P.9XCL;^] :B_" K))4W MIB+ J2OFA^G<^09 7G!)7_,)B_V0 4Z2#+NZ\GB@>.>3UUTDR]:[CP]2:%)B M27+XK,KLR)H=:VKKU,$SNUZW?&IE,FP'L]HF413/19?O?'9)M%/1"8M".,MY MSX\G3NS%]\Z[@AN6T/C*#'7&X<5%7?;W#(S"V0Q#CCG+3%E/DMILHL+F=!9P M<^88OR4%?BM<_^'=GE47%X6114XYWOP&/"'@Q>"O;UIOP$!VW3FFBWEWR;_# MN356_WXNJ:H^;/\OJ3/RA.8%O>$CY?8EO0U^])W1F?\H7(:2RND^:SAPR& 9 M8;S.FVUKSJZM(4R[E0S_;RWZ/R3#('>U'&]O0U"-H2/9FNJIKO\KV?_?Z5<E3HK MV]/XY_(4&=RZ/5%P(X*99O[7ROQG=W>8HAKMB_\N ?Z.%SKC/8W_WQAK/"3X M/Z]Q6Z'OLVU#D1(]S'2"7[-5*:/55/K']T1W3SF<[BF=;@?C454QF>[2\Y2Y ME["_/[V$56L(UW:S/]!@K2-8CTDH-OL=#;(Z@DQ+Q-56CJU^RQR-#E"%5V,M M[RI#*K66?\/SY=(['.M6W\]J]5T"2W'V3:WX27>4/SZ8]=K-TWJ9&1IEQX>R M>K5'U0C3"*O!*A]+G%:=3:\<#[XRM_"(8@\G[?I9GV7/\:V&Z[' M=UM=GKU M!>MKCI4=$-9XUGC6>-9X_DHP^);5ZU< MRF@NZ!JOPY&'[<:OJ_W4Z>L,Y]I";S=;?CPI?FM!W6MV-:1K">GCEJ;=9F>D M<5='W&E1^KP9]LU6;V2.V@UUFMG QFSW:ZSIWK$(LL&G3&M;. M7M=IB\>L9"H!=?-40[J6D#YR:=ILU2L]2^-.B](7S;!GG@Z[YFG-[/6GQM=_ MICJ-F652?U9:$O/#4VI=IJU;HTP/B[1;S%+33"XL(1MF]D^Y W&V6:;)96/S M1:Y557%JKB5+CV3@CW8LH9+Y\B"V8&0=4+#3(==^*@1 M63]6?IQ4.N8>+SY5V,X5E<^UJ,"VK;U>L]O#1WC3.J.DP#B5RG^@UB]IR^=D MUV0/X/Q*PP]M+@2=_SC=''C&"=*F&;(VOL55EJF\.(VUA(E!CV# G9PRU717 MBA5G>W?D\>%GSW$*.Y+*":NR\]2\-BE[G)3+]F +C6ZS]TC!\5TB:(,?G /5 MMP"+-$<+8J6+/V.'^G)MR0PK?1(KY8<,N5L8]GT?3QU/!$NO AD2!QY7[>9FZ#\H9]#DLLQQY',CA^1ELONV M\5C#$B?(U B/0X&MO[C'.,"-FE]C*7[@(H:.\0F;;2./8+O;P+_/-#]+.UPG MR,.)S2S4(1?A M?PI_H28+Q!0$$&[M)75EKU@=?:6GSI1*-Q)S27EO1/*8OYR)XT;ZT=A=\J:F0X?Q$10 MHW0T"&3#;MQ$U^%>X=0^-M\S+V["XKO] K>@=*ISO.J@B[BQL^TI]RA&.]LI*&<[$S*_&@RR;:ECWEL/] M]<2]8^.T3 ROIZZ@KO.'VB9,-3]B&V8D'@@8 N(^6YU3&ST"=_C0]21PZ)& M\E5SQVY;(O\N.^"H%O*YS5O(EFNTMVEC'N2\=/M)$X<&/HM])+&![S9-['JM M1KO5Z/0;G:;Q7;;_P2V3/=Z2W<@/]# ERY;;!IG$+:B.'3O%18)&VM0$ZFN0 M#D8[JF_JQ&0_ =2JQ15R"I@@P%7<441X%K,H-@')M=9HYAOG77JTI(%-O$ M M(+=>M1ZL6G^'/0"E6+U.I,"Y"ZN0D@&K/D&LW9Q57(SY#Y5_.2" M&V?3 TN-+[,;+!M!);]5;3E(Z,"FS-5 JAL?:K':,.1-WF=F&8Y-70A/W!.< M'6(+O2/5QXPF!@X@+ZT'LLJ9;!1@9"ED'R11=8N];$-\JVQ[_,-*>INB&VC] M(*3'P&,!P7A)ID9B/.5NHS, ;92PD1J%&P%EIA,N=4R1C7G3EGN%W6DY*( ] M>A/RD9/3IMM9FEQLW1U&R0+2]*?4Y0L\<6RJPTO3;_V%E\J9^BRR;@6U$9-R MF[O-4A\YV0,195;D$DW4?6=K&SL;'$%*<%>2;CCX8<[US2Y7S4RK3,MO?S9S M(NG5>-A7E0012$ZG1HV_/>,+^EZX&X.BS:#"PH1$;'/EI7VJTQZ[GV!VKA]P M@ZL?D9#FC&I0EKA>JH7R?PK+_C.V FKJC5(=7VMS.V?LY :N)?J(JK'/"3[S M[VE/U L: D@B#](X4P0E/VG_\E8VA59O(JK"A*=E:^MDXMT6@[-I?,LT)\=A MUXUE*KV(1HQ'@N6G=MML#_I(M70UE%VGEI*:VE'KXLR:R%5,PXAJ&NWA+QB] M@N5Y +F!CC/P! :S)&G)JEMLY $#BEP;'EC^M1VC_N/G.&S<6=;\W;63M*1* ME>4W;)H-*+V!A7OO^N,_?OW?_\LP_N/_-!K4U$2V>\JUL#T+ FS71\@ N9C] MG>PT;IQQ\T1N= 1R\B+IA0AB[AMM=N-"M>7*-47ZG\^T4?^OT6!"$N+Q1Y?4 M:Y:#LOP6[KQ"7\K!DI(?U-<:9G4E)G]],\9-;[5;[ M_ T(=C8IZ>4?$O_O/;M_5^)>>+'X+7;(\;KT^+'W E2[.//LLPFHHAM_[HP' MK8$<^]E;V\^R3^?-KPV84%[4/G6[#VS77K!R)2P630BTZ,_&>\NU*-SU.Q@P M?@S:W9;G7L K9'HR+!*_>P.C/%?4UHDUSBUWS.93SM9]\VN16[DQN)6ZG54D-^>\U8WKM*\SE-VHQ#6]WX6_*2T#7%8]4*;J6G#>P]VZK M34@&I3:]R0&MZX?HXW$;9@IV?^$@/O=BB5NXL!\"LPQ-)I.9L2D([8:-IG!N_2C,0SN XP M#N]X(@2_=6Z%L&@H4+#]+69Z."'%JY.(B'K:3 Z.!)#LSV LQ[/A2_AQ!)_; M\LB=6]V3'YP,+"=,?GS83 %F?(V#POV]98V,L8AH,<>0(YY,@P:F]48CP:1% MQJ@(10!Y 2P75F,.CNC,&HN8K7P_-S8'Y+I\/(X_H%P9 M*XU3PE\VA^F Y>Q"_QZ=(** H M2&45;2R5@I-#R([*D#C*@L5H3=ILW C,)A/QO7E;U\N/UZ>GWVY M,<[.S[]^_W)S^>4WX]O73Y?GEQ?7E1!D-(RKB_.+)0JNOGZ!O\\O/L,7>3K@ M]SL[%\\4.%XW 1V0+OBXP32H=^:JL\4_HM_0 M+YX34AV>CDX[N=C+RFM+)^M)P>CN,VD,F<:0SC*,$S 4^,^WCQ+,1Q_;4+QZ MN-)KMT;=WAHJ^<4[)K-@OTLB4^[X_]_>E?6VC63KOR+XWH0B&.PY>>[4K=,$4"90 M.L8"PR9"F01_+OZZ65#DT#SBZZ):G*-GEJ[C$)1:XY M!D2Q=N0H.U*\]QFZ&PV[SZ\-&G:XGO8AH<*M\COKH6*OL[WQ__B_$#;0P;B! M-6NQ>/?C1+WY^"R4KR$(#$PH)K#A:(JN9AENQI=5M9S.G>69OV>\W;Q,YTFI MPA+!*@([;-P6'&U0NK?'O(&UK)A-BG(*YA;4ICX??SKN_/'RY;DTIE#BV)(D M5DPCN;)BA?IGOU;*H,+6$;TJI(.1=<MC+0XKX$ W>9I=*L)/YXDY19L:PX?V-M M^0TK(V422"M7EU.-P*R-FCOET($\&E'3P#3!8&#]?Y?C*UZ5(7A,47)D,@#F M,!K1T5T[-)I#R=AB+YZ2BT!K1)<@Y 6,%DN,P:99@>V0 K:5U5WP1_.&8GYE M2/?"HKXHM46T'FK]%F.Q2^08*?-BPJ"OHWB9T7K2#7Q!5PH,9@3J=07N.E2Y"VWCE*VX4E;1T/ MHB R0K_V^K;'7-A=)[)TY A8\BQX9NK(;;!DG.5+.-,/Q)0W--S:E [%EEBP M)10OA(.M;&F:BN>,V6_7A&%P=@A>2/M5A^,&"#:.1N52L( UGZK3PS.P4SL# MW4%,PVHQ>BZ'Y5$AO('&E$/B@#B>/E(/'*,'X4@R&NG.DSH,H^X<'F-S>%.P MS*'9_LA":0X4#R@T\5[LB4SM'%;X(XC&O7;YLX.MR)^4 $%BV;DL.J\IFZ*6 MG%%9K*67Z)W+@M[ %_3SV\T0Y^$')F"'X=1\/T!"1[ZB%!%QH&#&QQ@4["FD M/5C3Y&!#0+1^OU!S)/?\)%6,CS^*"&71F5W="''D6NV MD$MCMW0/G#M^[Q5\SIR5,:E7*_T(3PCGP[/!N;SC,TW-H\EO%K6U" M6EG$6E.QWW53,4]6UIC@Q]*8WF-8[/UHTR&Q]UDZ>9/BJ&!DXC%Y2'G.M *#SM;N]Z!VOV^>E8,YHZ2Z5C'4 MG6G"4=#2A50,\^P*5]')A-?B;895U0?QKK@!V"_P4;VX'X2)UTB,:R3N\DT' MH49TN$VS2>YPN>J Q\Q)[$LU@CD%_?E7RQ4X0M;H#12]P5WHW?&SBF15M OB M501(HVI_M!1R^V_92@U0ZD*;>4\/[B=Q7O$Q(1' M+P:FR:3I&RW.=J- K%EX^O%>TY4FM'FRH%S!JF:QX0?.\>\D(WL'Y0@F]L/( MLCO5QCSH?+8%V,!\=IB*/@R4L6V#T5"=-RIKRIUWN8?U+MJJGZEQC.3%;#I< MEH1+3&LH43QA0ZM\[&WSD=? H6^8&Z6D&-K MVW# #(9)&,0L"LH>&ZXZ2QES@"5L!)B:F99;2NY+YA@A_E>J8E*L;QAI%?S[ MO"RJ=+1QH>HA. ?>ES2(C:(:I MDK.F')\P4H7!_TK+PD[KV1"?<*?-I?>VCJ'HX$VQ=1M;9_YCWK/;$G'KX2<> M[-QM4_XXLS=%@#F6:Q7 Q$X=FSE1J;A1J-ZC71OL30D5J*$49.>?QYT_TGR( MAF6*5GNYO!*SZ@1G\*73IUUS6\.@7.EQ'>;+N+\9)QCBI\[355G,LM2*ZQL+ MA0TK/E]BY)2<=3JC!/(E9AE+H-1).EBV4F=_;IY!^HV2=F4!LXR\IQ9TQXRP M_G%L)>=-*)6M >O#&P+]4=U_+J5*<66Z##WFW+K*N)N)HQ>.:5-"-)3IPTE@ M(6[.Y)QD9;7 OF@UD(,82).)?JR2D(39,O4/W /VE&$LFAWU2JOLBZ+Q@GH2LG:X6FROJ'8/Q>N_V%;=F7?9:BX+3FHR+'R)7&B36HTUT M$3WK#KM#YNG?*/%4HZ*QE7#:P&E?$T[W+@JJ2_D[.%!19GZ]B8J1@TN-5+1X MKLDZJSSWEKP:* /4]7C5B/VE65 :;0%2&;8!T*BD$=9>5H.05W MQ B/O#%$UJ2ZWFQM(/LX@Z#480KM$1+T.F$YY0D6>S3D0^RHVZ0D*YIY ;@8 MW:5%0T@Y*^1\"CZ X8S#;]$U";>Z&+*U%-R?*<(_4X0?-$5XNX*BDQI=05W. MJ/*M&I$CH.GE;/SWT9,XK\@1I?\#:$2R)9.E ^5HMI %[J5^D.AP,KYGI48O M10>?8+O%2MDV]$U=S.R+65QJX^6('0"J6!$?VI24 0!<3H"JY9M9#!K4@N:F M_B'FTD4EBF<@T"PD\YA]KL94EGA89X7E9$"!+.6A>JH( VR#.KHE995)"/%H$JHS40E0 <\@E/D.QW? MGZV:QQ9_DUU:C,5!%,#6+/Q#STQ>6JGL&GN!5 Z8&%BHD@((4?V42\<(9+@" M]>1*:"XEED3B4:4;F/] @C*&]W[7NS MD7X$6Q;8!T48&NU(Q>(GA-\ X:A%MD& MD=DNVTJV .P*#;M$15B@7$T4[RR"OV(;P9=FLG2\0\U6HV#">P$V3C!HS,1R M&6=GT]N)U"=NH!O*-"F_I@O&WI6XXWY6S/D)AW]H./S0"*JY,F8-F-\!)RNX M_CK/J,?*90E;725G;,/F\CU\3;[U&,&XT97$S2H/L#BY(+!-*U0K 3R6Y'1. MC^2D%S!I0E+*-&MD>A,TK=+R)ANELD8;G]ZR$"'>.'!'SXU>'S5#M4P)M[\K M /,,>Y:@94?^"1K4(II"RW.^2+!(Z3O";+.BG&)E2?$MO,R'@%2PBNAMJK[J M4AA 2V##5,-LH/CH#:6',T(L9E<%G OC]";-B[ET0>@[<%PNKUAKT-4"L, H M\PYN3:W'8,78Y?"_#*UGZ56QR!+E9KT!&(>*AB+$8"5[8E><8TWM:R$U3'E' M)GEQ*V8C X8,Q[!>CG$ZYVXMLK@K-CE**BX/>@V)^9)0J=# 5Z@2 *SCGOM3N6>D?ER#)>@_09VJ%/]>%5V$[?S,1MG MI=C:9Z.CL^V*OLK7 O\S*V3AP3(5N&-TC6=,4B$U22F]HZGQ9R OZ@:#4_DF M>6B2>L6Z_\4"<;H240G&L((.&]3LV3:S#7YOV)A&J!\5<\'S1L:UD]%'Q@7N M$.B'8[P50\@18 #Y_J,_$UP%<9JWY3;MZCM"]5?JKA>R!_$@W08\T@69NT&+D'(82U+%NE[AZL^I:FD"PJ 80KJN M"D26T#+05]&L9FT@)1%X,^>M4B MG3L'G!;CU"J&;QW:9$=0Q%&"*-!3L]W*-L/\(,(I!0IUA2ILQV#5TR^&@-,) MVPF0RN_D%*^MS'(+C M(7D5[?QID.HG8MBFI7\"$7) +GAO%EFUD33!%U='5U??^;76W0]Z_%VH*GA< MG"TKC=@2A"X+E9;AZHXM+OIY4:DB;,I+ NJ1V"PY!T?7@BJICP=:J:5$5L\/ MS;"#HE3;AKFO$9&>SZ"^HKA;PX&\LJ4?_@1\65][G^>@L;UF9?@/W-*?Q$5\ M[ZO5/\&CPPD/-.7HE/O-\E"2 48P9XG,D98".N_ F:&N!M[2>+5P&W A@6OA M^5H"T=91I=PM7OR_&5?#-.]=Y>U;BCC GM# MH\=3=X-W'E12P-;K\V$=(H5),>.#W,*^.]BMOAN_N'P!E?4FD/J2-Y,+RB4K.L::7B MP7;:8PZJ,+.Z "<;+L"*;Q',4\F3JL)();C&ZA?2L6J?B^!%;7?TJI 2Q2H; MNC7<" @31D"[@Z1W6=24U>T$IV=HO5).=.N_PVQ:&[_WGYHF-U_V,5B)T?6U MWZ:4I@CIWM1UT"C@1P"(.E=%[?=AATF25JH I[&'Q$30_!:::4LH'.4=3G"VL.=NX;3%[\#":M)P+W M+\6;O]"D3"#>0"LZM%&4,LSF$&LZY)Q@,/F;KCX4L5(<1V0Q(U4@7YDGA,0( MMYD0-M"44!F1UXXL.Y]GD[3.UN/.EWK?U*QYTBK 5]%.\7*RPX)Z'HU ''2+ MR3IEJGSYL+[9.#4E98 BS;7W^<*$3K355+O]S06D MR1)WA,QDUP6[HZ8)F$UA(])AJ\(IG-^\K)78)T]YCSZ-P9^C:],*1!H&W &J M_>O G_# M--W '"^(!LM8%W$^X\LM-8S84%Z/,BHZJX\.NQ[$-\MT%M^A.HW8T7O6D8D:YU MZ("#3EZ2O$+@F(H\\\H4C0<9R8R!E7<6_":/$N=5\NW/" 0PY64*VDH6A_(8!IYV2BHR>'\^E&1[3;SQW[SU6:1-S7M[2*]@GKOT-#\ M@]+>9)#>8[V;WIB L-'@:.XU .@"-A!"-^";N?$0KLLG4JT,0Q8RF\TI^=>% ML;KRN--V2SK^'7! A?J;=WAJGV54)S$$4 M<-Z*-+.9T1!,7;1@L%9^"6VB-W$%!#$DM5 ='38+R=_RNLXJ9D#%5T )!R7$ M<7Y8M^=I\SI,'TWLO);JYG0Z>\&*1[#<%A3XC#WUGGV0$[-59GQM;5"O,351 M0W3(L;!2JZ"^N7#?!+52(WP'0#90/4"S<8L0*Z2VN-9(2^V?ZZ12>5SVY=.Z MU?U@N13[Q5BM%V9DGEAQ6^\XK>I-2O]]-W,-_3Z3 K%7!YUZ^?1>$#\[ZX=, MSIZ??AAZ]FG"8/0H.8.^-]'ILWN21I=T"85@86^_33&@3':D!TR'QM%W*N&M M5D=PS1=2N6L,\G?$9][-Q$?T-P2>AR_H#]RE^.!_SLF.^K'\1%9(_+N:FYS: M]CXCT)WM\??AF5^7)17)\'I:7@"?SZ!!X_X M>;#?_W8DR,?XW",@M_]K#K=4_VN/#C%R]=R YWOU%0=4ZYQ1T2A8-%DQ:GVB;NH#%_6!=]0' M[5 ?N:B/O*,^:H?ZV$5][!WU<3O4#US4#[RC?M .]6J?NJA_ MZAWU3]NA_IF+^F?>4?^L'>K[IR[R^Z?>T5^;TN$8X$8\'D*>EC!//W0R(/2/ M 6%+#'#BGKY_P*??$O+I.R__OG^W?[^EZ[_OO/_[_@& ?DL(H.^$ 'W_,$"_ M)1 0.*_!P+]K,&CI&@R& P&D""?RS@00M&4$")Q *_ -"04M *' "H< _(!2T!(0")Q * M_ -"05M R&D."?RSAP0M&41")Q(,_4."84M(,'0BP= _)!BVA 1#)Q(,_4." M84M(,'0BP= _)!BVA 1#)Q(,_4."84M(,'0BP= _)!BVA 1#)Q(,_4."84M( M,'0BP= _)!BVA 1#)Q(,_4."84M(,'0BP= _)!BVA 0C)Q*,_$."44M(,'(B MP<@_)!BUA 0C)Q*,_$."45L104XD&/F'!*.6D&#DCHGR#PE&+2'!R(D$(_^0 M8-02$HR<2##R#PE&+2'!R(D$(_^08-02$HR<2##R#PE&+2'!R(D$(_^08-02 M$HR=2##V#PG&+2'!V(D$8_^08-P2$HR=2##V#PG&+2'!V(D$8_^08-P2$HR= M2##V#PG&;<7'NP/D_4."<4M(,'8BP=@_)!BWA 1C)Q*,_4."<4M(,'8BP=@_ M)!BWA 1C)Q*,_4."<4M(<.!$@@/_D."@)20X<"+!@7](<- 2$APX@=# /R T M: D(#9Q :. ?$!JT!(0&3B T\ $#=K*%73B@(%_.&!P;QP@![?IM4=1JF$K M6>R74%'&Z$RMRA!101=5BU[W>:^7HQ^N[ IA]4KJNGL>]J)^C_V5[]"3H*G! M.C=N:>IC?8Y0GF0-4OX4],"X0Z$#IT6G[Y]% MI[_%HA,>1(RBAQ2C9 JEHOZR3BUY+ V7JQYVW*1R8++![LJH\2U;U1M-.YL/ M-<>)]E#'5-$%/K^ 87^%J 0;16Q!J#@KBK@G\5DL,5BLIT!N^RQN-4]=EEP MG3NH/JZ.YT7RC>O3N5K<'N@4?\ACVVF!Z/MG@>AOL4#$!Q&I0=LB!37.H-8@ M"E*N2JL9PO2W1:$#)X(8^(<@!EL0Q*!1%&M,>2_^(7[_QPG,X\7_ U!+ P04 M " "3>*I,*G;KST4, D=0 $0 &)S=&,M,C Q.# S,S$N>'-D[5QM M<^(X$OY^5?6J,9=8#40\/1 !X)>G]Q M!7^:Z$YP; MJSTF]KIA7WHUG+8B+D<1B3F0?N\1;8HOGQ[%N/*2=>M+*TK"A!C/(]9)LZY]A;ZIK#]\H MEA_KE\WZE@G,\B4FT&HJG%"DJX9Z/<4>V4B?H \4:%Y?7S?TVPTI5$13JJ;, MDYA9)$IORPU#E/B'AGD9DE+V0KP=4H]8%W/^TC#OE*97<4V9[^Z7QI:BH ME$"9LNU-B,>(S)"V]HV2XK;F47?I*%/JLH4@L]N:\IYZZ"2_+P6Y /E"$L$= MD@*.>MT %@_\64OVN&TXK (+*U%+PAN@$KXD0E+POJTS-=Y,+0L[>=4"%LMW M2JV5369YM0(6RFB9E7+P-*]2P$*-A\UO8/E_"&'!YB>HHK"'ZB)F-3'4H4M^G MQFXEN_7['K$'[+-^WNW/ 7= DL:YTV6R,\:]4H6CL*JD>F M?O2='[;PSPK0 H .L0!K+(BDH%YN=./<42- 1FE>HA%(=),?59U;IGE.L[CG MH.]B"E2>E,V3>C"+<,G&\IFBPV&>5)C?90\0IH4M914C\B.[-=Y@UL;>XM[A MKYG@/<*8BO%5=HPCX/(94@TAW5(%=1K4 S''C/ZI184,JT,\2]"E^C68W?D> M9<3S#+:9*%/!_!#F8]2S'.[Y@L"/P>BAU>_]NS7I#?JHU>^@3G?<'O6&^O?@ M'MT]CWO][GA<0;<+W=AW72S6@]F8SIEZAR%)MBSN0UK+YD/H&!:DZ@:\C+1' MX'N7A&_\_/34&OVFD!KW'OJ]^UZ[U9^@5KL]>.Y/>OT'-!P\]MJ];@5@ L ^ MD69@&A(Q7D"V8;!*%A^!Y2H)2[\[0;U^>_#41C">5L9/&%OR%JAV" M>RY,1)K@5=@I#KT\ L*'/2",!C_WQFJXOQ^,PJ@U:?U:^?^I8_XI8__>'&!W MIIY]M#\R1?^Q6"X!D_- W"JE/]%')FHHR^4A <=9_.-C4?\PPE;><3SIC#K" MH9=IF.]+-8^BFS%EK7 \/7>-XIJ5. WG3!GK4>!/384K3\B2$T"23KK JM-S6(1)3)\>J6\B0AF_69;8CV%\76<)#WP625HYQ8M(V(A:) ME0O.X-$RZ]XQQWG+"L^2\ET72_F^1T87M%4&Q;6IW*^H^ZE-%?6W^X=/7["C MC HQJ:=/B)WJ@9GK/)L3OBOBA$H5\R^*:*2/FT1TJERQJ"O>8RI^QHY/G@A6 M,)WJ?JGUG,WEWA=Q.:4"TCJ@J!*5CQ4.=YRI$45@DVZU!;&I'%'O"P2H)_P? M+MJ^)V&R+%3$&I$7PGP"@Q"?&UU."89OT^+9_/9#H5 955;OV6MUD=)7!TRM M,=JHK,L"I5%$Z\K1"Z\%"ATWUF/)K2\JC8)Q2TW@U(2#^U,Y\YUP!4'/069$ M %0!%">X^9NT=S8G_UC$R4-5D=;5)*F!MMJ?0WW#M#4H#53>N'OEXH5G3M2= M^L)3EI\LJ+"76,AU=(U$%0Y5X8BOL:-..:L8JY_7=_[:YJ^G1/0W;?=<+M\L M. _;JHRT>G6M'S):(ZWV]^8-TN9 &]5-C#?*(]"^W@'U*^\OZOTZ^*CS^G:; MNVK%%Y^8H*17=#;_+#1%TSK4[[ Y0;C5HG*SPOO.Y@.1M?I4 R:_2U<'.1<, MM CTQ<2;"[M/SH 7$#L4C-%UK]T[82IND]PUG.(?+N:PS:S-1?>__UNL#^:^4,&39@8[#O*7^C+=CKXUNP%5PYCS7&H4NG287Q MX''&HZ#F.ASY?P'QI\;.I_NF(/Z!O_J\G[I++B1BB?LEHIQNYL,'=3 M/')+5Q:_96 O8X,XT@M+ZMNJ+E:>'7X+G2I.V@4&J>+L\JB'^I;Y- 'V7.Z0 M188(6_!4RCX7%\*BEJFOF$2+D40_U+7-F 78O4[@VXP@C60N660I[0?-ZIUO0E6#<42&J(4<=1T^G;FH2Y= UAH!8@ M:/C;T"X!9&Y/=#NV+X*+90X)/%C*'KLG9+M-!Q. +K86/693*W(KC=8D$[51 MT0CC<@B]6*S?0,<9=KR]2IJX)L-74W/#!2A/IE0>UGQ$YI#;BWP&R,/TC=CA MD5IJ.93-@ZU7+^&_!RG*YLR;7;6$"HDW91.]NR+"HAX90H0FD]<]0>0 0=D4 M42: ,2/Y2K7K,4N<:2(>8_WM,;0*H M6G^AV'FD>$H=*M<1/7-SGCML;)7/&S]U,+@7W-VGD=Z36D_(2MXYW/H2 MBZ'Y&&,>+L/R\YCDD/*Q SV'54TG*Z-B;8D MDK+!R9D@,Y_9JN+GY4Q @C 4W/8M:68A!&9=R?0^'UO94N8G"HA)2/6&>*V* M.[["C- YF^"52HT6W%$7E2?4SLM8-L6#0P&).VY"KTZ\+,N4VM(']_,E%\E^ MFTI5LHX9'__W*'.(H&1Z!#T%NDE)' 1N9^P3;:R#Z8.G>\NTN9C*ZW6=QP+>S#K4$$LR87W(& H(O9 M7X:P+\\]QE Z3?6IS[O=P_6Z-!3^F=E$Z.43H\80(J 76PL=838G08F2,%#W M%TB#%E!!ZX4(/"*6#XXP[BN#9&PF;9)CW5G,Q)+=7)Q?2-#0DL(A;>BNUMO28+!O?4*XUX& MG$?<<< O%/51C_P*+98LL3Q9[Z"K]9C2P:.6OHGAC6U[O(W_,6L&\+&H7G?%]=>NGMO*MF#KEJ\%]&_]9J$O6 MNY] RH6S'D')8/9(-)B"N'1S8[I9CDVC^E; [',)Z95QR EO*QY'Z]*:"V(N MVHDMO&>@+E]F=?QZT.32[)X-EWSL95R\UE^7F,.1G_\+4$L#!!0 ( )-X MJDR65(7&1@L )>3 5 8G-T8RTR,#$X,#,S,5]C86PN>&UL[5U;;]LX M%GX?8/Z#U_/L.&YFIM.@F4'B7! @;0PGW=VW 2W1,5%9])!T8N^O7U*B'$OB M3;)BT4'1(G&D?/O^KU[N!,22 P; S67>N+F_.QU,4<5+:&8WO^4?8^?7HA/\; M="X(!B%!X1/L]00SI_I^*GY, (4=WFA,3U<4G75GC"U.^_V7EY>CEY,C3)[Z M'XZ/!_W_?KE["&9P#GHHI@S$ >QV./TI32[>X0"P1.,M]M6$1)F D_ZF+2V% M^*N7D?7$I=[@0^]D<+2B85>J*&X[-)*1KTKTTJ;!IT^?^LG=#2D7A RB-V9S M[W4ZJ?\(CN 83COB][?Q[89[@C!=P !-44"/ CSO"X+^B I(WY12>G7UND\"/ R9G0$ MUF 2P?,XY%?($H97JP6,*=Q%4W?9]?5_6,[G@*SOIP_H*1;W0,QDN_PQ&.$( M!0C2,0Q@[CK!,?\8P#F_O(N)C39?WPM#'(?"HR'_0'FCH4@)#XS_3%JXGPX! MG5U'^(5^B\$R1/QN'6MK-=.P5;<\&<[A:Z/-&V1HH6%;+D D,LK##,*W,$0G M?MN* $3!,DIR]QW_.]YMB/1H6"2MULVG>3E M*:"3)#GS/O$)@ 5/TH./?1@QFET1'OK8.Q[('N07>?GO=E+7#<*? @DD(R5GW@RB-7B!ZFC%9 M)[4>ID>P2K7^"ME7' =+?C%FFKB9B0N!U!'[&%DGPRRAULF0L?_5G]BG:@Z5 MH5;>R^66H3J0>]1?=-F\,A._KOY9HF<0B3[OG T!(6M>J_P;1$M8L*L2C[37 MD:=M0!>#A>M9JX"WE"Q0[BA1@GW@$=AE12\*6JXV+^KY\ZG!O@-I]B@823U$ M1 7;S$ P"_(OV3W,,&&/D,QOXV=(65(>%^)N(I$^49-X&&<'6\SQ50OPKX 9 M$;@ *!N7\]1TSV:0F+JV"AS24TX<'H*@NJ5F3#C)DQ#YS1^(Y(IP-29,)*J! MB<]1=[#%'&:U !G7/RQQ;;>0KXCMI"-3PO?$'_C>Q@S$3TA,0V;CBJM5$"W% MO/H-QN$+BJ("G*NP2.^XL?@4ZQI&:B#@)LF_FO8.QT_FDL9 (5VBI/ IS'83 M-%%5,OK7.]TA,$$18@A2WJ,^,!Q\G^&(:TG% (NMBQ%U),_":R7WP7!UIZPG M*!OGP6P$CAD! ?L/8K/ADC(\AR13<*TVL I+-A?AQ-+>\VN(&:YE<.[A+DM/ MYB2+\02N8A;NOJX97^Q@&U" M5E;I[B;+5_ UZ2('5.[8G'_5AG9-W)K(:W 6YM><.'T%7GWS'6!62;A_@YM' ML(*9[FKP&"BDEY04OH+!;HY#T)5"'.=<6W*%N5C%#M6>SB]*R &O% M;ZWQO:KJQV)+4 S#*T!BL9N/9Z/E7(0-AI=PB@)4?+[=&:2Y+@SM0=X,\LK& MYD"OAKF+3/^*W_,P1,(J$(T "F_C(5@@!HH361:JK$K04?D* S>S'&*O%>1? MGGLD$- E62>&J);F]019/Z\@\#7"5F,<@JN2H1H6]%I?@4O7"[21-5"\KK"5 M*7R-K=TO.-_[WF+N7[/ M?EL/P%?(4J7N,"W.,ROOR3@6[K6X8)XI<H4S4VMFKS:6!C?KV9@13O-WBT@.% M_%$3[Z=TO1P MB4BLAH=S%"/*Q /WK.EQ':FEMZS4?@*BFI%62%C%>=C'FC(SMF:ZG$L4HM*9 MB:((#R?LQ_P1CIIC8ZTM(G&0I6;1%10>0LWFT4N4%'(L'7*7BP,6$XG\NO4A1$D"(NU#+%G 5[" M]'=Q*%F#U7@&@XZUO0EMR(2*(X*?$8? Q?H;%2L\F^1_'O :6;5_OSKCZZ*+ M,V.;22P7H=M8ODJSJJ(=,O;7: MEYGYDT?#I4NX(#QC)V[@GR.8A)V/>^>8,/2_Y'H!JE58-J^7N[ <&@QK.&(' MT+FUEG7^C11YY?/LQ!5%PC/N6;!F.B=N;8JS8._S%C,FT'1!3$9O'^W9]XES'K\L:8-2%5$:+-2VY"#@UJC3BKT2SEUKZ/ M9W8! B] ,BZ>BW)156N9B3;G=JF)#@U;3L;N@!V=_"RQ>02.,LRSH<76S)\U MCQEXM&E+R7-H2*KCBD:3DK*Y#&>_>33^*ZN^I?+K\8=6J!FYM+*IVTZ5V@5L*9B.7R@61WQ)K66 F(^[0%0/1[Y0]#4IS%4 MYC,D-@W?X2/.S24-)S=-DQ)['VW8V^LVI3KK0'B'19+\;J8*KD5(RMOC2,@X@#),]! \@&1-_ 6Q)$%O?3[\ \ATRD;L? M8""NE;U3FW_SPG-E?N_RH@D*>'<7N>1'A0KIR]65F_9OY\<(K)/5_T=\'O \ M1: ++*OP9%!TXSDX^-5PQ2Z0L;-6_AUJC_36*01S4 MZ(X-C.;N6,GH1W *YGVX=TZ'I.^T,A8[3Q'!PJ*KJ MA%U@Y="6*H._L_[2GL+?HK]4MNK9>1E-?D7IN]IO\6/_^?O>?_[CC#%PWWV]\S>N_SC^WNGX^_UZ1N@T MQFL0;6G$M=6>EE>%Y=47#BPM?G-1C2CC6I[(?]^1>[/RZP(B2M8WT,UI M&_)O8:A@X",!H>8+<1PHU>5CGO(0P>-H]X[(T;=B6>78]YAIQ+O:F"5G#K4] M.O+W2VKWZ(1K%'.TWZ%G,<&>UW3K2UD,[PW7%R =5$= FP UFW)#RVH0KN1UXDOQ=P$QE>M.@DFW4G9^3-\2/":#PS_\# M4$L#!!0 ( )-XJDSWA8604B8 "J@ @ 5 8G-T8RTR,#$X,#,S,5]D M968N>&UL[5U;<^,VEG[?JOT/7N^SXW9WTDFGTC,EWWI $HBV'Z^?#D MNW>'!R -812GSY\/B^PHR,(X/OSG/_[[OW[YGZ.C+R %*,A!=/"T/+@X_S*Y MG\8)+IH=W-W?XC_!P????<#_=W)PBF 0H3AZ!D='I#(N]@@P<8*)I M]O-;%G\^G.7YXN?CX]?7U^]>/WP'T?/Q^W?O3H[_[^OU0S@#\^ H3K,\2$-P M>(#+_YR5/U[#,,A+CAO5WYY04C?PX7A-BUF"_.NH+G9$?CHZ>7_TX>2[MRPZ MK%@DGR6(U,7?>N4KF4X^??IT7'Y=%\4-Q9RF&V*7Y?.3=>%FP1_*?T7Y(5;R MP<%*S0@FX!Y,#\C_?KN_6M=[BF&V &$\C /9.+Y(0/W;#('IY\.G+ ^Q]DY^>O=AI;O_ M%;5XK,\KQEZ:G\$L'\0?I15]GB9A"(LTS^Z"9?"4@$D:X5]0 :*+MP5(LT&: ME&];G_\;D*^,= ?0PRQ 8 "_[+;T^7LHYO, +6^G#_%S2KX%:5[I!?<\=S") MPQAD&',+@/(E5M'%GT6\F)<6GB\0F&%%Q2^@XHL.35P+%Y['.:FV^E?9.NX* MXT$&](AYVQ9XR&%8=H:$&X+.LH>VKCL!6=M2WX-X_E2@C+CGXRQ&T2+ AFST M,.6/=^3'>[@,DCPN#;;Z>WE:+"/X:E])9KFTK=-'!(*L0,O2M/<@!/$+89QP M= Z+IWQ:)'7'2'X"4X 0B.[!"TB+(;W7-KFSK4/ M7PNWZ#E(X[]*-RR[JRQ$\6+EE*=%%J<@&R*E4O-&U@6/96<\<%E0-V)Q5:#/ MIW33!M<$^MPRF[(^B]!F6:U]ZRN;ZG\M+C_6% 9X('UM8C!\8*A_&-@S6.T3 MK/0&1OL!(SV ?9^QYRNVQUI;@^P0OO%2W;(U USAOTE4%*9' M$9@&19(;Y)'2MEF.X3R()8RMPW#5M E^RZ:.YF#^!)!)9MOM&N!TAIE"8?$$ MCM:*,,@OM?4FUQ@D\2H@=8W_V2(,WO"<,=KT1X3=0?V#/;K:W9\S-MH#2\E1 MS5,"PQ8C"=DJAHB*@-+ZTR![*B%09$?/0;# 4#CY\1@D>5;_0GK='X_>G51[ MP_];_?S;>A#'TH,K_.=Z]I8$3R#Y?,@N@*U+]$$K<.Q*G.LX>(J3N(K]E^'M M&4PB@#(2ALN7$SP"H2#,.T*J5JM$EZ_65L@&@V=--$9QS MC0>UI=YP__-!G\!!#@_D&X8(_UJ=V7 &&FF82*MHYZ!@T/@2YG[OU-QWJ-K/ M*CG%W? M*B6)RMV*;I2@,KU:I4I9LI6\A(26Q&)XR#9;0>6#1U I.C!HM5?AX >G."#'DV"J,F0HU*AT)57#2TRHRRK&A52;%38^^H(- MP1@A4;*/A1T9'>1E4[(]=&&%-EL?NV'-ZJ--ZS7VJ.2"-1R^90(T[>JUI!2"ECM MB!G;I!U[,JT&)62BVK3;8CG:4EK:5;O^]MX?R[:W[ >9MB?6 ..2MKR(L#\ M1+9^VH&=KZVY2=U!BTO6732OI*.I%<=3H8IL39OWVRP[:EY;?9?^Y;BC"#P! M^&.[F][L,V+.)PV]2=5.;G57%XHN,1+)94FRP?9KG,_J.T<7;V%2D&75),L M_D_T&+PQMC4-M%0I:%!+7JZ/S.E&/#$?1,N/<9T<+R='?ZISVPS B8JM@R6L M8EY"15(JF2 )JR$O1O?;!2ZNKRBG&@$2+7NQW;R!:CT-Q6F">*PSC&=XI MF$($&K>:+MZP )CY. W0LA08"TN"1M@&22EN#A#(NEC: J7*.E8I>8G?[>E6 MC'RKO'AQ-F#->>72IR#%6J'CG5FJA55**8]Q)I))%B.4=KS8WU_?_J/,=:C? MZM&O_*K?NQ\<]@NL*\Z$2/9FT^I-BU M=PE4DCK0AA6[_=8Y!8=S_3J!TVKBPUS<\HNM9_NL8EYB0E(JF?D^JZ':RHYC MG/D,(&;(IAONE"I<1SX%A;VTNY*$$O%007,U!CR-C&GX09?@+&4Y@,UX65$R\;L+F-1^YO%LC?+/BT.S<+ M[A",BC"_10\ O<0AH%PJX!597^RF%?'T*H&$//Q;!/0&O#B05K%6IJ%9,9=1 MSYL+R[4-2ROG[E8!UX!07KBFE6EM-FQ-:VL7.I0R61LEAWU_-!FZ>MD MUC;+@2 %N5EBBAG9S1)GIJHW3$8F1[\+%&T#3?KO0UA&M7V26F^/6$.X?6(J M[]>X"[PF>.H 5T'A"4)!^KP:9S##Y=%?^N='_%<6A.4AXEY 8QVT-=_T.N!K MLFEG:Z;.^V[D]<7R*;.N)H7E*K5PRKFZJ&L# U!>(ZT+O@9Y(3-(#@^^K,A# M *+R\/]JM@LNP>I5,"QA/XFF5.G-VIQ?>F1X4]..3=0).;$3%;A=X.D")K1Y MLQ)/WBZ"<':51G'8>H5B?1=1NL;Z;J)$C9$!2UU+-L$EQ-,O>)ZQU"^XLA0IZTSF^!38% M()?&@A=KJ9M@CD5ML4?=W126JX\DL\NYV\[F #*B]9$2;_%\E0RNZ5Q&+NW MU>O>W+2M;$U[R%2UN;QO[(HT@=8NT_Z&^G-KXX&B^+_8QR!&@:0=F2^6% MU$8+7GC<> ]_61VQ50^061FSN8?07#\XM3^$MC^$MC^$MC^$YNVIIOTAM/TA M- \/H6!C7H_A[.[?0R3H,TQ"+F=9.(RX07D[U.HG,&Y@2E6LG_**5&@2PY'9@'$Y.N M%ZO#?1YW'[%J)^^[&3R;R!/O-K7*R//$FX6B1EYY,S@3YJ%W>^YAM[.RFL6( M;!97,\"@9WW=YW#9;0SIYWPQ@RK9'#%N4\2,.=>WC>F^2FYPD]-]=B[Q?9*: M74I2XWQ:[^-TWI.%_'P5.8EN_BSB/,E,V(O*KB.T[,+ MC@)!TIJP$9-GD_8C-S=M^"Q[2;Q@[866Q$77X25>T5&@2D$;-L),/.)^Y ._ M)YO(*8CJ-S0F8;@2#D3G6"%A;P$H7V$])Q=7& 76E#5C8\8M9F%H#G+&T15Q M\HE9C**[ .7+]6&:[L1Z0!/U]%NKB5' SX#V+$SEM9CR(W6<[_\5*K(@&UZQ^+9E.JUEK%$#3T]&6NZXF'ZT4_<[7$)MD M*S<@YR\:>$4[JP1ZT5'@34$;]M8!=.+UX5JW6PQU=KSR+!L=4;PBG8R&[2*C M0)"$].:10R=:(\;M)@*-M^H^LC1\J.4Y6.J4'RVP>'K9#LHZ'-20<[N[4#-* M#FJ7F_JX'Q7BC5^X S96X5$A34HC]F#&(E]CS.V1>VU9:1GAS#0V]/JABTQO M5HZCF=&CM9-IVNS5R/]^=]*UJY=AQC.=>!AOO$4U+ MX.,.TMP,0-L'M8$40H:6@C'F#Z\;0G *\E< TFK8^E+$48!_O4I7 IR"*43E MUOLT!^@1+N+PX[N/U#PX)INLEY5&FG2T^!S<"T,K.AWF )MD/F98\Z*//PN2 M<'4L[UN*V>$*PG6!X0W5NUD#&MIAN!O3GRF0#V'(BWY^$OU>9'F9H.H2HAOP MRDI?15E>:M6M]\34ZHYD,3E$8V;7D(J<>('51TS@=CJ)8/EH'+6#Y16I3Y=0 MB[A;SNEA DK)VL2,$IWRX BU?2\&9$TD]";[3K% 6P@9!0-W;6,$#MXL5]C\ M4\$A6WR=J454W-&8L/C0QZD48"B[-N"O!V- MRW__[A,5%4IUVF=[1'5<)="7M3_4D[X)&!&MQDD=$0TO$#3:)/SFIK.*"?>' MSUJYR?7=[FOOD^OOD^OOD^OOD^M[G*W=T^3Z^_?MK _42F_9#1^F.>_6.4[5 MN7^W;O]NW?[=NOV[=7^#=^M\?"'E+,AFY/])VJ:7(*F>6+M*7T 5BJP?2:EE M<,;I91"C?P=) ;Z"("N0'T^XK)FJ4NZES4P'%:/1;7H/R)EODJFQO&2 ZG^> M!EG(-MRVPW, V0SSUD'P6KKS.",GB[$PO6U_Q7KK77[I>HYZ M.CNH@?HJ:W:>1IE;[?9+,^7%#*C1L8I!*E=X?4 M@)A"C:Z;\&HX#9F9QRW4491IF*\C:U*L>#'WH"V@UGQ2XS *-;IXY-5P%XA3 MP0W4D9\*,S:Q%H!X1,8+H%[0RR<(T8)[YC'$C?N90Y$W1\.HD9QU;TN-+:I4 MX>"H7\7ULDBB9V& 2" ^%4-L:BP,]:GXU16=+M=__BL&"*M^MKP&+R#A3Z\D M*O5G6-Q*HYYDR:MK&_,L+C?^]G!]MJ7'3&%=7I_'KNO%1$P&6ZPN4%(MC/&4 M0YG9';(I^M4OV@:>U+3-/?0$$S@;V).=S9E$GW]3NZMT4>19*=$)?T;'+ME% M%JVD1_,W<6\$5<063>"8Y%KHH9'QJZ=J&BGOI9'R?DQ(H8MM'"GO.TCQ MKT_Y((V4#])(^3 FI-#%-HZ4#QVDN#WQWQA=RR7'61)DM(.GPG+]M5^WW*B7 M>URE;&.%UV7 +W2MA*6(5\KS+85/&4!EUN/24_!GF(98*>61W:9P_&FX)3+T M#5:#9+Q853(@W-](M:5?QJR_S1=EC]0@/W[-\W;3:]CKW%WU&\&2>/N.([M@ MWI[K>+.<_@I3L/P:H#] ?EFD$?T^%+]0?96&4 MB*@Q\VJG5-GU\T'+.#. ,K+ZR4YR&ZGYV !LYB>C4:B M9(U"7LDQ8U!:0UM#((\C+^ZZ/H0S$!4)N)W^"R31(_P:Y,1-EAMWN69^ M@@ _'CR68QA"4B_C&$(1[1D-//@[!%O,X"_M&NKQ2G'CPL@CQ7D\U8UN3$U.27+1L=U!DE[T1U)7$G&< M#YXGU<&+&T">62=D;Z=G"$1Q?A]G?TS2J)/'*8VJY&XDQ/6\8M1U4IL6^X1M M5EA*7' =JV<7-)>9ZJ8@(,'ZKK7;89?YO4XFUO_NR!LE% O%\C1]C]UBF4:L MWY(7TY_*-RZQ4K F/LP_S7.9S6;%V]A4D3D7%F6 ?P?\M!NQ^8#6F@_0JO6 M@M>X&:X3>61IT?(B(%1UZ^0")(C+K8@;D-,#TC)%V]GI&46]AHV"E/+XX#?J MQ[9A5P!:()!?B#4,N@CSR1E;2AYY,[.::^[+[4:(;H19C06V5LU63&].D(5X MQQ/3=F>2SM/2[K,0[[,0[[,0-\789R%V_3#'^![N$8^T%5G+^$J&O!:G@$O)G*=OH*!2T&I2HG,4CN$ M*#E)=>'";-V+51QM>Z[.YK'L[W:(RVXV/7AE=P@=*E+K8D1 PXL-L;_1SJB9 M84EJGW38P$/9-?7ELEM+L%(J+-UEG.(ALIR2UR+P[U=HM=*[;Z'8RE8W9G6P M9D8_NC#4IEXA](?]MJ\7-S/TL*.Z+ZQ);[]Q[#KTO=\XWF\<2]A[OW%L;1JZ MWS@>V<:Q@;%7<6=YP.B[WWK>;SW[,@;OMYY'LO6\W^/<[AZGX2WJ_L0F&)E M?Y$R2 V26%&EX<6$_(H(%B23Q2(A5[BQC'< Q3 Z*^9%@O_] BZF4Q#FCPBO M.U;&I&6Y&=+(.JV%7B.[OBXTHCQ#*T==7KS8YE1GGKH2&=J,-IS=+UP'0E$+ MS,*5KQY3>FCV:NGL&,^4O$.>(YJ>C<@5I 5YC+8-:F_>2#B/,7\(I"$X!?DK M &DUD_I2Q!$YA7>5K@0X!5,\>R+G\Z8Y0(]P$8S.+8_-.#U9+%ZP"U ML+BCF16W"X#*/Q4H*^=5LQA%BP#E MRSLL39J?P2S/RA_OR(_K[3N2L+/\>WE:+"/XND[66(PJ5T&NKW\^S ($3KM<31!>ACV7V#I=;HI4&QV35XRK:]93.,8:K"\'&&C0 M? [34X@IW$[/8X07GA!E7S [.8ANR\ZR%]Z%FPB/,@ M(;].YJ3+ZF#7,I7Z#*\M*J/PCNW8P+P[6>/;BR61MHZ:K^P5\U6?1"E$;_G#8H"MBO7^S@6U_L5Q,\SW+-,7@ *GL'%&T!AG($[A%?K M1/"I;;=49,"\RTHSL'=G$Y;SVM6E1:JZ@1_-WOO1EJ3#]ST@:,+RU+G*BB"Q M,,;J41WJP:I4_]YN.\A&'OFJJAR5@_[DB8-670U>5:,XS>*PG.#;F_8*Z1@: M1CET_MYNIV@'CQQ-S'GE6I]V>@H\B:)2WT%R'F-+E-REA1.5' 755 MO9B'JP0'->3<'H8I92E7:K3NN_6AV==6'T:!%J:DEGJQBE1M?[>',:2.FMS M\H5[O(X@$F6/, ^2YG=RW.0&YO\!^>8@2A/U.D>C3-%4.2@UG.8H',*%?1P= MHAHN1>W&;L]E6!-V=9X,KV*JGTBY[LZO&^*V'9M!?._A0RVV0Z[.$*?V>0]. M=IB)X+?C%O:VK>ATS.].=>F,PFFW90?_%N\SW!\HZ#=89'L!&T!C=THD"8T]$:!!*'Q^.TV+.'1C0()UFM_ M].!0QP )V2?%R&6*]X8==0 'ACQ8BX.]:QNQG7\^KR53?;=>]PB)T@R[ M_+5.K_$MQ90;NU)W2;!9%JQ.81/!&SU9):>D<%+3;B<<<>?B6^9H/+V!:TTZ MF;5O6<:ZMS#\!@J]YUO)MCY[9%LZN>F!*Z:X,X;M,S6>;L,#93J95VQ?S+KS M,/S(%J]CG!3Y#"*R)RXI7V,.M5Y)+6($HEM4A3V S/44Q?F'#VQ*3$K M+L=+]3JLV\F\/4EJ.VJ$]SY^4R9QS6N^PFG1J\Y1E'=LD MY;^'2>'_03B=P[$[5-/]$5Q:I_7 M/1KHQTR]<99JDD:4PU1;G+\;X<7\.4,=7OX>'<06[>G?"F"@='7WX<&AQ %* M8,W>4T+M_CD?AN'[+PVVZJ:&"M0,+7Q#,C#UJ)Z9@\E)KE\+>T:1T[Y^K47FN MG5SMV\LD>]-OH'85C0;&X0E#-6 MT=?;9%>;VX[%;#O>,A:GVK)=_!ML)"2H7=:#$U%F5HY6EE+,]LW'._9+*06] M^^=R%(YK%W-\SBB<@:A(P.U4?_?FD8C5=2W3[=8N9:Y=FZX4)(E5![*D70N. M8X[3VF'*;2)WAFB@LGL 1_A5;!3?;0:YQK$&^\"T0FB).L-@AZL6; M[OIB;:1)(W)(_B:8@_-R!#=V+D1,8O#I#QX)JW.=&NQ'44N@%>;I\!QT8D-: METWXM_@8=L2"1W_O"?HD?J/>S]Q57P#3H$ARA\[04^?6W>&WQCU%/U)C;Z)J M7P%E%2LLUTTXW2_GZZIR2&\*Y36C-.W5X*F5ZKG/BQ?=KU0JZDE2HEAF0E1UV# M+O.@J-HLR,YK@QX\LT.C%DHS2V&I%N!**NTA#.\=P#=S&$D^M*3$I82J)D93MN24]"5C:0"U641 ]F&62+ MP)S+CA=#!H-#ZBI=JBP?@^XC2#((80-)&!CB-,\!A%?Q'F.0Z(4,_ %+91B M A7<",D07'@3^/@"4H""!"^C)]$.LWC%U#-@JE!$*4ZE>(DZSA: +I$TBCS8&VECJ?8I@M0!A/ MXS#[#C-_7.KRH9C/ [2\G3[$>*C$WX(TGX0A+-*\B4Y M^?)G$2^(R&3416!&//<%K-2!B[W$Q)$O(5K]\AB\E>=E<.%YG)>1H/)?9>L@ M)6V?@SR(D^S0X3.\I6PD^I0W!62%9>0K;![B%59P^0HQG;EO&9@6R74\[:XR M%6J(%-"LX:C'4+ FU)&]V6F(:56O"8MI>#$;V# M+,MXL]#[BEF=%W.J=:C?*B$[WQQ-MVCN ?F,]ZRS*D7LTZGFA>]\#=[8]J%] MJ^W3_N:9?3B,\^S3KM;WG^TN=F] 7BU4 2K#QZ[7GA.\#H[BI""!@0<0%@B+ M2I*+ATF!);O$%B&K["*O MH7 2+I-[.:?=8*U72S]>ZWL6;='148)L)D3@(C M9K7=;M.,JNLV'74BQO$'[6BY=4S.$,_EP00SO'HQG!G,A[#/J>LXU8X-OW1C M*5N>NS5IO%A*&+P3:_\^M_T;W,[O;/OHGV(+^.J+5,[K^W">Q,T'ZHL?73?9 M>"\&;Z;QK4;JK;B736U;\RS#3%=.]?WN[" ,E/MT26^ =F/5/B4S:T8^)4_V M38PZV?!5I8)UZ/LU)N0QL.+DR^'%.I3.(//6HFQQKN]XU2>8-1ZGU7/T#*OPGK%J;>[""*[L:*;G[ZAG M]27KRZ60F\,(!1OO&KN?2]MT%M//% NGW1:$,?[DL%5L3M>:6!!\I3E(?&VG]Y]J'R-_/);B^+C*Z2GX.$6JK.4, IYE7S' M3 6Z,$0%B*I;=>O+9#5W%GBX M"_+R]EN6.[^Z=DG$ M=X AY=I3DV84R4DF6 G5-(I4J%-[DJS@9U-GO,&VPJ M581*\. .FY)1H9;\S4Y'AASI1>3(>#$SY(AT _+)4U:^=R_O2Y1*8F]J5=IY M*'%T8!9,;4)>K/PG]+Y)N2MQ#232U(P TJ"_#O9D$^>9Y&Q_!2V'^'A#38;9O MIY=Q%@;)?T#071 :;%$,9?D6=Q_1FMHS#&QY+BI\_[!#^":,XX7R($1WVM#" M\+J-4:*6KB'[.%W3K9#Y<=>0B*3HJ4M(71%N<+HCSN& MT4M8#)L0=!O11NBJD=$"E**C[>!S1;B"YT^[!D]<=C@\&XWHP[-L9+SP[.MH M2_ L"5?P_+1#\)Q,-P"F]DOI)][NO$S"L)@7"7GAH8E_A1Z.WX!$Q\9J8/=Q M)J<;T]T8BVB-1;?;-I2-I=5YUCA]_@)A]!IOKI2NDVS+5UEGVI:ILB,(TY!? M!U-R9&H4^7*[FR,=_^:V;,7>K6QQQ:W>N%9%D[8&=#"E0JQ&U@Y=<>8(=;K\ M&OP.T5D29+0KRQHUQ4-IOZ8G]S&DD<8?3P6:H=^A$-$6#*=]FKX?IMGPR[P7 MJ5E;C$!Z;7=W$73 Q,>@A'XD.\HN P(@T@G__<#8.QCN*QQIY_"W@T?NV7F[ MB/3F N[J"'%&/15/_5:_H]#^YM\2@=L!0;YPDCB@D2A?36@W[47?L_MYZE4F M1VK71V6F/KY=Z-SGJM_GJC<\Z.YSU>]SU>]SU>]SU?>OF='?4FM=<*LX(O_U M%&3@'_\/4$L#!!0 ( )-XJDP]'^); '( $D(!P 5 8G-T8RTR,#$X M,#,S,5]L86(N>&UL[;U[<]PXEB_X_T;L=\#6O1%=%2%76?+<[JF>F;R1EJ5J MQ94EA23W3*]C8X+*1$KL8A+9)%.V^M,O )*9?.!)')!(V3$]93MY'B#Q^QT< MO/_]?W]=)^@99WE,TO_XX?CGMS\@G"[(,DX?_^.';?XFRA=Q_,/_GOW?_]>_ M_S]OWOR&4YQ%!5ZBAQ=T]N&W^>TJ3JAHCFYNK^E?,?J7G]_1_SM&[S,2+;-X M^8C?O&'*5.KW/[/_/$0Y1M1IFO_Y:Q[_QP]/1;'Y\R^_?/GRY>,O M)V_?'O_R7Q\O[Q9/>!V]B=.\B-(%_@%1^3_G_,=+LH@*7N*&^M>'+*D-O/ME MYTLJP?[UIA9[PWYZU^->>?/5.Q[_^^NLO_.E. ME!J*%:9WKTV_'D+E]\M(@F_Q"K$_/]U>2+5__85)_)+BXC)ZP EUR=6+EPW^ MCQ_R>+U)U)$"4PY MN;U^67MNW M]!?5I546^@OS*E.)XA*_<<.->Z!NU9V9;$3NY:QYLN>6=;;)H64U8 M*T(RX>MP@SE>_/Q(GG]9XI@:/OX7]I_M$O+]%OES7!.MMD"=SST2O#?R4-B]:5:%5T6 M369TG5"W+#? Z9M/=S^@>"F3G>U^0NRW?_]E7^;^>\ZS=M5$V:(N$/VKYB4J MB5\6A+:7F^)-ZWU6&5G+:H%H/E[U+;B]/Z.6&"H(DNC^,@[H3K=9QOS&^2)* M_H:CC :O#Y15'73HQ*IWE(LYH%)F% J@&OLRK"K59M535#Y&[#FB HA)3 MB M;542\\_>AK9,HT:YVN)(@/] %EO&M%U3+4"[4J9Z9XF, \Z%%J% KC(N0[A< M9U8_0N6S0*"MKC=B^)G;H!:*UXA6V!H)SF[+?^(D^3\I^9+>X2@G*5Y> MY/D69QV0&:%4J_EA8'M4GOR5)-N4=F]>SN.$]C&%_)#(M'C1DW'F0\[KI'XG@TJA$/"OJ6%B5Q,B-HBUVJ1061Z5 M&YR4IS0;>R39BY 20HD6$SH2S@1HV8/%OS9&1>@M?HSS(HO2XBI:=Z&C$FGAM"OB#-6V M05BT"FVK 2M0J3&[?X38LQ!@*ZDP8O:!1>!M2[?Q*[(T;N),4Y0L2B[2)?[Z M?[ X/9#(M%/EKHQ[CMRV")P<"XUKLF*!SBX=+I\A_A#1IR% 659OQ/ S"S/? MMG@GY179&A?.9+TFZ5U!%K_?/4448]?;@BW[8,MOQ-@V4&@#7:G@CGJ%>6 * MZ#UI^* SL",'%T1<\@B5LJ@A' 173'! AM24D$4*W0ZEM%Y&GBS:3UF=TU^Z M0RP:JA7L&RIBX/=LC@S]>VI6@O;FHP[ RT< F&:&H&'_\)P]Z<&[JJ?_WO^ M)380?L)20&!095@$1+G\C/_$H8@^LU__OXE7_PDK MA1A\RS8N6V(,F K]Z="Y6)!M6DWAI$M:L/S39AD5F$71M[]^Q.N'WOH2*YT: MS68ZKB@W\0**?@N'2E88VYG-[SZALHG[%7TN'TQ-&"L\$(?JZA#,1+U%/'-_ M 1#RAB3Q(L;Y_($-HBZZ\T1ZP1[U^H)@?.N:]D,RB1?/GZGJ_N+J-W1S?7EQ>G%V1QNG2C,8ODEK7D@R M51W)F-75$=-);'EJ#N4WT4OTD.#[+%KB:L6"F$0JR3:+Q)(P-!+9MN51T=^Y M)223PI2V_2+I&#@DJ_PX MP.B89CDU@BJ1(\2%CNJU6:\)4<<^(74<3AR>ITOZ2[;%R\LX>HB3N*!-QH1CC';$"(LRS1<&+7%E?CW0 2+EG;7__S."HNNZTBT M.)!6=7AK.KP5'3-B3-1U'3R(J;5FUDX>3!API#](8SB0[6,W?M:-7M$_GLX) MR8 M7M72\9/MOB6LNC=1#F#M-TF>T7HR08I6^P4$ZLF E.Q; O7)E* ^"2#/ MNB(%SFE!+TF4YK=X@>-G5O3+.,47!5[W%MI9JG4R++T:$,MUCKR-2!@Z-J&X MD:D]O?<2)<.3A'QA1]FBQI@2T-VFOL54 MUUD0\=S,ZXB0!A]8,'4*A>?&$,(1X@I'B,MS3)_'*44TV_[4 /NW!V1-)N8+ MR2$,"^R+=H4+]3B 2K33+(E%@7@K,NYA59_*CPD[I>K[%B;;B83!,V4-"[BE MJPDQG41:(@K)K7L&DE70MQ@D4OES0=3Q-P I38AVQ=3$H9AU:6[)2Y0T!Y#3 MY17]OK*0;*RR#\T&*N[,TCH!#M6F_C0$,S,SNW^*LR7:1%GQ@K):?'*FF6.! M#*^K'O&TVAT"&GJ;FH^*;V9, T ME8%9/926X,IN/709>X/ (JL:[.31 U8UL+?""1E MW1\OF)RT,[0KXDT4+R_2TV@3%U$B;1B$4KW&H",%1KF67=!$2^G"C%A]S2:7 M-O3IFSA%B_)Y*.01UZ>0,-*/+^-(2T',"X'-":GP]VU>\#-J2#9?L_.L_\FO MB^R102.WHX-4SID0$LNPE% [49-"I3NCOVQI(AV5#VC7(\,)OQZ48B1ZS# / MD5,S1%?)Q+(^NBR1J+1YHK0; %/R>W*+V6>,^0C?1;H@:WQ)>",, M>7YP*HN6<-[$@1;Z;4*(T;3QN,)?YOM#.C*2TK\NJIZ(X#2R(;K]J&JB"Q*W*M2(:H4N.\%M16"^- M4&X$D<=N^J6AA.]&4F<,/4_ M70!(N'&\Y"09^5NA2[SK91JRALJN7+=R W\4+"-6R7% MS0W-^%'8;QZ8#%HTA.I-)A/SV XEQ*4..\PUTF]1UL+C: "%&QVV<@F#3C9& M7 N7Y]Q70&W*H[-O!:BRH6*/2)UTP+@Q#'&]^H ?"G:T 6L$;S*\CK?K;HMB M*E\W)GIY5YKJ/(#FB8;.E-0TLC&;[X;3-N7/K/N:;%E?-4[I_VA+A_.Z3SLQ M+XU!00;66X>,.M46#\W\!,+ B[2@N(G9;IT\QT6O*V7QB4>%WS\(F; MB3MSW@D-S%I#MU5RQGMC&QK):4<@))Y):U]*,E4=J1C6U9/32^S!.]#@$C C M5VXH.^[ C*S07@R5&+V(!H-,^_I[K]\.G)-2;X*QMHONB]F,I8 MY-G[K/D<[07"&)T<@2=D=$!VHJ<_IZW0Z_O=#C5L7\JVI0.;A0G(EW#;VH$* M$E"H[9;)8UR][.R8EP31VAYB\0PU++*,L;;)[B,K1^U"VG@,#7^X."N$'FA0 MO13N:P8M=6#ADMT"_8&LH[BWM,Y07!G>FN)>PM;>@?]PU/-E'V8Z)F3AXXA? M3HX^EZ)!!@0!$+1$%U>6"8'WFGIB=KT$1CCCN%&NS(1-3MHV83*3VN:T:4E9 MBH!RDE:!/"8D#3_M<)+OLQ'N<:9ESL>YJ"(' MR@#05Y@%,9(LKA5B\BT[C&C)M: ML !>P7:GA6KGLH3V[2KXN*[A4"F M5&P\7=Z8%N>'"Z,HF 9%CCA= ]('&&"# 3L5;3[EW)I:/I!*4@9^<2U-.K_+ M2]&YG$ 8#20RK>#0DP&!7\K#Y_I8PJ4^^S4E9=#\"*+RV" M\CVZAO3"PKL*X"MNPF/;4#%JCG8,A^6^A'$5O7;W*1M:D?J=L9Q?K_9[LCH0DCZO7E;PW!&L M/8N03:S,N JR8IT9_YG-$M_0%Z(UR0?UIL6NO+*(X?=M0[@GVH2QQ,YD2#ZM MAL;Q\E.ZQ-DM?L;I%O^VC9?L0/R+]&RUPHOB/5Z1#-^33;SXX]L_?L3K!YQU M@.ANJ/J*+H8<233<-23;G$NAHJ6C\6HK,%ZB7RC.$Z:3H_^,BR>R+=!\23;U M(A"V1;@RCNZ**%U&V1)]+BU-/$($@%0"C9EV!!ENLQEJ7$LV84S*G^;IDOUQ M]H]M_!PE;'_##4GBQ8OLQG8KG5VD,=)Q#BH&7F#CA[E#=:@PM3-C,C039:>6 M-$3Y":\7Z3.N-K)/37L;A!"'"NR2V4"]S5MC?X%1=%Z<1EGV0K,:?@*A$44E M.DJ*]G2\4+3CQ3]%Q0[M*2JRPRG*"L<%93)9GZ5(U]&3E&@28QPIDHJA F!T2OD)EZ5\[5"5C(OZPZCX_ M;>S*:MJZK&[:;\@*$+CJ)K8M#*GA^H ?XY0M3V*@?<%1]MHA*YDZ]P?9*2?: MC0HIF8$;I&N3!8'-V%EY&STKLICAL[=GV)$)9K'+,%#9\EP_EVAEQIKV@ YP/&+Z0FYO5OR)^ M>/H!=9JVYH=H5(/[?#^ M8ZTZ\9:(L=%MU=^"A_>4,]CBLNXN#V'G4"6$70]DU)(I])3-F%#/"^<%GL"/ M@;+U;$]XF:V2[(&W4BJ0:$FLJ3\3 @M,Z-DK]3LF2CTW2PJO8!!5-TB-ZY_V M:M\*AJU:(4@03]K^X*R(5S$[A31G1Q]N2!X7XH4E>LFZC5%)NO)5;AMT"$3K M1LE(C?:L*Z6Q/1YPDRFF1^+'=PI,MY (U M300"KNSHF00EA4^V!6^)I>E031): M<,)N.'G&\RRCM5I=;U!>(RUY?$__EK,;<4B:7TH.O/)ANF82J&E7#@(6!I2] M\.52\A[:W:QE$35-\FR6&GVSD(F@IMV CL'R0@KB'XR=( ?HI14>P4L_86!= MK^.B+OPIX6O.<;J(L6Y!I;7B+BB:*SJ'/%-7\&,]MJ[5,1X5N7#C/]9NX6![K,'M$2J5T.?J3Z:-N/KDC>5X MF)8-!HT ZDF'@VA)2&9%):Z1!K$V7HF<\ ,FXM61<[ M:YSA&0[-M/@04\ZD J7TDRE+J*CV%0(M6PO/^QQLKTOO$>ZO,+N^.@9MJ61P M6*;$A2%]]BH=KOS/G]^^/=XSYM_0\=NCMV_Y_U>M4B.9^S?TIZ,_4H'C/_Z) M=[KHO]Z6_ZI$RR;MB#XX_O77HY-W[RJQXW\M_U6)D6V1LXW<_!)Z/H/RD1+G M";T[/D*TPO^5:WW BW(NK?KU3T>(ZFXPN[,<)R_!D%B^\4$!"BD]^[L9A%8\ MX!5T9$!DW!:JQSNLWI58Y4^.4)D7'&;]*_KD-@ (JG]]O6>SKI\@$)5U%EJB MT#V&AG$OP[D:9U8=B*YZ)X W8VFX70E1Q:OZ$Y(*TG0J&EK*GD7/NF=\^0BM M4DR] '9"5H3!^I-AI]PFM.$Z8)?H'R%B^O5??15MK'0 M7&,?MO4:[NS2^? 1Q U]:NAF9&76$D2E9#@[ RU000976X]_.N4.#:/A ;2!-2'E;)]VP8>5FKPQD:C!TUCH"'A$U,:G)9WEIH24#HZ<:GBH&:JM M.BU+A18T5%5XG9"N])NG1<9/0KV-\]\OI0M9=8([2LH%G4DH,PU+.XT7-=&4 MRK/6<\0$@EJ7J:UC8EL;72;)=-K<45L.ARVG&5[&!?N;CBY]21E?FI+0A-G; M]LJ8GALKRG2T.YRAZ60I4+*'C?M_C/Y.,G2ZS0L:9;/)UR#J:U[%(G$5:6BT M5U+RJ&L['"+=LUZ!CD,M(1E]*B%HYG"S7DG3]&#%E[VBL'GACT-K6=I5J>)# M[\-KJ'!?]R]-+$Y)@)PF@DM>*%W72"^Z)X-"U)T24N/ Q-#YT=!#K3Z[R>)T M$6^27B1]@IEFXU)#.V-+LDJ2/;PJ3S\Y/2S MP@=QJKP>*4T,=/AI[G,\<,)>"&OI& BCQS_,/G2@>802PB;R*&R_!91*QZM] MPG3:<6M%,6T:$IOFPR\O/4QQZKT-9F#9-G1I%S#7K!DV,/H;D\E_I >>J33P MY 0G/CM9RJ O5&@W1'2$=G*O#6!# K<5PH(-TN)[.6U43$(VU"V>)DZ\K DW M=CN8>JW+0 \HH"LND+2M+0OR"6Z;-/U$/3*R-^Q[RZ?BQY5U+?4^W$.Y]-JI=#9=$ MM:"G4*VEHT[;^H2,R3;L2"'\GJ3+.TS[Y'$1XUQ\)*:)[(XS2EEGTBBLP[)& M[TA-&YW^;">"F$P>RJ&81G5-!E1)ET(*M3:'M/8G)%'.CSHY^[K!:8YSZ9)Y MM=B..C(Q9]:(#<,21NE#S16%ZHP_Y8L^8436\8<'$E,>6%' M!1WZ0?(*F6&PW$+E8 @PFFNC^+- YD]<<2%).(8"(YC$0Q4#5<$/%MG>$@7; M$*>);>C-?IW?$4IQ2*#6HMDPO$GA&T@+?ENN%&"'1O/]2C((2^4ZA8005DE8E+T5$0$ MD=@-ABSBN0:-E(0H4#,-$KL^26(^SZ#2W!.D>AK,>+&N0A6,T$XV2!14;%!- M-8S/!78,"E]U<(4+[2B+6KC##)DP$$'$YGWP1.G)A"X* WO6%-'7:OU'0#F4 MIL(%S-%7BYA 8CT1CU0>O&,+=O[.S)\;Q(Z_)8QI.J00( NAD]HLG4&H-@C0 M7JCC;;Q.X,26)-+H&QXI3*E@%V1UJ/<64+V,U(D<#(%$,UK29VA>1/%(F": &;:X+C)\"+FU4/_GF#V%]KWG*])5L3_Y+_W M@J6YRBYXFJ@XTT;O!#;3-?:G)I6AF5GSEZD)9 $!,KR*NOS2:[?Y9NIM.OK% M*QH3,/W0[W'Q!>.TZN_^MHV7+$Y>I&=48%&\QRN2L3&A^8JV]_=D$R_^^/:/ MPE73D"9K^H*8=*4W0"% Z0]7'F5X@'(SFR__OLVK:RE_0:46/Y?FB=WLB_X2 M/S[AC#[Y\9)\P=E/@2P,!X4S\0>G3J@"L-X*96"EG3#4Y1N21\EO&=EN+M)% MLF4'T=-?%_S"SBU>7F]P>7;6?+'(Z+_KW5YQ;TDFB*U=<'.RY1S5'+S#AC/W M@JCCF*O]6?4[2O8/6/Q:-FP@4AN9NDL*@E#B 2C=0.5@MAVAG,LW66@ZB[*4 M%C:O+Y#[$"?;HG>SJ$:J^JY2*<= (;$+&0+4+E3D5FG.JG^PL5,4EZ?V[^X[ M#/(61%U%$ZM::?--HM!DDM)F,!R1'2*IE9/P!.[X2*EE#Z=.35 MV3VZN#J]_GB&;LYNT=U?YK=G8?%">62D42VHN2$\+%)CUR=VP,9?M5X&P^;X MAUG]'%&!\HXL])G)("XT<6\.#D*2,5AW#$TY&MLMV/LHCQ>: -N2D0372@:8 M'-RJSP2DZ<"&$GN]&?_KX:8>[XP6N M&S;XBZ3/.:<]A_B7*ECG?K-M\SE9B7Y'B;[BXQ0ORF+);M/EM MD=<;/H#2I=F8/FO.CN/3-0",44K0:#)B@96A:;1RS#ZEV>XI6C34^?;UB'8)D MPS3.$)ITF,:D'6%K'1?\;]>K?4M!.Q(QJ?;P1IN8MBWLU_F:;'O[1SQ[L4FQ MAW@9(ZFV+]?H:?3@(CHGS@,]S^K&[#&+T@(MV4F1JRC.T'.43'VJMF]*V.;& M;O@;D W;.[3.?X>^4]C1>$A67[[S.[<]_"(Q'FHXR3"XA[$ M@(FJY).,G,@+--L+M0=0-ESE !H&>!J.,9:B!?=(@RK"#UHALO>.FA'NV$]B [V MKCSA=:R[1?/?H6Y[G'$K;QZ8&=2T@^99QK;5NHA?^,V\>C]IJ MS ?ZS)P@[B6404)@NH!WPH48]='YWCF"[W1WWF&R"'P>Q1G;SXT_XBC?9AS# MY97=ZKOEK?6J^K'0N^]?=G_]2XPS6B]/+Y?XF5;OU[B;%-DI=5FK48*BK-*-%[Z: M>#0BJ]Y0@ZE':">#/C.!B5, 2W"(N&I<=1*B*O6%+#7P& )%&\'D/,/_V.)T M\:+FITZC3TZY!APS93X\T5+CSI"32BNSQE.T>QP:(;5H$+/1I+JD5)0I2WBH M]A4""?DY/:=)E.=JZHGE^H3KRL'1K&W9$[F$3@PI)="=\=\0_S$T^DAJ5$P: M^<>74J6M(B&(R.[TM"@/KYJGS?'!BLK+Z_26W968Q>EC>6='5O^3[2C)[Z.' MI MF<+M=VKG;A:*I:TF\T!JH4$9A ,27K.MZA'8&^*A_TP3ZS/5#B2]@4!?% M(TB42>*7JPMAO(,I]T''1]G4A!?;@'$2;EH"M#2AQ4N;*0EX?ZV!A-(JCY/- M$UUJP^RB!D4TY=8#FHOPPP_@X&HP#P'J!CK(ACP'L>L_?B#K*.X>66JAH9AW MZ&EXF''H^/ ]UR!V9SO+(++2"C:2 9-2/)3088 -S62#HO+TTPP=9=T$@]#7 M])0LPXL@H/ (\BDE#SG.GEFV=I%NMGR15[J@88C/?38[O&H>>W(CSH@ W< F M1V % ]]QY[F@%GD3K.OVB%58\'NMJZ_I#8VT@@A&](#1Q"(/!8VD]OS:9\&^#4 M-4C Z RNH>@OBS(>3-/JJIH.N:X/^LJ\^1YJTSFVIK/27G..M+%F,*P$U@I M.D*;U*L!L65FM Q7^Y^>Z>I45[MNWU+=;B3-PRI^0X=3C7P-6MAO8[(9 *JY M/O'<'M<-)"#8@LR^IVJS!\#0TH".)>RAY4.2K%4$H MF+/1IV*!VS@,& V"2(?Y*$_.=P,$=W4]2 A5E])R"&9;;\8@F\@Y'X< -0)^Z70$7K-J-+%:R=8 MA1:%3XRC\(EQ%#[Q&(5/1HS")TY1^*0?A4\"YDNW>C5\$=2#GBXG9G0Y\1R% M3T:*PB=N4?C$, J_3E191&%[6(46A=\91^%WQE'XG<%&2Y%WU MV\2Q A"RQ!MF.J''W7@K1$&5-<1(=BG;[6BAHH]%EW![$PV?+25_H:/A9LSVL>]V8'3H&IK1']!-5+!=Z_P0YF NQK8$B!FQ)=5GS..& MOB%O>QY'P^88S9C )0PP#9HIAMQO":SVK8XS6@-M5>:+Q7:]Y==W-)M%BQZ; MVH!!;TUFP&/2*G9IW K]6A(]Q8_\VI.!::NR$$,S5H716>-A*S$-EN\Z;!EF MH/K:-D\^Q;9,$T]522:!^RC],[5[>*2;],N^4T&&A.FY$&I3V>\VSE>T)P(R MRBFT-&BHLV-IU*&?EN_I)DI%Q8 ; NI;G]T_X0Q'[/=P X@IY@8/ZT@KWV5H MIV5T^/B.H&PAAICW+Q^COY-,>H*\O:8^A/0U_86,KJ^10H3$[<"0(+2FFPM] M>$%<*Z33ZP>@R2PXJ*K9.!ATC1B27^P[1+*?;XMMAD7!RGJ8U]B4/AP8F/(7 M'[3.QQPH-BW,P#!B9GYVEA?QFO=3HL?'C(\XH*B9;N-2ZQ#&[\QA:A9GK.!B M''BT5@TCD6'I)F;3&", Q@7Q226S87#9E&VY/JZ0E59&7TY"?<[W7A"MPBPRTGVEMD*JK?!AA(C9#DM M"NE5L^NB$&[0;55(HTP!!HU/.5YMD\MX91XA^BK:<-!4\<;]O9,1D_R>TV'4 M[IAI).U;_@0E5&GJ4Y-L$&%$8W&-F7)VKVU&T*ZWD8 X0G[<=PB!0EV^>X1* M><047C5GYY3EGBOD"_863X GUN9/RURM38?&J)Z^E?B?LC.GM=?B'N0SM[&\,'=IB- M\8=UOI =L;M2P$\KE/9I6WO\:_!,MH 5&YC.NTZ=A[1^4(HKIAG(YQ4"8F44+7=T;APF1(<, (2_#9)'A-YSB+$KF MZ7*^7-.2LZG=@I:]BE_"TP>M=*KO:JCCR'TC+Y",MW&HXKFYG5DERF^&;PL' MU%++&C*#2#;8)I9 M$&QJ:A&R_!(GK'C=AOI#G"\2PF[.D"P@'J1;T\Y.UY6$-MY *3G L9*@UO9F M-_/[LZM[='I]=W\7S K#8= A #7:X;&-F1:K[?U/QO&_X&1Y3^I5IG?L#IRX MB'%SR^2G-,,+\IC&_\3+OY!D&:>/O_7[P.Z&JJ_O8L@Q% QW#1D7G$NA"A*. MQF=,_TU!WJSK=2!1=\3K=9 MAM-N2F$HK0DC.VE/L:*R/T9 :+L:POJF!36U%Z5DF(3N(L" M8)J,J-FI6C" MOY:/X$@FNU;56%Y#-+B+4[4>P"=V33T.X5SG+M2[Q1->;A.,R*K>[!-/O7S7 M' (&3#.XUE2K:L(VV(M+C;R 3:\:>W,&W+$@SN]%@[MXU!\2)=.?\%"< MW65G':)KR8(+/H:AQ3!P> L+HR65#KRNSEK<'=:P8G=L/;-KHU@Z&:?/."_6 MTR_RU5:Q 1'M:69"(J^YXB@IHDMFJ$\(7P=N+',]4^"$F-E=T:]I-7K65] $ MW*:")^+L78R1>?6\#:%2QX@ZDTIWPF'R2X ) Z:):\V,G MUQ_/T/W\O\["F<,VJ6YB72]M+BF4FB32VIZ8/:RG[E@EY2Q6$ U:870\CU>I#0-ITFOD'U> M/;78Z\D3"/N]E,VZLT2**%%UEOR751^"_'F?E8KH@5NA'37^KR+Z6I^P%T+T M\DN77O3SCDM1]/3BM!]]/;Y;V#$!K/L[0CDG# C'NXCP(_/Q$V(\1'LW:.^G MCAF5/'=UA-JF46W[>QCQ .77&$>F',HHBWQ71+2(M$MWR3S1%Q*<26X@V4K# M))(@(5-H&[X3I7*C#UAR[3K>["10+1+$>>$F-=VCOK9*1,P5*O69I[ =&G&$ M6U2-9-7D =I^JK0./NEBXFT CYJ[215,"F+;J%G5Z]FDVQ*J5#-@E&*[)SC& M@/-2C2*2X9]=C@F,]0BS6G-'<>,F& M4):L_Y23)%[RPU&[',K1C]LTVBYC^O"GP,:-Y94NYY#I>'%/04$;T,L#%+:M MHK%MDV]S[K]2M1>&P[ET&08V9D'7$C?3!]K6U(=LU;N)J'R"#FZMN\JX;?!] MQMD#,>&*TIWE5%UG>;M\KBX$QFCJ6SU#9["P7:6EF:.#7!47HN%-W;H*>PO=<&YC 8J. MYCX]C8P,*8,1?RVM-EB-0\NKAJ%+Q/!AU2WAO;DQ83BP+\![ MNQFK3X;YL=+^Z4@R]_>=%R8-XJC$"+#Y-&LBS9I!7[PW;LY^+:F=\@T.RP$- MVO!&J^K!9.0YSME@ZXID@2[5D5>NGFW6+8T!:7RV&+X&C*2.!B+G6 Z=J?=5 MP(#&+@P;HJ8?3@%A<^(YF:A]#$3,B3HI> V8.?&!F9,0FN ;DL2+%^WPHD2L MVPCWQ*!(T3'L9=6_V(<1*42JG3#:["@&0@E9I8HXH:@ "20)<(#0$H"NQ,>@%_U[H1[-M*LY"PW:\A$:J%WU2"YYVL$,D= M2U-B.,-1CC_@\L^+=+Y8D&U:Y+=X@>-G=DY*']7&*GN<&ZBX(U_KQ$]_S-2M MAB1F9F;U[RC;/9B<1.: (,,KK$H;>1L(AY)B?L4,("):C>EP$_5@+ M_T0[?F@'S=MO!)KRSJ$7;$X\"B++(M#9=Q]! GHE-0W(QH M6Q.U$6^\5KD%SKZ&EV 8\[6&]\W1IA0M#\4OA>O!P^FS/!?4&<4%4PR8!@J5 M/;/0H2]10+&DD1A;))Y*+6FTD&B!AP>AGU$R4)5GNS@@MU0/XK$Y@G S435" ME,S65I^.RD(#:NXJ?(X'3X^)J=(G$#+EZ6EK\46X*:H/S!HGJI"@#2M=_8!7 M.,O8;6R[XFH;&(6.M'D1ZH"S5^!EE*9%[M>.OC([L_I!4)//%K!0\E-3:SIR M"M35U)3Z&PN/'ML2A4<0*,K;D1U$@YJD\8Q1XQ8$"J1AM1[=*X[$EW=8ZRDZ M*1(]#WF@T--('165;]N$4&YK=D/+EA9H0?*I3XFUAX@FX]/6GC[E$YK0)7T* MOV-BU&MO1>D5#)ZJ'DOOUN;3$([4' _$%AT76!2'U?S<9'@3Q 4S6[-.WTI(VL5 \\=D@\^9VV5CNUBP\J6[/3 M)VJ(-I T"I!:KFH;>1A(]E.B?PXM#.BPHV2^0;7JN"XQH::WTN^$A*95'"7S MS2:)RR.2;G 6D^5I>;40NXI^M<*+XCZ+TCR6'LOH8F1']6%&G'D_Q"UL$' H M@3HB##8\JW110QF5VFBOCDI]M#<0R-F13G DD.#HAI(A]MIQ97B)#BC(2(ZP M=#,S.-" '7PYS/&TP<;BI$P'T\,#3B '(#I"TRGHZ _F'&;1+? HCO,<,_2T MAS&O<''V=9%LES01^XV0Y9FGH;"7YV6_/UU\"8>X5 X?$/,[8QK8+B:0B3 MHGY1*!W@\@/#:0>OVF4T.1326$/2$O@Y(E+KP\M)D:9>;7@H/S=R?G]V=8]. MK^_N)S\ITAP$"@):GANI55:QS]\IDD9^ &=3C/T!@([/DW16%81ZPJ1/2!HV M"3"8G+A!X!?@R,XH$#[=!_KV4W=J->T!)_("TQK"]#1FH=PI):X58O0I>XAN M"G;0V[1I*TAIH;(JD>\ *;M:B=#H7+< MC+35%I.C8.ZZA,&--/EV \ZT:78SU@O7#\@$A-D)T+Q_UZ2_[,-XOEZHU,0\ M>Q#('+NTRJ3YA&YNO"LKSQ>"F-/>I7SG49S]-4JV>-_%E0)<)=P#NU@8#/@B M\[8D,#A;U\"=&2ND!IKY=RBT4%:TD"*ZZI#11:0GIH[<@W=,><@M5*[< -7* M,_(CQ,00EVL,![X^H&E3#W>D39F&7.(\Q_@21SE;A)EE;/TK+^MN929[QDYJ M2/&7*+G'V;H#=P<+U2<=9,&1G -\>N@]#B^%BLM#K<[FRR5?I!(E*.$;(VA# MMD;X:X%3?M#PAB]NF9;C+G C8/7?#@8#C#4CQ."R3,,!L%;+P;\'^-/VK=0\ M0CM!Q"6/4"6*F.RW#'])8S@-_B=M-O<;0>;I\JX@B]^?2+*D>?_9/[9Q\=)M M(PW%ZP91*^[*?(T#ZPZ/;L62H4,EK4U,S.Y929K[=/B^G;PA_0>$N?S$/#9% M!!E6:QV":C1;;#3R,@( X=H90V>NZ&,M2 =X9Z\8:K+& !AKH81Y\1Y.A80@ MF$/MRQ38!!^CDOLPY4EK:V63&:%J/ D9M!LC!<(RQ$->)"FQZR6&6EP$ M*55[A7@PB(?F@ @EZHFBLD$H-%$S3':]!$V5(\@I+TN?+AF(/-P>9@9LRD#3 MJK3+4G14U7L-@;[B4P?E GU*0ITCV#?ILX]I?BZ@1*GJ1];'(S7ZD\&01G%B MFOIC2XD@. )-9LD+&GPD*Q9G\,FTFK$TD//T7&"@3U.,<1!(DE*52)^62 2E M4<]'ZM$Q[2G9$'NQ0W_G:)Q^*)SX"!R#BE62P2I)Z.BHN1%*(D#21S98WIB! M[G)#+E&30B3ARH:^35 :2,TK\2_1FK$';_A$:!S*@AI5M1'C[]S!>E^X!7*9 MKG.1@".T^R8AD2VUK@*V1&FV^RF(I9.* MRB*FG[<-Z+YL$\\R2U[JWV[WOVY@5N[#'@;'>QPT0'$R9V'Z,OL;K M[5JX@TWX;!?-6L^<@=RP!AO#^H;5N.W*SZJ?T.?RQ\DA*ZH38O INSAMB+4A MVM.?#IQQ*@>GZ%D-SO8S5W VK8&"4V!8"_*SZ*11P"NN$&'S*#CB;8BUP M]O6G R=)\!%OHN0]D?) (5*S0"CBR@&! M4?"U"PHG2A+(U&:[)X@_"@7WJCHDYM^\@WF!= OQ4FN>H $V+Z!R, 07QZ\5 M&+*NU$!D3-F=NHK6^'K5ZN8)S]'5RE6?0B'G"'^I9<@$0>=$10.U;F,@(8C# M/O052BR_?9L,4I4F(S1VIV,%+DZC_.DF(\_Q$B_?OWS*V86*YW$:I0NV"G]1 MQ,]Q\UK[FB;6BC5O+!1=B63L"GP-@K5K)=_LC/$S.A=4 6TJ#?3P@E:U-(IV MXA,3TQY"Q+5R.]0UMM'BLJ7G45$,EB/9NX6#<'7.+-- -PT,_\BT4)S^A':* M:/X-HEF2EHT!YTE3...22I: ##=@W7B!+1FQ=PF:)@[U#A,,.DM/6#Q8)>1+ MCACGA$W:Q&M1'! V*!KHUZ[8VQH6' )9ZR(I<+ET%BL8]CX$'"A.8Z0.%8<4;!0J%+8- H2W) M),CWW9$V< \/>WW'>G_D2:.W&,J^S"D)8=?G]LJ( /O@@L9^<%X].)\>,8\> M:\!8[AHF>58,&(LRYR#IKX+0H(09(E$>EB#[;.\D[GRWAO^BF0425_07@VU] )9=&Z,"S*L[KK44FNVV6;B M)4#^Y309 M_T!<&?%;7]>F?!=;,N._JA03P!RP=SO,.33&>5(G;[GR(U0JH<_5G\'<)CX5 M^J69Y+CPGS0?I26L>^=EEGSV=8/3O,LTK5S=PLGE7#DNLPP_]*KQI"2N4KF4>XS2^)\1.R+JE*0Y[4\N^3_FZ?*& I%V-?D_KU?5#K(HN:._E'U02=H!:K,. MJC V7:D'40K(% >R0$IR@_F97=_^-K^Z^'_G]Q?75VA^]0%].+L[O;VXX?^^ M/D?O/]U=7)W=W06SAAT6SL0CFCK!",)\*WS!E?_/H*F]@=1,N!FU%<(0 M])*:!QUF,_&D)9?:0,6MB E%R<0K" VKN4LCH\H0L$BJUV.1QL.T)#HEZTV& MGRBIXV>\'^._PL7UZC[Z>D,RGMP5118_;(OH(<'WY":2L#K< M/SB1G8NB9;JCARH4+)I6PLGC '#9C1LPX! $EN&&>Y''M8R3A::;C"RWBX+? M?(ZSYWB!<^$Y^EJYZOLJY!P#A=0R9 C0.5&16ZT[JQ_S$9Q:()!#]?6U2RPK MHDTWJ4J32!J[TU$D*MB0BG#3G/!9387V,U?X-ZV!0EY@6 GSGORL^BF0#6OB M.B$&G[(#VJ98"ZA]_0G!^<):$T::>=4YD"R\,)#< 5M&HF3DVP<4IQP!KTMX3^:+ M?VSC#)>W@K)F[ XOMIGHP#DKG4[SH-$!XJ32B\=&PL2O"3WU=F8W%9IR1LGU M3JPZ"36 G?AV*!'PT[@2Q0Q5JHM(:N!O+'B"MQI&'D&0V6P[Z$>NI-%>'.WE M7SM -6T(/$(G;4FH+9QE>,G;M9LHN\[XBIWE7Z-DBV]P=O<495UFV"GM1F'- ME)R'9$WW;H[=OWY9DRE&T+9Y(%O\3+_\-I22E/:QM MD1=1NHS3QY"8UJYV*:UZ]:3B$!>6$Z9A*Q!V<+[FU_L:4C)%*BUDC4 :E$$] M^_[8)'-ESBRQA7Y;U2 +;ZU*4@751,E1("61LJI4A.HIRLDE\1$4T>:[V&C ML[ZP@F9-80\LVYOW3;*>)UN.=0ST*;9OH,)FF*#^-003UY*>7WL]';VZ'J9D MUR:*E_6)(^FR7%&8Y[B0K':UT-CS3*_A3C:=#V#&&;K3T,[(RJP21+B4+!?3 ME&><+:I%H1'7FIQ]QM @@^NNQT.=,9KZF7)JVP'B9G]-/>ADO6#'/,<[9 MZ:KQLZ#!,Y+>+U-32[LO5E/9!UZR9N!*LW!-:V%6"Y77:R9]U6PJQ\D2E9$+ H1QAA@:7JUQNV>CT_ M^XJS19PKFUZEO(CV8GE(FHL\>*.UPIDQC:4V.HTP[WXBPB5I1EQ*AD1<)19D M1-55EX*8(E4I$>5^IMZ,<9U5Z]_G7V-!DRL5:6_!Z(C [+YH&?6P\4)DWV#/ M15]-MMV""4R]'%=5A?U]%M)/+MQBT9(6[*X06)L2[AN<%2\WM'H+VBB>_6,; M;UCRH;X8Q59M3PM#-7>J&#D"IH^-3PVES$W-:FE.LYWHY 2S PAQJ[P>$8TL M=,AIX34\PLJVG)C*ZR@*M_U$Y\&6E-I;B4P]#J)D>U=*+7:$N&";DN'L1C$& MA0DM#7:FZ%2-B*C(%A7 K'$V].4/P^#L&90L:P4$X[4)&20$OXQ1?%'@M MZ+48*NA:@H:"+Q+N7(R2H'6]#2)AVXB.A$P:Q^CD+'G;A ;.U9F9WD1K]FB5@HL M]@0E]%&@S!/ P(1ZXGHRY-Y>V8A\75^3L>^6(@,+CX40/*F^1>N)(VL:MB#9 MT3>K8D%7>L9_".1<$U$]$.T';,.V(=2$9T]W6A@*AHI[OSY ,9M;W&.Z3=XHD'Y W[&">%AN5I)5(Y8 M=:%HKE&#U$3#%;YZ'^##0>8^E;@WM#*K!7D7H"&**MF)9PMM<$$&5UR'6GKE M%NE,?8T#1K!1(0M_ $@\UD,QW#NC_:)4,F+D!Z93CAHIBVC38-@T%7YY"9KW M&#@:S$1!:[#<"P5,+VMB#0S\QER://U.PR,C*KY1"N!*?FEG'MDZ'UTV693K=- M-3-/HP#.*K#C;8#B6/9IJ4%=/OG7!B/[#C>T2,/ M9E5*6$R1-JTA4"6 QO@BC8LX2N:;31(O^$U\-SB+R?*TS!WB9WRV6N%%<9]% M:1ZSYY>2U3%P!MM-LY-!F%#D4 0/#;5[:0PBDJN3.BX=HOEV MI%+)PP0BN0H_#Z9S>I'R%6YJH"*.C]CH UP M#L_0FS/4]NDR:@@>H2X 0YR\\P5*=8(,B,J#3';OV99VJ$2W9< XY@ P!]TB2>O$1)\2)9:B=\6+==G8>N9&V9 TV"19:5 M!.LKS*K?=J>+3DP><<40D\_907Q+K@5F@87)8,I/!'Z(*&?8==JT0#S-G&<9 MV_? UK&\?]F+5#>^S+]$V?(\BC-^%#[EW'9=G^FTH=DHI1_.UL<=./IW5'U_ MGXXBO:)"T]EY*58CP['Q6_X1H*KV>-M:,P @R-O;:,="?SV8\]?UFAQ>; MVT?LL2&!_\3QXQ-]K?DSSJ)'?(O91E&:,-79U#9*0(.V>PE0YMT05\L3O-X MP=M@CTV/Q!%\"]-S%$Y#TBE:H.V%N)0C-0LBY\WH?X0PN_ADQ2Z=C,GRU30& M,GKXB?D*('H+[1V?GB*X\,T.-E W[F S;)I.@".X0PF 0ON@$DP<\P>4.:3& M8'CQ?;820TLUNP[EVM0IR0C8D#BB&[:%&5 8R*9G\+>8KDU:/.'E-L%D=4Z+ M5^!+=A\3;3;I"\>T 2TO0CO?%ML,S]^L"8"[::QD?!QJ3M\0^SVB3KG9=&WW"K:&\6E7:/5'RN%KR&LY#^ MT"@N6?US*!R?_FACC,C=8"AD=K==KZ.,7S[)55"I@VJ=, (= %@%X0T&+N*8-MRV*)*Y MEC2 \*4(Q:+]2?:*O7"D5P0+.SI7?L*+H5>S,&)DS"*C"F.7T 8"0.%307+ M H+.AICX9IX/@.#ZA,3:@C7E?:0I0\YGM[HP7/_-7Y,[2#7J,+YP L3D$5R4_> M#EPZLQ@'ZK05 5N64=,T/]R<&G^SD(F@IOW0N@S@S!$&4!]8E857*%_BZ O[ M)@'$YOEB0;:T_#?1"RL7?0WZ2[;%R\LX>HB3N(BQ:=]FN*E>O!UB"BRRVCOW MV.T97!BSD#G0_*S60Y4B#X.5:B"W_8 4QC.W B"USV5L4A:FCI)N:/AZ[4 M\(+X)$^G,CI-/9 MU99?BLI[8^LU6[KRCVW\'"6LB\7E()H],H6? #PZ@\U?S 2D.? MLW'<"YJMKS$[#:Y4#R::0C-('&,]8%8:>(%\2<(QZ)L$&11\Y$; Q1L_(G3S MJ(9IM+?=B0D-\TRI=K"/ B&G60<7&/0IV<%$AM>1OBE'T2&-@Z=MP*/G$,7Q M,W(.6+)Q8K)XQ!PV'+^:&*P?*X=&IJ_0*Q\CAWN# "+NV7J3D!=,7R1[CA=8 MO$9QGO"R\->I#E?_)UY6)Q:S=2+JP.O!1R_^@OH "\. I?(3C>$+:!:4H?VV M8G-M'%76RU#[AN^V1$T'1VCO@BGNG>P.46=N0@O2/O@DC-6>X"L+V8#NQ)$; M_'T"".!_PS;HTO)]6@#-'O!UD 3+(1J??D)C*9NS<*=F;56 M$&,J;PKR9ETI-9/,<*XD&X(F8:BQJF99 -$:$8<%0]\!DUV=?QEI&9,<.D=2 M^AF7W/9YC-Z2.:G#2C+,0&/%9>-$0&G CL-A-=97^$LUNTI[A#<92>E?%[L% M5J=/;#U5?I$V9>)T$6\2^B+:J4E(X[UH &,<+&A %,=/; $LF5D( G/8BE34 M*MJKH+9=OH;C8KUAMQ"SL; E*7>41@4M/IM1W_#UJLI\R4RM%R)U:F#!3^W( M3U@S\FD6L Q,S6J9(\2E>,#9R866*AGB11@QS.M2%@O4%L0L-_$: '\E S2- M9>G506KONP>IJ0D.9-?P] P+NYX/T3 NR9AG:=@6RN5(#3M?K81(-H;:6(\0M'"%N@W-H9Z5)KN_$Z0,E).9,N@H29S'.YS?4),XRO.0' M@WW$;%- MWW62]9ML$K2-4C(;8-V'[1NE%37:,]* 31'.Y'J$+W/I=347#6H M:F)=)QW*R95:M-+9GO9"C)LL[D&U_Z!Y?43U .)6!VX*/H/LFM9>A+ 7GITF M)&>MSX;]Q-JJ1;FK*.?H_C%.T9)MYL]R=ND-RIGV3P%<9-"NK>[] KWO+#CV MG\OT3N-O:()6.%R^TS-K7MLL*^&KB?DOAU.+LAS H!HG;:G%8P0/.;^1012# MM,+-N*00AH"NU#SX93$Z3UJ JPV4F'_SOC\D][F6F[KU-JO[+C^,:DA &:E> MCT8:#Z$QRV#TK7UI%YNB+%=L=NY/J9]+LX71G:N9[\VYGTCBJ;A^,JNQBS\@ MW/DL4'T!(@V>P6:#X[-1'XM'P+A1;/=4#H.VPNL7.+C !-L#&+WH846ENB?C M--%Z5-V D!^A70$0#7%E$8Y070A4E6(G%4S_Z1N+>ZI^X#<2^,+KSQIEQT99 MK*>@[K^_.CAQJ_JG;*BM"E"+9B3#05PRIZY0;4"P35CT_ J]\RGC_*5LJQV8 M0=-.HH%!W_F5M@@C##/9E\8I"S)S8I38:!:070:S[P\.VC:9AQ6X+),)K6VK M!,&PI(<7[+17%+=2FUN2)"N2,46HX.A< -=@ZE" J8+OX"*//_+FZQ6\1'BW M0LTT'5'TF6FP-7A,Y5 COCM?(5H($ 8 M2B#RP+2 CE^B8,,8>.-T7DK?GCQ MRW"LSG2HKE$([1!=Z#.\WT14'#IJ]PK#8GBC=Q9CE;]1R6*2"7-[SU"SY3:> MIYZ1,B]K>//DUF7W.AUE69I9*?\ZI\<'< ]RCF@8J('GA\P+ 3HY9/ONAQ6 MPID/MR]W0-$'>B:\BF7?S#3X0<4W7Q/@!Q'@@DZ>K=[TMXSD8). >@] ]E" M#Q,/\PC*%,2\H;9X/H=I9%Z;>2K/3?/0DU,'S ,.>VA !CNL(7 &.6XA?9># M#:U5.\&VYI978P$'5JE]H+ JL#]Q4.V5R#:DT@;\@?B=WY.5T6=<%?N<-7X^ M0CA=LDV4F_)8^%<3:>4D (RS2MS!1MF>*\@8*WF/$%D=S(27M'2C$QIXNJH5 M'4HOWT.!(U@//18<9$_V/(JSOT;)%L_S?+NNWVZ#%[3+_E?"[A9-XN+E-BJL MIW_@/+JF9#8>IPKGYF4,HB=L75PO =^R%+/];RBC/QYHQ!Y ((@8/@RA0$'= MW#E(F+=]U\.+^U5#-E\N8_:7*/D0YXN$Y%L:X.S.LH#U!=3]UOB:.&E7EBZ( M^&Y14)^IO-[_;"^"&C*O9HF8&6D W8;Q15I@^HJ%[QQ>Y<]'!B_V%U+^+BIA$-'=LK"CY>[2,LS8$[2BCUY;XJYD MC:^T70=,CTF[R+6WE%W^GH<7XOLC3Y!K=6&]PL^A3;M&%Z:'_Z];EP90UQ6M#[NES(HOB; M0CSLU;BO(GKYGX<,,'P=Y)RE[)2M>U)$"]D!B1VC9 MJU&!0P@H$9APK<1H0XY1VT<*.$U,=7Z@3_V++ 45%JR M8<.N=T64%2,=939ZRJGV/6N=Q?. '^,T97=)[898#SNZZZGBYVR=L1)-J4M/ M!^4$F%(J2V>51XXR!Z,M[F2QX+@3#%HS+=_# # @7UL3DM4:3D]?1#1QQU8ZEUW%/Q@ZI;8!H;B-^C0MT;*DV_O&MDY]D/<$YK:%U1D$7Z(S=-9UZI8Y5413=UN_Q9[+X M,^V9T1,%H*!ZP;K"6O6)QQ\I-RE^(#'H1#^._CT231:)_/>2 XQ$A]R#/B?9 M"L<%WZR9+L^^;N*,6_!R*6R:GTP2THA'@;GZV7>_EF#1.( M9.PJT]K&JVS,8)@.V,2!$0:VW7,J%F1K"/!]#CTD!K-.$N1-@HZ'P"LKF\&5 M9G2H4:+7\CK.[4O/W;78^SN1?CMI7$WX=>R24SQ8T31 M.FE'(83.@%'"SY/\0S\&VYQ48[8K$V;KHS8/AY%U'U9F'43V/%6&_#T8>8;_ M:X]&KR0A]9^"^D\Z0TPS#R.QG":5;">/U7.TB&BX3!+\BJY.4;' 3V >-2_T M''M#S?U"S_8FRN]&RNA>7P8W06CPGZ6-&!L..1-K+,SP!G99GO.^QZKCPM%@OH#CMAJ0:LA1]S M)>IXU]E)G)JM+OU.<1@0'CK'@UJ$OB]6B%NPVZ4;G=D^MUR_AHLJIPL&_M>, MCQ0,#GD=>..%;DF2T'XC>^BO:R5P M^_:CD))TXWBA7<6FME,4<*VEW'L[N" M+'ZO8R^:+XKXF=TU^9D)HDKRP.\CTU##3PR6 -%;'&[X\Q2,>V\4+.N#&097 M%W$:R@,/AC<J)&>*/C_-=\OBV>2!;_$R\_I4N<\5:Q?)D;RM'\ M_4MK"? M^P[SKW%NE,2!>%!F<(X>O 1RIS+Y/\$&HGCV =S=ZZR]QYDQ(4!OS;<@J'-)-0Z.=/'68!W.<08VW^?#V0=Q2E8JQ2J_2!/FH# BTG[RSCK;,/&IVHQ'W<(3$D;KT<[BQ6DLBF%AM M@EJP6"US!A2KU>\26*QN9/FY+,WG_[FGY9NG2_:&5]':)EC#N# =TQSDPO?8 MQH!"C7JJX_#R.8UJ#'4[._O'E@U; F"2I_^8YR)>_L0IK=: M3K2\>=_+*4,,4F;(TL8@XZHV"3%*8_H(8E"6"0,$R8I[G*TOTF><%SS*]2* M7&1'<9&(,X?[1F%)*K6O9J%$;<:?H((^0O'^V=0D4U0>,?_879KTI=L\D%F; M#NCQ8QJOXD5$F^S%@FPI#]-'3L$8Y_?X:_&>.O^]"WTKI9H,ADJN]#!R8TN8 M9YP]$,U:!!O'2B:9&YK=??KX<7[[-W1]CNXN?KNZ.+\XG5_=H_GIZ?6GJ_N+ MJ]_0S?7EQ>G%V=W$?+-##'&ISPXGC?1;++7P.!I8X2;0K5S"X)1-<.^%T5X: MU>+H,U- 7&/J3N((4)5-(WO$ZJ33O$54\)[B:1+E^?6*)]ZBR5J=7-V4R.5< M"2FS#)IA:9PH2:?4G?%?V>K]_H,WN"^*-0 -^O,A'2A1]9 O&= MK!#;'4O3@_IZ=1KE3^<)^9+/'_(BBQ:%#-X*T2[0A:)0D!<8]P)^N1\C&LC4 M9Z*T'-%*\)C$/WR^^@AZ=UO(GS8;1.JAU",".N][RD!-9<3PK=A84*S/_]S^6CRE%!695W2R+ZR@!)-T1[B^W9\8 V MQ(NL6P/@>+>TN=I;2+*D@:"L'E%0$PHTHUI' +2+9/6 M<8T44:*-:R(76ESWE6;WS!O*&T__@#!_'@"VQ777!;?T:PO W9+MH5M@R0L< M8$.=K M.(;V660X\RIP #(.J_8(FC3,;C>;A ^_1$F]%N B79%L':FFW.VTZ@!LJN5* M*#,_H*'9RJ628Q:69DUAM(SS14+R\D;"%5JP%3$KJHWBO?K4$=T2-\2I4CM, M-3/0HJV-S\DH?!]]Q?E-],(2V--MQK+7#C$4$M4W$DHXTE!@$Y)RLFT M9A?I@JQI!R#ZBC;EXVFIHJHS8OR1VQ00"#?A+K4U';2S:,EV6E\73SBK=@/D MMWB!XV=62.$V9BN=&OYF.JZ$,/$"2A$+ATK2&-N9[7\M+Z+\0+8/Q6J;U#MD M)MXD:0<.XE!W'>:9J+>X:.YO0G;BB*8;+SR[_6N4;+O EPOL>-<7<"99UZ2' M-012)VH6"95F]>_E*.41^I?CMT>_OON7:C4 B@JT('F!(I[5X6CQ5-]C@=,E M7J*/%/9/Z-WQ$:+5]*\EZ2A.^/!V]>N?IB:=% ;$M.*Z=.K*MKDCMN0%66!C MG7+S]J Z;J#JKD05?W:X.)!TOX< 8M!42U.>+?VSCK+>4T4!2 M#OV])#P%:MO@2S?TOBQYT=+N\ -MZ%L_14$M,C2I9/&"#6Y^ MV(\F2R8!($R)XKJU*4B"6CKWEB0-*X8[P2 8&;Y0' H"PT.>%"$#DNK MTM@RJ'1AQ)XZ(,Z?<18]XE.2%S4S9L?OWT=?W.,6KN,C+V6+ZPPU.HZ2(>>-[D=*. M/VV S[ZR_4U=B )8JKZFDR5'@CGXAN2A>S%4='6U/JM_Y+,QFUIZ6DI#X(^ M Z$=(!R,-N.(<]E""S=FH<0L3/@* ;;T-CA_5NUI (-+=C8?\@4_#]7C( EJ M03YK8AF0!F0,5&$;;/Q3XV,@6HX[<*&/T?M7!!?)0*<;7J8K::)TT6R M90L,5R1#Q1-&M)U8;)/RV!:JN"Q=HA073)8MG@]E1@@*W<0+Q-KQQ]%P,V"! ME#&L %=/;34*_C[*XX5).-/IJH*77-='J))Y\QZ8-(ZMPY#2WJQ:M;9E*Y'B ME$6>S;;8Q9,')MB,)KMYI'"6+0W#F2Z,F%2_0="0F=&&"+7_T *"+*"9A02= MMCHHR+7]A 69OQ$"@\;U@-"@M*@)#H)DXW#"@Q9S^@!A @2C$"$S9! DU&48 M$"9HWK%@Y/_7M^\JZK-?_KO>[53M1)RG2_I+ML7+:H@^OW^*L^5-E!4OM^2E M',COT,K%1/49AYD8& 8&O[=M(%B2Q9;O9V;$ZKRQ:R%$(<'-YNQNNV;L+WL? M6?;"@/K,]G'DU78H]N2A.M0[9X=Z(W8&/7M"'I+X,2H/M*,1@VUG75+QC&P? MG^B?427)1K:66XR^Q,43#2,DQ>@%1QGZL>KT$!IF(CXNMGA9)/@(Q2N4D/01 M9S\=55TD]C")HX)KPMJJ(=H:C\\"BGWRR+JY&]!Y+2L$N?4K<4)4EIBC]:L=,?\6Z" MY.=IXZL3K0D0S=IA=H@U5JV.19DBSC@/5SI[!X\PQS_,:E54Z99CW15-:G7T MAAM W +:F?B&V2 939V$#OUAV5'X< (RG^-36U0+-5M"9I\<32T93EY#$5I2GP M,GJ9.L&T02T9!JMV:#!0WD4"8TB>H%(8<6FT M%W^U$)3D;!XPZ)B1&7JQ2L 4RPUM?;IB\62'Q2HJTZ];!N5N+'Z]6)2D2AZP M")H(?60-5_)RRR]!X\Z6-QE>L]M(.D VD*Q>72GI0B.%8?!$1^]+RAJ=ZNR> M9A31FF7!+)58E^+E\%:=OM!>2*6"EOS&$IZ&E/2:.*
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end